id	sid	tid	token	lemma	pos
ajlm-2565	1	1	abstract	abstract	ADJ
ajlm-2565	1	2	introduction	introduction	NOUN
ajlm-2565	1	3	methods	method	NOUN
ajlm-2565	1	4	results	result	VERB
ajlm-2565	1	5	discussion	discussion	NOUN
ajlm-2565	1	6	acknowledgements	acknowledgement	NOUN
ajlm-2565	1	7	references	reference	NOUN
ajlm-2565	1	8	about	about	ADP
ajlm-2565	1	9	the	the	DET
ajlm-2565	1	10	author(s	author(s	NOUN
ajlm-2565	1	11	)	)	PUNCT
ajlm-2565	1	12	simon	simon	PROPN
ajlm-2565	1	13	p.	p.	PROPN
ajlm-2565	1	14	rugera	rugera	PROPN
ajlm-2565	1	15	department	department	PROPN
ajlm-2565	1	16	of	of	ADP
ajlm-2565	1	17	medical	medical	ADJ
ajlm-2565	1	18	laboratory	laboratory	NOUN
ajlm-2565	1	19	science	science	NOUN
ajlm-2565	1	20	,	,	PUNCT
ajlm-2565	1	21	faculty	faculty	NOUN
ajlm-2565	1	22	of	of	ADP
ajlm-2565	1	23	medicine	medicine	NOUN
ajlm-2565	1	24	,	,	PUNCT
ajlm-2565	1	25	mbarara	mbarara	PROPN
ajlm-2565	1	26	university	university	PROPN
ajlm-2565	1	27	of	of	ADP
ajlm-2565	1	28	science	science	NOUN
ajlm-2565	1	29	and	and	CCONJ
ajlm-2565	1	30	technology	technology	NOUN
ajlm-2565	1	31	,	,	PUNCT
ajlm-2565	1	32	mbarara	mbarara	PROPN
ajlm-2565	1	33	,	,	PUNCT
ajlm-2565	1	34	uganda	uganda	PROPN
ajlm-2565	1	35	hope	hope	PROPN
ajlm-2565	1	36	mudondo	mudondo	PROPN
ajlm-2565	1	37	department	department	PROPN
ajlm-2565	1	38	of	of	ADP
ajlm-2565	1	39	medical	medical	ADJ
ajlm-2565	1	40	laboratory	laboratory	NOUN
ajlm-2565	1	41	science	science	NOUN
ajlm-2565	1	42	,	,	PUNCT
ajlm-2565	1	43	faculty	faculty	NOUN
ajlm-2565	1	44	of	of	ADP
ajlm-2565	1	45	medicine	medicine	NOUN
ajlm-2565	1	46	,	,	PUNCT
ajlm-2565	1	47	mbarara	mbarara	PROPN
ajlm-2565	1	48	university	university	PROPN
ajlm-2565	1	49	of	of	ADP
ajlm-2565	1	50	science	science	NOUN
ajlm-2565	1	51	and	and	CCONJ
ajlm-2565	1	52	technology	technology	NOUN
ajlm-2565	1	53	,	,	PUNCT
ajlm-2565	1	54	mbarara	mbarara	PROPN
ajlm-2565	1	55	,	,	PUNCT
ajlm-2565	1	56	uganda	uganda	PROPN
ajlm-2565	1	57	jazira	jazira	PROPN
ajlm-2565	1	58	tumusiime	tumusiime	PROPN
ajlm-2565	1	59	department	department	PROPN
ajlm-2565	1	60	of	of	ADP
ajlm-2565	1	61	medical	medical	ADJ
ajlm-2565	1	62	laboratory	laboratory	NOUN
ajlm-2565	1	63	science	science	NOUN
ajlm-2565	1	64	,	,	PUNCT
ajlm-2565	1	65	faculty	faculty	NOUN
ajlm-2565	1	66	of	of	ADP
ajlm-2565	1	67	medicine	medicine	NOUN
ajlm-2565	1	68	,	,	PUNCT
ajlm-2565	1	69	mbarara	mbarara	PROPN
ajlm-2565	1	70	university	university	PROPN
ajlm-2565	1	71	of	of	ADP
ajlm-2565	1	72	science	science	NOUN
ajlm-2565	1	73	and	and	CCONJ
ajlm-2565	1	74	technology	technology	NOUN
ajlm-2565	1	75	,	,	PUNCT
ajlm-2565	1	76	mbarara	mbarara	PROPN
ajlm-2565	1	77	,	,	PUNCT
ajlm-2565	1	78	uganda	uganda	PROPN
ajlm-2565	1	79	rahma	rahma	PROPN
ajlm-2565	1	80	udu	udu	PROPN
ajlm-2565	1	81	department	department	PROPN
ajlm-2565	1	82	of	of	ADP
ajlm-2565	1	83	pure	pure	ADJ
ajlm-2565	1	84	and	and	CCONJ
ajlm-2565	1	85	applied	applied	ADJ
ajlm-2565	1	86	sciences	science	NOUN
ajlm-2565	1	87	,	,	PUNCT
ajlm-2565	1	88	school	school	NOUN
ajlm-2565	1	89	of	of	ADP
ajlm-2565	1	90	applied	applied	ADJ
ajlm-2565	1	91	and	and	CCONJ
ajlm-2565	1	92	health	health	NOUN
ajlm-2565	1	93	sciences	science	NOUN
ajlm-2565	1	94	,	,	PUNCT
ajlm-2565	1	95	technical	technical	ADJ
ajlm-2565	1	96	university	university	PROPN
ajlm-2565	1	97	of	of	ADP
ajlm-2565	1	98	mombasa	mombasa	PROPN
ajlm-2565	1	99	,	,	PUNCT
ajlm-2565	1	100	mombasa	mombasa	PROPN
ajlm-2565	1	101	,	,	PUNCT
ajlm-2565	1	102	kenya	kenya	PROPN
ajlm-2565	1	103	ritah	ritah	PROPN
ajlm-2565	1	104	kiconco	kiconco	PROPN
ajlm-2565	1	105	department	department	PROPN
ajlm-2565	1	106	of	of	ADP
ajlm-2565	1	107	medical	medical	ADJ
ajlm-2565	1	108	laboratory	laboratory	NOUN
ajlm-2565	1	109	science	science	NOUN
ajlm-2565	1	110	,	,	PUNCT
ajlm-2565	1	111	faculty	faculty	NOUN
ajlm-2565	1	112	of	of	ADP
ajlm-2565	1	113	medicine	medicine	NOUN
ajlm-2565	1	114	,	,	PUNCT
ajlm-2565	1	115	mbarara	mbarara	PROPN
ajlm-2565	1	116	university	university	PROPN
ajlm-2565	1	117	of	of	ADP
ajlm-2565	1	118	science	science	NOUN
ajlm-2565	1	119	and	and	CCONJ
ajlm-2565	1	120	technology	technology	NOUN
ajlm-2565	1	121	,	,	PUNCT
ajlm-2565	1	122	mbarara	mbarara	PROPN
ajlm-2565	1	123	,	,	PUNCT
ajlm-2565	1	124	uganda	uganda	PROPN
ajlm-2565	1	125	department	department	PROPN
ajlm-2565	1	126	of	of	ADP
ajlm-2565	1	127	biochemistry	biochemistry	NOUN
ajlm-2565	1	128	,	,	PUNCT
ajlm-2565	1	129	school	school	NOUN
ajlm-2565	1	130	of	of	ADP
ajlm-2565	1	131	health	health	NOUN
ajlm-2565	1	132	sciences	sciences	PROPN
ajlm-2565	1	133	,	,	PUNCT
ajlm-2565	1	134	soroti	soroti	PROPN
ajlm-2565	1	135	university	university	PROPN
ajlm-2565	1	136	,	,	PUNCT
ajlm-2565	1	137	soroti	soroti	PROPN
ajlm-2565	1	138	,	,	PUNCT
ajlm-2565	1	139	uganda	uganda	PROPN
ajlm-2565	1	140	sylvia	sylvia	PROPN
ajlm-2565	1	141	a.	a.	PROPN
ajlm-2565	1	142	lumumba	lumumba	PROPN
ajlm-2565	1	143	department	department	PROPN
ajlm-2565	1	144	of	of	ADP
ajlm-2565	1	145	medical	medical	ADJ
ajlm-2565	1	146	laboratory	laboratory	NOUN
ajlm-2565	1	147	science	science	NOUN
ajlm-2565	1	148	,	,	PUNCT
ajlm-2565	1	149	faculty	faculty	NOUN
ajlm-2565	1	150	of	of	ADP
ajlm-2565	1	151	medicine	medicine	NOUN
ajlm-2565	1	152	,	,	PUNCT
ajlm-2565	1	153	mbarara	mbarara	PROPN
ajlm-2565	1	154	university	university	PROPN
ajlm-2565	1	155	of	of	ADP
ajlm-2565	1	156	science	science	NOUN
ajlm-2565	1	157	and	and	CCONJ
ajlm-2565	1	158	technology	technology	NOUN
ajlm-2565	1	159	,	,	PUNCT
ajlm-2565	1	160	mbarara	mbarara	PROPN
ajlm-2565	1	161	,	,	PUNCT
ajlm-2565	1	162	uganda	uganda	PROPN
ajlm-2565	1	163	department	department	PROPN
ajlm-2565	1	164	of	of	ADP
ajlm-2565	1	165	medical	medical	ADJ
ajlm-2565	1	166	science	science	NOUN
ajlm-2565	1	167	,	,	PUNCT
ajlm-2565	1	168	school	school	NOUN
ajlm-2565	1	169	of	of	ADP
ajlm-2565	1	170	applied	applied	ADJ
ajlm-2565	1	171	and	and	CCONJ
ajlm-2565	1	172	health	health	NOUN
ajlm-2565	1	173	sciences	science	NOUN
ajlm-2565	1	174	,	,	PUNCT
ajlm-2565	1	175	technical	technical	ADJ
ajlm-2565	1	176	university	university	PROPN
ajlm-2565	1	177	of	of	ADP
ajlm-2565	1	178	mombasa	mombasa	PROPN
ajlm-2565	1	179	,	,	PUNCT
ajlm-2565	1	180	mombasa	mombasa	PROPN
ajlm-2565	1	181	,	,	PUNCT
ajlm-2565	1	182	kenya	kenya	PROPN
ajlm-2565	1	183	charles	charles	PROPN
ajlm-2565	1	184	n.	n.	PROPN
ajlm-2565	1	185	bagenda	bagenda	PROPN
ajlm-2565	1	186	department	department	PROPN
ajlm-2565	1	187	of	of	ADP
ajlm-2565	1	188	medical	medical	ADJ
ajlm-2565	1	189	laboratory	laboratory	NOUN
ajlm-2565	1	190	science	science	NOUN
ajlm-2565	1	191	,	,	PUNCT
ajlm-2565	1	192	faculty	faculty	NOUN
ajlm-2565	1	193	of	of	ADP
ajlm-2565	1	194	medicine	medicine	NOUN
ajlm-2565	1	195	,	,	PUNCT
ajlm-2565	1	196	mbarara	mbarara	PROPN
ajlm-2565	1	197	university	university	PROPN
ajlm-2565	1	198	of	of	ADP
ajlm-2565	1	199	science	science	NOUN
ajlm-2565	1	200	and	and	CCONJ
ajlm-2565	1	201	technology	technology	NOUN
ajlm-2565	1	202	,	,	PUNCT
ajlm-2565	1	203	mbarara	mbarara	PROPN
ajlm-2565	1	204	,	,	PUNCT
ajlm-2565	1	205	uganda	uganda	PROPN
ajlm-2565	1	206	citation	citation	PROPN
ajlm-2565	1	207	rugera	rugera	NOUN
ajlm-2565	1	208	sp	sp	PROPN
ajlm-2565	1	209	,	,	PUNCT
ajlm-2565	1	210	mudondo	mudondo	PROPN
ajlm-2565	1	211	h	h	PROPN
ajlm-2565	1	212	,	,	PUNCT
ajlm-2565	1	213	tumusiime	tumusiime	PROPN
ajlm-2565	1	214	j	j	PROPN
ajlm-2565	1	215	,	,	PUNCT
ajlm-2565	1	216	et	et	PROPN
ajlm-2565	1	217	al	al	PROPN
ajlm-2565	1	218	.	.	PROPN
ajlm-2565	1	219	association	association	PROPN
ajlm-2565	1	220	of	of	ADP
ajlm-2565	1	221	obesity	obesity	NOUN
ajlm-2565	1	222	with	with	ADP
ajlm-2565	1	223	hyperuricaemia	hyperuricaemia	NOUN
ajlm-2565	1	224	among	among	ADP
ajlm-2565	1	225	hiv	hiv	PROPN
ajlm-2565	1	226	-	-	PUNCT
ajlm-2565	1	227	positive	positive	ADJ
ajlm-2565	1	228	patients	patient	NOUN
ajlm-2565	1	229	on	on	ADP
ajlm-2565	1	230	antiretroviral	antiretroviral	ADJ
ajlm-2565	1	231	therapy	therapy	NOUN
ajlm-2565	1	232	in	in	ADP
ajlm-2565	1	233	south	south	ADJ
ajlm-2565	1	234	-	-	PUNCT
ajlm-2565	1	235	western	western	ADJ
ajlm-2565	1	236	uganda	uganda	PROPN
ajlm-2565	1	237	.	.	PUNCT
ajlm-2565	2	1	afr	afr	PROPN
ajlm-2565	2	2	j	j	PROPN
ajlm-2565	2	3	lab	lab	PROPN
ajlm-2565	2	4	med	med	PROPN
ajlm-2565	2	5	.	.	PUNCT
ajlm-2565	3	1	2025;14(1	2025;14(1	NUM
ajlm-2565	3	2	)	)	PUNCT
ajlm-2565	3	3	,	,	PUNCT
ajlm-2565	4	1	a2565	a2565	PROPN
ajlm-2565	4	2	.	.	PUNCT
ajlm-2565	5	1	https://doi.org/10.4102/ajlm.v14i1.2565	https://doi.org/10.4102/ajlm.v14i1.2565	CCONJ
ajlm-2565	5	2	original	original	ADJ
ajlm-2565	5	3	research	research	NOUN
ajlm-2565	5	4	association	association	NOUN
ajlm-2565	5	5	of	of	ADP
ajlm-2565	5	6	obesity	obesity	NOUN
ajlm-2565	5	7	with	with	ADP
ajlm-2565	5	8	hyperuricaemia	hyperuricaemia	NOUN
ajlm-2565	5	9	among	among	ADP
ajlm-2565	5	10	hiv	hiv	PROPN
ajlm-2565	5	11	-	-	PUNCT
ajlm-2565	5	12	positive	positive	ADJ
ajlm-2565	5	13	patients	patient	NOUN
ajlm-2565	5	14	on	on	ADP
ajlm-2565	5	15	antiretroviral	antiretroviral	ADJ
ajlm-2565	5	16	therapy	therapy	NOUN
ajlm-2565	5	17	in	in	ADP
ajlm-2565	5	18	south	south	ADJ
ajlm-2565	5	19	-	-	PUNCT
ajlm-2565	5	20	western	western	ADJ
ajlm-2565	5	21	uganda	uganda	PROPN
ajlm-2565	5	22	simon	simon	PROPN
ajlm-2565	5	23	p.	p.	PROPN
ajlm-2565	5	24	rugera	rugera	PROPN
ajlm-2565	5	25	,	,	PUNCT
ajlm-2565	5	26	hope	hope	PROPN
ajlm-2565	5	27	mudondo	mudondo	PROPN
ajlm-2565	5	28	,	,	PUNCT
ajlm-2565	5	29	jazira	jazira	PROPN
ajlm-2565	5	30	tumusiime	tumusiime	NOUN
ajlm-2565	5	31	,	,	PUNCT
ajlm-2565	5	32	rahma	rahma	PROPN
ajlm-2565	5	33	udu	udu	PROPN
ajlm-2565	5	34	,	,	PUNCT
ajlm-2565	5	35	ritah	ritah	PROPN
ajlm-2565	5	36	kiconco	kiconco	PROPN
ajlm-2565	5	37	,	,	PUNCT
ajlm-2565	5	38	sylvia	sylvia	PROPN
ajlm-2565	5	39	a.	a.	PROPN
ajlm-2565	5	40	lumumba	lumumba	PROPN
ajlm-2565	5	41	,	,	PUNCT
ajlm-2565	5	42	charles	charles	PROPN
ajlm-2565	5	43	n.	n.	PROPN
ajlm-2565	5	44	bagenda	bagenda	PROPN
ajlm-2565	5	45	received	receive	VERB
ajlm-2565	5	46	:	:	PUNCT
ajlm-2565	5	47	16	16	NUM
ajlm-2565	5	48	july	july	PROPN
ajlm-2565	5	49	2024	2024	NUM
ajlm-2565	5	50	;	;	PUNCT
ajlm-2565	5	51	accepted	accept	VERB
ajlm-2565	5	52	:	:	PUNCT
ajlm-2565	5	53	15	15	NUM
ajlm-2565	5	54	nov	nov	PROPN
ajlm-2565	5	55	.	.	PROPN
ajlm-2565	5	56	2024	2024	NUM
ajlm-2565	5	57	;	;	PUNCT
ajlm-2565	5	58	published	publish	VERB
ajlm-2565	5	59	:	:	PUNCT
ajlm-2565	5	60	19	19	NUM
ajlm-2565	5	61	feb	feb	X
ajlm-2565	5	62	.	.	PROPN
ajlm-2565	6	1	2025	2025	NUM
ajlm-2565	6	2	copyright	copyright	NOUN
ajlm-2565	6	3	:	:	PUNCT
ajlm-2565	6	4	©	©	PROPN
ajlm-2565	6	5	2025	2025	NUM
ajlm-2565	6	6	.	.	PUNCT
ajlm-2565	7	1	the	the	DET
ajlm-2565	7	2	author(s	author(s	PROPN
ajlm-2565	7	3	)	)	PUNCT
ajlm-2565	7	4	.	.	PUNCT
ajlm-2565	8	1	licensee	licensee	NOUN
ajlm-2565	8	2	:	:	PUNCT
ajlm-2565	8	3	aosis	aosis	NOUN
ajlm-2565	8	4	.	.	PUNCT
ajlm-2565	9	1	this	this	PRON
ajlm-2565	9	2	is	be	AUX
ajlm-2565	9	3	an	an	DET
ajlm-2565	9	4	open	open	ADJ
ajlm-2565	9	5	access	access	NOUN
ajlm-2565	9	6	article	article	NOUN
ajlm-2565	9	7	distributed	distribute	VERB
ajlm-2565	9	8	under	under	ADP
ajlm-2565	9	9	the	the	DET
ajlm-2565	9	10	terms	term	NOUN
ajlm-2565	9	11	of	of	ADP
ajlm-2565	9	12	the	the	DET
ajlm-2565	9	13	creative	creative	ADJ
ajlm-2565	9	14	commons	common	NOUN
ajlm-2565	9	15	attribution	attribution	NOUN
ajlm-2565	9	16	license	license	NOUN
ajlm-2565	9	17	,	,	PUNCT
ajlm-2565	9	18	which	which	PRON
ajlm-2565	9	19	permits	permit	VERB
ajlm-2565	9	20	unrestricted	unrestricted	ADJ
ajlm-2565	9	21	use	use	NOUN
ajlm-2565	9	22	,	,	PUNCT
ajlm-2565	9	23	distribution	distribution	NOUN
ajlm-2565	9	24	,	,	PUNCT
ajlm-2565	9	25	and	and	CCONJ
ajlm-2565	9	26	reproduction	reproduction	NOUN
ajlm-2565	9	27	in	in	ADP
ajlm-2565	9	28	any	any	DET
ajlm-2565	9	29	medium	medium	NOUN
ajlm-2565	9	30	,	,	PUNCT
ajlm-2565	9	31	provided	provide	VERB
ajlm-2565	9	32	the	the	DET
ajlm-2565	9	33	original	original	ADJ
ajlm-2565	9	34	work	work	NOUN
ajlm-2565	9	35	is	be	AUX
ajlm-2565	9	36	properly	properly	ADV
ajlm-2565	9	37	cited	cite	VERB
ajlm-2565	9	38	.	.	PUNCT
ajlm-2565	10	1	abstract	abstract	ADJ
ajlm-2565	10	2	background	background	NOUN
ajlm-2565	10	3	:	:	PUNCT
ajlm-2565	10	4	hyperuricaemia	hyperuricaemia	X
ajlm-2565	10	5	is	be	AUX
ajlm-2565	10	6	a	a	DET
ajlm-2565	10	7	risk	risk	NOUN
ajlm-2565	10	8	factor	factor	NOUN
ajlm-2565	10	9	for	for	ADP
ajlm-2565	10	10	gout	gout	NOUN
ajlm-2565	10	11	and	and	CCONJ
ajlm-2565	10	12	independently	independently	ADV
ajlm-2565	10	13	predicts	predict	VERB
ajlm-2565	10	14	hypertension	hypertension	NOUN
ajlm-2565	10	15	,	,	PUNCT
ajlm-2565	10	16	diabetes	diabetes	NOUN
ajlm-2565	10	17	,	,	PUNCT
ajlm-2565	10	18	and	and	CCONJ
ajlm-2565	10	19	chronic	chronic	ADJ
ajlm-2565	10	20	kidney	kidney	NOUN
ajlm-2565	10	21	disease	disease	NOUN
ajlm-2565	10	22	development	development	NOUN
ajlm-2565	10	23	.	.	PUNCT
ajlm-2565	11	1	while	while	SCONJ
ajlm-2565	11	2	elevated	elevated	ADJ
ajlm-2565	11	3	uric	uric	ADJ
ajlm-2565	11	4	acid	acid	NOUN
ajlm-2565	11	5	levels	level	NOUN
ajlm-2565	11	6	occur	occur	VERB
ajlm-2565	11	7	in	in	ADP
ajlm-2565	11	8	hiv	hiv	PROPN
ajlm-2565	11	9	patients	patient	NOUN
ajlm-2565	11	10	,	,	PUNCT
ajlm-2565	11	11	and	and	CCONJ
ajlm-2565	11	12	weight	weight	NOUN
ajlm-2565	11	13	gain	gain	NOUN
ajlm-2565	11	14	is	be	AUX
ajlm-2565	11	15	linked	link	VERB
ajlm-2565	11	16	to	to	ADP
ajlm-2565	11	17	dolutegravir	dolutegravir	PROPN
ajlm-2565	11	18	-	-	PUNCT
ajlm-2565	11	19	based	base	VERB
ajlm-2565	11	20	therapy	therapy	NOUN
ajlm-2565	11	21	,	,	PUNCT
ajlm-2565	11	22	data	datum	NOUN
ajlm-2565	11	23	on	on	ADP
ajlm-2565	11	24	the	the	DET
ajlm-2565	11	25	obesity	obesity	NOUN
ajlm-2565	11	26	-	-	PUNCT
ajlm-2565	11	27	hyperuricaemia	hyperuricaemia	NOUN
ajlm-2565	11	28	relationship	relationship	NOUN
ajlm-2565	11	29	in	in	ADP
ajlm-2565	11	30	this	this	DET
ajlm-2565	11	31	population	population	NOUN
ajlm-2565	11	32	remain	remain	VERB
ajlm-2565	11	33	limited	limited	ADJ
ajlm-2565	11	34	.	.	PUNCT
ajlm-2565	12	1	objective	objective	NOUN
ajlm-2565	12	2	:	:	PUNCT
ajlm-2565	12	3	the	the	DET
ajlm-2565	12	4	objective	objective	NOUN
ajlm-2565	12	5	of	of	ADP
ajlm-2565	12	6	our	our	PRON
ajlm-2565	12	7	study	study	NOUN
ajlm-2565	12	8	was	be	AUX
ajlm-2565	12	9	to	to	PART
ajlm-2565	12	10	evaluate	evaluate	VERB
ajlm-2565	12	11	the	the	DET
ajlm-2565	12	12	association	association	NOUN
ajlm-2565	12	13	between	between	ADP
ajlm-2565	12	14	obesity	obesity	NOUN
ajlm-2565	12	15	and	and	CCONJ
ajlm-2565	12	16	hyperuricaemia	hyperuricaemia	NOUN
ajlm-2565	12	17	among	among	ADP
ajlm-2565	12	18	hiv	hiv	PROPN
ajlm-2565	12	19	-	-	PUNCT
ajlm-2565	12	20	positive	positive	ADJ
ajlm-2565	12	21	patients	patient	NOUN
ajlm-2565	12	22	on	on	ADP
ajlm-2565	12	23	antiretroviral	antiretroviral	ADJ
ajlm-2565	12	24	therapy	therapy	NOUN
ajlm-2565	12	25	in	in	ADP
ajlm-2565	12	26	south	south	ADJ
ajlm-2565	12	27	-	-	PUNCT
ajlm-2565	12	28	western	western	ADJ
ajlm-2565	12	29	uganda	uganda	PROPN
ajlm-2565	12	30	.	.	PUNCT
ajlm-2565	13	1	methods	method	NOUN
ajlm-2565	13	2	:	:	PUNCT
ajlm-2565	13	3	between	between	ADP
ajlm-2565	13	4	april	april	PROPN
ajlm-2565	13	5	2024	2024	NUM
ajlm-2565	13	6	and	and	CCONJ
ajlm-2565	13	7	june	june	PROPN
ajlm-2565	13	8	2024	2024	NUM
ajlm-2565	13	9	,	,	PUNCT
ajlm-2565	13	10	this	this	DET
ajlm-2565	13	11	study	study	NOUN
ajlm-2565	13	12	conducted	conduct	VERB
ajlm-2565	13	13	a	a	DET
ajlm-2565	13	14	secondary	secondary	ADJ
ajlm-2565	13	15	analysis	analysis	NOUN
ajlm-2565	13	16	of	of	ADP
ajlm-2565	13	17	data	datum	NOUN
ajlm-2565	13	18	on	on	ADP
ajlm-2565	13	19	uric	uric	ADJ
ajlm-2565	13	20	acid	acid	NOUN
ajlm-2565	13	21	level	level	NOUN
ajlm-2565	13	22	and	and	CCONJ
ajlm-2565	13	23	factors	factor	NOUN
ajlm-2565	13	24	associated	associate	VERB
ajlm-2565	13	25	with	with	ADP
ajlm-2565	13	26	obesity	obesity	NOUN
ajlm-2565	13	27	from	from	ADP
ajlm-2565	13	28	a	a	DET
ajlm-2565	13	29	2023	2023	NUM
ajlm-2565	13	30	cross	cross	ADJ
ajlm-2565	13	31	-	-	ADJ
ajlm-2565	13	32	sectional	sectional	ADJ
ajlm-2565	13	33	study	study	NOUN
ajlm-2565	13	34	of	of	ADP
ajlm-2565	13	35	hiv	hiv	PROPN
ajlm-2565	13	36	-	-	PUNCT
ajlm-2565	13	37	positive	positive	ADJ
ajlm-2565	13	38	participants	participant	NOUN
ajlm-2565	13	39	.	.	PUNCT
ajlm-2565	14	1	we	we	PRON
ajlm-2565	14	2	used	use	VERB
ajlm-2565	14	3	logistic	logistic	ADJ
ajlm-2565	14	4	regression	regression	NOUN
ajlm-2565	14	5	to	to	PART
ajlm-2565	14	6	assess	assess	VERB
ajlm-2565	14	7	the	the	DET
ajlm-2565	14	8	factors	factor	NOUN
ajlm-2565	14	9	associated	associate	VERB
ajlm-2565	14	10	with	with	ADP
ajlm-2565	14	11	hyperuricaemia	hyperuricaemia	NOUN
ajlm-2565	14	12	,	,	PUNCT
ajlm-2565	14	13	and	and	CCONJ
ajlm-2565	14	14	receiver	receiver	ADJ
ajlm-2565	14	15	operating	operate	VERB
ajlm-2565	14	16	characteristic	characteristic	ADJ
ajlm-2565	14	17	curve	curve	NOUN
ajlm-2565	14	18	analysis	analysis	NOUN
ajlm-2565	14	19	to	to	PART
ajlm-2565	14	20	assess	assess	VERB
ajlm-2565	14	21	the	the	DET
ajlm-2565	14	22	predictive	predictive	ADJ
ajlm-2565	14	23	performance	performance	NOUN
ajlm-2565	14	24	of	of	ADP
ajlm-2565	14	25	body	body	NOUN
ajlm-2565	14	26	mass	mass	NOUN
ajlm-2565	14	27	index	index	NOUN
ajlm-2565	14	28	for	for	ADP
ajlm-2565	14	29	hyperuricaemia	hyperuricaemia	NOUN
ajlm-2565	14	30	.	.	PUNCT
ajlm-2565	15	1	results	result	NOUN
ajlm-2565	15	2	:	:	PUNCT
ajlm-2565	15	3	among	among	ADP
ajlm-2565	15	4	328	328	NUM
ajlm-2565	15	5	participants	participant	NOUN
ajlm-2565	15	6	,	,	PUNCT
ajlm-2565	15	7	hyperuricaemia	hyperuricaemia	ADJ
ajlm-2565	15	8	prevalence	prevalence	NOUN
ajlm-2565	15	9	was	be	AUX
ajlm-2565	15	10	23.48	23.48	NUM
ajlm-2565	15	11	%	%	NOUN
ajlm-2565	15	12	(	(	PUNCT
ajlm-2565	15	13	95	95	NUM
ajlm-2565	15	14	%	%	NOUN
ajlm-2565	15	15	confidence	confidence	NOUN
ajlm-2565	15	16	interval	interval	NOUN
ajlm-2565	15	17	[	[	X
ajlm-2565	15	18	ci	ci	X
ajlm-2565	15	19	]	]	X
ajlm-2565	15	20	:	:	PUNCT
ajlm-2565	15	21	19.19–28.39	19.19–28.39	NUM
ajlm-2565	15	22	%	%	NOUN
ajlm-2565	15	23	)	)	PUNCT
ajlm-2565	15	24	higher	high	ADJ
ajlm-2565	15	25	in	in	ADP
ajlm-2565	15	26	male	male	ADJ
ajlm-2565	15	27	participants	participant	NOUN
ajlm-2565	15	28	(	(	PUNCT
ajlm-2565	15	29	31.6	31.6	NUM
ajlm-2565	15	30	%	%	NOUN
ajlm-2565	15	31	)	)	PUNCT
ajlm-2565	15	32	than	than	ADP
ajlm-2565	15	33	female	female	ADJ
ajlm-2565	15	34	participants	participant	NOUN
ajlm-2565	15	35	(	(	PUNCT
ajlm-2565	15	36	20.0	20.0	NUM
ajlm-2565	15	37	%	%	NOUN
ajlm-2565	15	38	,	,	PUNCT
ajlm-2565	15	39	p	p	X
ajlm-2565	15	40	=	=	PROPN
ajlm-2565	15	41	0.023	0.023	NUM
ajlm-2565	15	42	)	)	PUNCT
ajlm-2565	15	43	.	.	PUNCT
ajlm-2565	16	1	overweight	overweight	ADJ
ajlm-2565	16	2	(	(	PUNCT
ajlm-2565	16	3	adjusted	adjust	VERB
ajlm-2565	16	4	odds	odd	NOUN
ajlm-2565	16	5	ratio	ratio	NOUN
ajlm-2565	17	1	[	[	X
ajlm-2565	17	2	aor	aor	X
ajlm-2565	17	3	]	]	X
ajlm-2565	17	4	:	:	PUNCT
ajlm-2565	17	5	2.01	2.01	NUM
ajlm-2565	17	6	;	;	PUNCT
ajlm-2565	17	7	95	95	NUM
ajlm-2565	17	8	%	%	NOUN
ajlm-2565	17	9	ci	ci	NOUN
ajlm-2565	17	10	:	:	PUNCT
ajlm-2565	17	11	1.01–4.00	1.01–4.00	NUM
ajlm-2565	17	12	;	;	PUNCT
ajlm-2565	17	13	p	p	X
ajlm-2565	17	14	=	=	PROPN
ajlm-2565	17	15	0.046	0.046	NUM
ajlm-2565	17	16	)	)	PUNCT
ajlm-2565	17	17	,	,	PUNCT
ajlm-2565	17	18	obesity	obesity	NOUN
ajlm-2565	17	19	(	(	PUNCT
ajlm-2565	17	20	aor	aor	NOUN
ajlm-2565	17	21	:	:	PUNCT
ajlm-2565	17	22	2.50	2.50	NUM
ajlm-2565	17	23	;	;	PUNCT
ajlm-2565	17	24	95	95	NUM
ajlm-2565	17	25	%	%	NOUN
ajlm-2565	17	26	ci	ci	NOUN
ajlm-2565	17	27	:	:	PUNCT
ajlm-2565	17	28	1.09–5.73	1.09–5.73	NUM
ajlm-2565	17	29	,	,	PUNCT
ajlm-2565	17	30	p	p	X
ajlm-2565	17	31	=	=	NOUN
ajlm-2565	17	32	0.030	0.030	NUM
ajlm-2565	17	33	)	)	PUNCT
ajlm-2565	17	34	,	,	PUNCT
ajlm-2565	17	35	and	and	CCONJ
ajlm-2565	17	36	male	male	ADJ
ajlm-2565	17	37	gender	gender	NOUN
ajlm-2565	17	38	(	(	PUNCT
ajlm-2565	17	39	aor	aor	NOUN
ajlm-2565	17	40	:	:	PUNCT
ajlm-2565	17	41	2.31	2.31	NUM
ajlm-2565	17	42	;	;	PUNCT
ajlm-2565	17	43	95	95	NUM
ajlm-2565	17	44	%	%	NOUN
ajlm-2565	17	45	ci	ci	NOUN
ajlm-2565	17	46	:	:	PUNCT
ajlm-2565	17	47	1.07–5.01	1.07–5.01	NUM
ajlm-2565	17	48	,	,	PUNCT
ajlm-2565	17	49	p	p	X
ajlm-2565	17	50	=	=	NOUN
ajlm-2565	17	51	0.033	0.033	NUM
ajlm-2565	17	52	)	)	PUNCT
ajlm-2565	17	53	were	be	AUX
ajlm-2565	17	54	significantly	significantly	ADV
ajlm-2565	17	55	associated	associate	VERB
ajlm-2565	17	56	with	with	ADP
ajlm-2565	17	57	hyperuricaemia	hyperuricaemia	NOUN
ajlm-2565	17	58	.	.	PUNCT
ajlm-2565	18	1	conclusion	conclusion	NOUN
ajlm-2565	18	2	:	:	PUNCT
ajlm-2565	18	3	our	our	PRON
ajlm-2565	18	4	findings	finding	NOUN
ajlm-2565	18	5	indicate	indicate	VERB
ajlm-2565	18	6	a	a	DET
ajlm-2565	18	7	relationship	relationship	NOUN
ajlm-2565	18	8	between	between	ADP
ajlm-2565	18	9	hyperuricaemia	hyperuricaemia	NOUN
ajlm-2565	18	10	and	and	CCONJ
ajlm-2565	18	11	obesity	obesity	NOUN
ajlm-2565	18	12	in	in	ADP
ajlm-2565	18	13	hiv	hiv	PROPN
ajlm-2565	18	14	patients	patient	NOUN
ajlm-2565	18	15	on	on	ADP
ajlm-2565	18	16	antiretroviral	antiretroviral	ADJ
ajlm-2565	18	17	therapy	therapy	NOUN
ajlm-2565	18	18	in	in	ADP
ajlm-2565	18	19	uganda	uganda	PROPN
ajlm-2565	18	20	.	.	PUNCT
ajlm-2565	19	1	nationwide	nationwide	ADJ
ajlm-2565	19	2	studies	study	NOUN
ajlm-2565	19	3	using	use	VERB
ajlm-2565	19	4	primary	primary	ADJ
ajlm-2565	19	5	data	datum	NOUN
ajlm-2565	19	6	are	be	AUX
ajlm-2565	19	7	needed	need	VERB
ajlm-2565	19	8	to	to	PART
ajlm-2565	19	9	better	well	ADV
ajlm-2565	19	10	understand	understand	VERB
ajlm-2565	19	11	this	this	DET
ajlm-2565	19	12	relationship	relationship	NOUN
ajlm-2565	19	13	’s	’s	PART
ajlm-2565	19	14	epidemiological	epidemiological	ADJ
ajlm-2565	19	15	spread	spread	NOUN
ajlm-2565	19	16	.	.	PUNCT
ajlm-2565	20	1	what	what	PRON
ajlm-2565	20	2	this	this	DET
ajlm-2565	20	3	study	study	NOUN
ajlm-2565	20	4	adds	add	VERB
ajlm-2565	20	5	:	:	PUNCT
ajlm-2565	20	6	this	this	DET
ajlm-2565	20	7	study	study	NOUN
ajlm-2565	20	8	is	be	AUX
ajlm-2565	20	9	the	the	DET
ajlm-2565	20	10	first	first	ADJ
ajlm-2565	20	11	to	to	PART
ajlm-2565	20	12	link	link	VERB
ajlm-2565	20	13	obesity	obesity	NOUN
ajlm-2565	20	14	with	with	ADP
ajlm-2565	20	15	hyperuricaemia	hyperuricaemia	NOUN
ajlm-2565	20	16	among	among	ADP
ajlm-2565	20	17	hiv	hiv	PROPN
ajlm-2565	20	18	-	-	PUNCT
ajlm-2565	20	19	positive	positive	ADJ
ajlm-2565	20	20	ugandans	ugandans	PROPN
ajlm-2565	20	21	on	on	ADP
ajlm-2565	20	22	antiretroviral	antiretroviral	ADJ
ajlm-2565	20	23	therapy	therapy	NOUN
ajlm-2565	20	24	,	,	PUNCT
ajlm-2565	20	25	highlighting	highlight	VERB
ajlm-2565	20	26	obesity	obesity	NOUN
ajlm-2565	20	27	as	as	ADP
ajlm-2565	20	28	a	a	DET
ajlm-2565	20	29	key	key	ADJ
ajlm-2565	20	30	metabolic	metabolic	NOUN
ajlm-2565	20	31	complication	complication	NOUN
ajlm-2565	20	32	of	of	ADP
ajlm-2565	20	33	hiv	hiv	PROPN
ajlm-2565	20	34	treatment	treatment	NOUN
ajlm-2565	20	35	.	.	PUNCT
ajlm-2565	21	1	keywords	keyword	NOUN
ajlm-2565	21	2	:	:	PUNCT
ajlm-2565	21	3	hyperuricemia	hyperuricemia	ADV
ajlm-2565	21	4	;	;	PUNCT
ajlm-2565	21	5	obesity	obesity	NOUN
ajlm-2565	21	6	;	;	PUNCT
ajlm-2565	21	7	human	human	ADJ
ajlm-2565	21	8	immunodeficiency	immunodeficiency	NOUN
ajlm-2565	21	9	virus	virus	NOUN
ajlm-2565	21	10	;	;	PUNCT
ajlm-2565	21	11	antiretroviral	antiretroviral	ADJ
ajlm-2565	21	12	therapy	therapy	NOUN
ajlm-2565	21	13	;	;	PUNCT
ajlm-2565	21	14	dolutegravir	dolutegravir	PROPN
ajlm-2565	21	15	.	.	PUNCT
ajlm-2565	22	1	introduction	introduction	NOUN
ajlm-2565	22	2	serum	serum	PROPN
ajlm-2565	22	3	uric	uric	PROPN
ajlm-2565	22	4	acid	acid	PROPN
ajlm-2565	22	5	(	(	PUNCT
ajlm-2565	22	6	sua	sua	NOUN
ajlm-2565	22	7	)	)	PUNCT
ajlm-2565	22	8	is	be	AUX
ajlm-2565	22	9	the	the	DET
ajlm-2565	22	10	end	end	NOUN
ajlm-2565	22	11	product	product	NOUN
ajlm-2565	22	12	of	of	ADP
ajlm-2565	22	13	purine	purine	NOUN
ajlm-2565	22	14	metabolism	metabolism	NOUN
ajlm-2565	22	15	in	in	ADP
ajlm-2565	22	16	humans.1	humans.1	PROPN
ajlm-2565	22	17	almost	almost	ADV
ajlm-2565	22	18	two	two	NUM
ajlm-2565	22	19	-	-	PUNCT
ajlm-2565	22	20	thirds	third	NOUN
ajlm-2565	22	21	of	of	ADP
ajlm-2565	22	22	sua	sua	PROPN
ajlm-2565	22	23	is	be	AUX
ajlm-2565	22	24	produced	produce	VERB
ajlm-2565	22	25	endogenously	endogenously	ADV
ajlm-2565	22	26	,	,	PUNCT
ajlm-2565	22	27	and	and	CCONJ
ajlm-2565	22	28	the	the	DET
ajlm-2565	22	29	rest	rest	NOUN
ajlm-2565	22	30	as	as	ADP
ajlm-2565	22	31	a	a	DET
ajlm-2565	22	32	result	result	NOUN
ajlm-2565	22	33	of	of	ADP
ajlm-2565	22	34	a	a	DET
ajlm-2565	22	35	diet	diet	NOUN
ajlm-2565	22	36	abundant	abundant	ADJ
ajlm-2565	22	37	in	in	ADP
ajlm-2565	22	38	purines.2,3	purines.2,3	PROPN
ajlm-2565	22	39	the	the	DET
ajlm-2565	22	40	kidneys	kidney	NOUN
ajlm-2565	22	41	excrete	excrete	VERB
ajlm-2565	22	42	more	more	ADJ
ajlm-2565	22	43	than	than	ADP
ajlm-2565	22	44	70	70	NUM
ajlm-2565	22	45	%	%	NOUN
ajlm-2565	22	46	of	of	ADP
ajlm-2565	22	47	uric	uric	ADJ
ajlm-2565	22	48	acid	acid	NOUN
ajlm-2565	22	49	,	,	PUNCT
ajlm-2565	22	50	with	with	ADP
ajlm-2565	22	51	intestinal	intestinal	ADJ
ajlm-2565	22	52	and	and	CCONJ
ajlm-2565	22	53	biliary	biliary	NOUN
ajlm-2565	22	54	secretion	secretion	NOUN
ajlm-2565	22	55	accounting	account	VERB
ajlm-2565	22	56	for	for	ADP
ajlm-2565	22	57	a	a	DET
ajlm-2565	22	58	lesser	less	ADJ
ajlm-2565	22	59	amount.3	amount.3	ADJ
ajlm-2565	22	60	hyperuricaemia	hyperuricaemia	NOUN
ajlm-2565	22	61	and	and	CCONJ
ajlm-2565	22	62	gout	gout	NOUN
ajlm-2565	22	63	development	development	NOUN
ajlm-2565	22	64	most	most	ADV
ajlm-2565	22	65	commonly	commonly	ADV
ajlm-2565	22	66	result	result	VERB
ajlm-2565	22	67	from	from	ADP
ajlm-2565	22	68	abnormalities	abnormality	NOUN
ajlm-2565	22	69	in	in	ADP
ajlm-2565	22	70	sua	sua	NOUN
ajlm-2565	22	71	metabolism	metabolism	NOUN
ajlm-2565	22	72	and	and	CCONJ
ajlm-2565	22	73	its	its	PRON
ajlm-2565	22	74	decreased	decrease	VERB
ajlm-2565	22	75	excretion	excretion	NOUN
ajlm-2565	22	76	by	by	ADP
ajlm-2565	22	77	the	the	DET
ajlm-2565	22	78	kidneys.4	kidneys.4	PROPN
ajlm-2565	22	79	the	the	DET
ajlm-2565	22	80	prevalence	prevalence	NOUN
ajlm-2565	22	81	of	of	ADP
ajlm-2565	22	82	hyperuricaemia	hyperuricaemia	NOUN
ajlm-2565	22	83	has	have	AUX
ajlm-2565	22	84	been	be	AUX
ajlm-2565	22	85	rising	rise	VERB
ajlm-2565	22	86	rapidly	rapidly	ADV
ajlm-2565	22	87	,	,	PUNCT
ajlm-2565	22	88	worldwide	worldwide	ADV
ajlm-2565	22	89	,	,	PUNCT
ajlm-2565	22	90	in	in	ADP
ajlm-2565	22	91	recent	recent	ADJ
ajlm-2565	22	92	decades	decade	NOUN
ajlm-2565	22	93	.	.	PUNCT
ajlm-2565	23	1	reports	report	NOUN
ajlm-2565	23	2	indicate	indicate	VERB
ajlm-2565	23	3	that	that	SCONJ
ajlm-2565	23	4	the	the	DET
ajlm-2565	23	5	prevalence	prevalence	NOUN
ajlm-2565	23	6	of	of	ADP
ajlm-2565	23	7	hyperuricaemia	hyperuricaemia	NOUN
ajlm-2565	23	8	ranges	range	VERB
ajlm-2565	23	9	from	from	ADP
ajlm-2565	23	10	0.1	0.1	NUM
ajlm-2565	23	11	%	%	NOUN
ajlm-2565	23	12	to	to	PART
ajlm-2565	23	13	10	10	NUM
ajlm-2565	23	14	%	%	NOUN
ajlm-2565	23	15	globally	globally	ADV
ajlm-2565	23	16	,	,	PUNCT
ajlm-2565	23	17	with	with	ADP
ajlm-2565	23	18	an	an	DET
ajlm-2565	23	19	incidence	incidence	NOUN
ajlm-2565	23	20	of	of	ADP
ajlm-2565	23	21	0.3	0.3	NUM
ajlm-2565	23	22	to	to	PART
ajlm-2565	23	23	6	6	NUM
ajlm-2565	23	24	cases	case	NOUN
ajlm-2565	23	25	per	per	ADP
ajlm-2565	23	26	1000	1000	NUM
ajlm-2565	23	27	person	person	NOUN
ajlm-2565	23	28	years.5	years.5	PROPN
ajlm-2565	23	29	other	other	ADJ
ajlm-2565	23	30	data	datum	NOUN
ajlm-2565	23	31	indicate	indicate	VERB
ajlm-2565	23	32	that	that	SCONJ
ajlm-2565	23	33	hyperuricaemia	hyperuricaemia	NOUN
ajlm-2565	23	34	is	be	AUX
ajlm-2565	23	35	prevalent	prevalent	ADJ
ajlm-2565	23	36	not	not	PART
ajlm-2565	23	37	only	only	ADV
ajlm-2565	23	38	in	in	ADP
ajlm-2565	23	39	developed	develop	VERB
ajlm-2565	23	40	countries,6,7	countries,6,7	NOUN
ajlm-2565	23	41	but	but	CCONJ
ajlm-2565	23	42	is	be	AUX
ajlm-2565	23	43	also	also	ADV
ajlm-2565	23	44	rising	rise	VERB
ajlm-2565	23	45	more	more	ADV
ajlm-2565	23	46	frequently	frequently	ADV
ajlm-2565	23	47	in	in	ADP
ajlm-2565	23	48	lowand	lowand	ADJ
ajlm-2565	23	49	middle	middle	ADJ
ajlm-2565	23	50	-	-	PUNCT
ajlm-2565	23	51	income	income	NOUN
ajlm-2565	23	52	countries.5,8,9	countries.5,8,9	X
ajlm-2565	23	53	lifestyle	lifestyle	NOUN
ajlm-2565	23	54	factors	factor	NOUN
ajlm-2565	23	55	such	such	ADJ
ajlm-2565	23	56	as	as	ADP
ajlm-2565	23	57	physical	physical	ADJ
ajlm-2565	23	58	exercise	exercise	NOUN
ajlm-2565	23	59	,	,	PUNCT
ajlm-2565	23	60	obesity	obesity	NOUN
ajlm-2565	23	61	,	,	PUNCT
ajlm-2565	23	62	high	high	ADJ
ajlm-2565	23	63	purine	purine	NOUN
ajlm-2565	23	64	diet	diet	NOUN
ajlm-2565	23	65	,	,	PUNCT
ajlm-2565	23	66	and	and	CCONJ
ajlm-2565	23	67	alcohol	alcohol	NOUN
ajlm-2565	23	68	consumption	consumption	NOUN
ajlm-2565	23	69	have	have	AUX
ajlm-2565	23	70	been	be	AUX
ajlm-2565	23	71	highlighted	highlight	VERB
ajlm-2565	23	72	as	as	ADP
ajlm-2565	23	73	independent	independent	ADJ
ajlm-2565	23	74	indicators	indicator	NOUN
ajlm-2565	23	75	of	of	ADP
ajlm-2565	23	76	the	the	DET
ajlm-2565	23	77	emergence	emergence	NOUN
ajlm-2565	23	78	of	of	ADP
ajlm-2565	23	79	hyperuricaemia.10,11,12	hyperuricaemia.10,11,12	PUNCT
ajlm-2565	23	80	in	in	ADP
ajlm-2565	23	81	addition	addition	NOUN
ajlm-2565	23	82	,	,	PUNCT
ajlm-2565	23	83	increased	increase	VERB
ajlm-2565	23	84	endogenous	endogenous	ADJ
ajlm-2565	23	85	uric	uric	ADJ
ajlm-2565	23	86	acid	acid	NOUN
ajlm-2565	23	87	synthesis	synthesis	NOUN
ajlm-2565	23	88	and	and	CCONJ
ajlm-2565	23	89	exogenous	exogenous	ADJ
ajlm-2565	23	90	protein	protein	NOUN
ajlm-2565	23	91	consumption	consumption	NOUN
ajlm-2565	23	92	are	be	AUX
ajlm-2565	23	93	associated	associate	VERB
ajlm-2565	23	94	with	with	ADP
ajlm-2565	23	95	hyperuricaemia	hyperuricaemia	NOUN
ajlm-2565	23	96	in	in	ADP
ajlm-2565	23	97	obese	obese	ADJ
ajlm-2565	23	98	individuals.13	individuals.13	NOUN
ajlm-2565	23	99	hyperuricaemia	hyperuricaemia	NOUN
ajlm-2565	23	100	is	be	AUX
ajlm-2565	23	101	a	a	DET
ajlm-2565	23	102	significant	significant	ADJ
ajlm-2565	23	103	pathological	pathological	ADJ
ajlm-2565	23	104	condition	condition	NOUN
ajlm-2565	23	105	that	that	SCONJ
ajlm-2565	23	106	not	not	PART
ajlm-2565	23	107	only	only	ADV
ajlm-2565	23	108	causes	cause	VERB
ajlm-2565	23	109	gout	gout	NOUN
ajlm-2565	23	110	,	,	PUNCT
ajlm-2565	23	111	but	but	CCONJ
ajlm-2565	23	112	also	also	ADV
ajlm-2565	23	113	acts	act	VERB
ajlm-2565	23	114	as	as	ADP
ajlm-2565	23	115	an	an	DET
ajlm-2565	23	116	independent	independent	ADJ
ajlm-2565	23	117	risk	risk	NOUN
ajlm-2565	23	118	factor	factor	NOUN
ajlm-2565	23	119	for	for	ADP
ajlm-2565	23	120	the	the	DET
ajlm-2565	23	121	onset	onset	NOUN
ajlm-2565	23	122	of	of	ADP
ajlm-2565	23	123	several	several	ADJ
ajlm-2565	23	124	other	other	ADJ
ajlm-2565	23	125	illnesses,14	illnesses,14	ADV
ajlm-2565	23	126	such	such	ADJ
ajlm-2565	23	127	as	as	ADP
ajlm-2565	23	128	diabetes	diabetes	NOUN
ajlm-2565	23	129	mellitus,15	mellitus,15	ADP
ajlm-2565	23	130	hypertension,16,17	hypertension,16,17	PROPN
ajlm-2565	23	131	chronic	chronic	ADJ
ajlm-2565	23	132	kidney	kidney	NOUN
ajlm-2565	23	133	disease,18	disease,18	PROPN
ajlm-2565	23	134	end	end	NOUN
ajlm-2565	23	135	-	-	PUNCT
ajlm-2565	23	136	stage	stage	NOUN
ajlm-2565	23	137	kidney	kidney	NOUN
ajlm-2565	23	138	disease,19	disease,19	NOUN
ajlm-2565	23	139	obesity,20	obesity,20	ADJ
ajlm-2565	23	140	and	and	CCONJ
ajlm-2565	23	141	metabolic	metabolic	NOUN
ajlm-2565	23	142	syndrome,21	syndrome,21	NOUN
ajlm-2565	23	143	which	which	PRON
ajlm-2565	23	144	are	be	AUX
ajlm-2565	23	145	defined	define	VERB
ajlm-2565	23	146	as	as	ADP
ajlm-2565	23	147	a	a	DET
ajlm-2565	23	148	collection	collection	NOUN
ajlm-2565	23	149	of	of	ADP
ajlm-2565	23	150	risk	risk	NOUN
ajlm-2565	23	151	factors	factor	NOUN
ajlm-2565	23	152	for	for	ADP
ajlm-2565	23	153	cardiovascular	cardiovascular	ADJ
ajlm-2565	23	154	disease	disease	NOUN
ajlm-2565	23	155	,	,	PUNCT
ajlm-2565	23	156	including	include	VERB
ajlm-2565	23	157	low	low	ADJ
ajlm-2565	23	158	levels	level	NOUN
ajlm-2565	23	159	of	of	ADP
ajlm-2565	23	160	high	high	ADJ
ajlm-2565	23	161	-	-	PUNCT
ajlm-2565	23	162	density	density	NOUN
ajlm-2565	23	163	lipoprotein	lipoprotein	ADJ
ajlm-2565	23	164	cholesterol	cholesterol	NOUN
ajlm-2565	23	165	,	,	PUNCT
ajlm-2565	23	166	hypertriglyceridaemia	hypertriglyceridaemia	NOUN
ajlm-2565	23	167	,	,	PUNCT
ajlm-2565	23	168	central	central	ADJ
ajlm-2565	23	169	obesity	obesity	NOUN
ajlm-2565	23	170	,	,	PUNCT
ajlm-2565	23	171	hypertension	hypertension	NOUN
ajlm-2565	23	172	,	,	PUNCT
ajlm-2565	23	173	and	and	CCONJ
ajlm-2565	23	174	high	high	ADJ
ajlm-2565	23	175	glucose	glucose	NOUN
ajlm-2565	23	176	levels.22	levels.22	NOUN
ajlm-2565	23	177	among	among	ADP
ajlm-2565	23	178	these	these	DET
ajlm-2565	23	179	disorders	disorder	NOUN
ajlm-2565	23	180	,	,	PUNCT
ajlm-2565	23	181	obesity	obesity	NOUN
ajlm-2565	23	182	has	have	AUX
ajlm-2565	23	183	been	be	AUX
ajlm-2565	23	184	found	find	VERB
ajlm-2565	23	185	to	to	PART
ajlm-2565	23	186	be	be	AUX
ajlm-2565	23	187	spreading	spread	VERB
ajlm-2565	23	188	quickly	quickly	ADV
ajlm-2565	23	189	worldwide.23	worldwide.23	NOUN
ajlm-2565	23	190	according	accord	VERB
ajlm-2565	23	191	to	to	ADP
ajlm-2565	23	192	the	the	DET
ajlm-2565	23	193	world	world	PROPN
ajlm-2565	23	194	health	health	PROPN
ajlm-2565	23	195	organization	organization	NOUN
ajlm-2565	23	196	,	,	PUNCT
ajlm-2565	23	197	16	16	NUM
ajlm-2565	23	198	%	%	NOUN
ajlm-2565	23	199	of	of	ADP
ajlm-2565	23	200	adults	adult	NOUN
ajlm-2565	23	201	were	be	AUX
ajlm-2565	23	202	living	live	VERB
ajlm-2565	23	203	with	with	ADP
ajlm-2565	23	204	obesity	obesity	NOUN
ajlm-2565	23	205	in	in	ADP
ajlm-2565	23	206	2022.24	2022.24	NUM
ajlm-2565	23	207	in	in	ADP
ajlm-2565	23	208	addition	addition	NOUN
ajlm-2565	23	209	to	to	ADP
ajlm-2565	23	210	having	have	VERB
ajlm-2565	23	211	a	a	DET
ajlm-2565	23	212	negative	negative	ADJ
ajlm-2565	23	213	impact	impact	NOUN
ajlm-2565	23	214	on	on	ADP
ajlm-2565	23	215	a	a	DET
ajlm-2565	23	216	person	person	NOUN
ajlm-2565	23	217	’s	’s	PART
ajlm-2565	23	218	health	health	NOUN
ajlm-2565	23	219	,	,	PUNCT
ajlm-2565	23	220	obesity	obesity	NOUN
ajlm-2565	23	221	places	place	VERB
ajlm-2565	23	222	a	a	DET
ajlm-2565	23	223	heavy	heavy	ADJ
ajlm-2565	23	224	burden	burden	NOUN
ajlm-2565	23	225	on	on	ADP
ajlm-2565	23	226	the	the	DET
ajlm-2565	23	227	healthcare	healthcare	NOUN
ajlm-2565	23	228	system.25	system.25	NOUN
ajlm-2565	23	229	furthermore	furthermore	ADV
ajlm-2565	23	230	,	,	PUNCT
ajlm-2565	23	231	it	it	PRON
ajlm-2565	23	232	has	have	AUX
ajlm-2565	23	233	been	be	AUX
ajlm-2565	23	234	identified	identify	VERB
ajlm-2565	23	235	as	as	ADP
ajlm-2565	23	236	a	a	DET
ajlm-2565	23	237	risk	risk	NOUN
ajlm-2565	23	238	factor	factor	NOUN
ajlm-2565	23	239	linked	link	VERB
ajlm-2565	23	240	to	to	ADP
ajlm-2565	23	241	several	several	ADJ
ajlm-2565	23	242	detrimental	detrimental	ADJ
ajlm-2565	23	243	health	health	NOUN
ajlm-2565	23	244	outcomes	outcome	NOUN
ajlm-2565	23	245	,	,	PUNCT
ajlm-2565	23	246	such	such	ADJ
ajlm-2565	23	247	as	as	ADP
ajlm-2565	23	248	diabetes	diabetes	NOUN
ajlm-2565	23	249	,	,	PUNCT
ajlm-2565	23	250	hypertension	hypertension	NOUN
ajlm-2565	23	251	,	,	PUNCT
ajlm-2565	23	252	and	and	CCONJ
ajlm-2565	23	253	high	high	ADJ
ajlm-2565	23	254	sua	sua	NOUN
ajlm-2565	23	255	levels.6	levels.6	PROPN
ajlm-2565	23	256	a	a	DET
ajlm-2565	23	257	number	number	NOUN
ajlm-2565	23	258	of	of	ADP
ajlm-2565	23	259	studies	study	NOUN
ajlm-2565	23	260	on	on	ADP
ajlm-2565	23	261	metabolic	metabolic	NOUN
ajlm-2565	23	262	syndrome	syndrome	NOUN
ajlm-2565	23	263	indicate	indicate	VERB
ajlm-2565	23	264	that	that	SCONJ
ajlm-2565	23	265	sua	sua	NOUN
ajlm-2565	23	266	is	be	AUX
ajlm-2565	23	267	strongly	strongly	ADV
ajlm-2565	23	268	associated	associate	VERB
ajlm-2565	23	269	with	with	ADP
ajlm-2565	23	270	a	a	DET
ajlm-2565	23	271	number	number	NOUN
ajlm-2565	23	272	of	of	ADP
ajlm-2565	23	273	indices	index	NOUN
ajlm-2565	23	274	,	,	PUNCT
ajlm-2565	23	275	including	include	VERB
ajlm-2565	23	276	waist	waist	NOUN
ajlm-2565	23	277	circumference	circumference	NOUN
ajlm-2565	23	278	,	,	PUNCT
ajlm-2565	23	279	body	body	NOUN
ajlm-2565	23	280	mass	mass	NOUN
ajlm-2565	23	281	index	index	NOUN
ajlm-2565	23	282	(	(	PUNCT
ajlm-2565	23	283	bmi	bmi	PROPN
ajlm-2565	23	284	)	)	PUNCT
ajlm-2565	23	285	,	,	PUNCT
ajlm-2565	23	286	and	and	CCONJ
ajlm-2565	23	287	dyslipidaemia.20,26	dyslipidaemia.20,26	NOUN
ajlm-2565	23	288	consequently	consequently	ADV
ajlm-2565	23	289	,	,	PUNCT
ajlm-2565	23	290	hyperuricaemia	hyperuricaemia	PROPN
ajlm-2565	23	291	is	be	AUX
ajlm-2565	23	292	thought	think	VERB
ajlm-2565	23	293	to	to	PART
ajlm-2565	23	294	be	be	AUX
ajlm-2565	23	295	a	a	DET
ajlm-2565	23	296	prevalent	prevalent	ADJ
ajlm-2565	23	297	lifestyle	lifestyle	NOUN
ajlm-2565	23	298	condition	condition	NOUN
ajlm-2565	23	299	associated	associate	VERB
ajlm-2565	23	300	with	with	ADP
ajlm-2565	23	301	obesity.6,26	obesity.6,26	ADJ
ajlm-2565	23	302	obesity	obesity	NOUN
ajlm-2565	23	303	in	in	ADP
ajlm-2565	23	304	the	the	DET
ajlm-2565	23	305	last	last	ADJ
ajlm-2565	23	306	decade	decade	NOUN
ajlm-2565	23	307	has	have	AUX
ajlm-2565	23	308	been	be	AUX
ajlm-2565	23	309	linked	link	VERB
ajlm-2565	23	310	to	to	ADP
ajlm-2565	23	311	various	various	ADJ
ajlm-2565	23	312	clinical	clinical	ADJ
ajlm-2565	23	313	conditions	condition	NOUN
ajlm-2565	23	314	,	,	PUNCT
ajlm-2565	23	315	including	include	VERB
ajlm-2565	23	316	hyperuricaemia.27	hyperuricaemia.27	PROPN
ajlm-2565	23	317	because	because	SCONJ
ajlm-2565	23	318	obesity	obesity	NOUN
ajlm-2565	23	319	has	have	AUX
ajlm-2565	23	320	detrimental	detrimental	ADJ
ajlm-2565	23	321	metabolic	metabolic	NOUN
ajlm-2565	23	322	effects	effect	NOUN
ajlm-2565	23	323	that	that	PRON
ajlm-2565	23	324	lower	low	ADJ
ajlm-2565	23	325	life	life	NOUN
ajlm-2565	23	326	expectancy	expectancy	NOUN
ajlm-2565	23	327	,	,	PUNCT
ajlm-2565	23	328	increase	increase	VERB
ajlm-2565	23	329	morbidity	morbidity	NOUN
ajlm-2565	23	330	and	and	CCONJ
ajlm-2565	23	331	mortality	mortality	NOUN
ajlm-2565	23	332	,	,	PUNCT
ajlm-2565	23	333	and	and	CCONJ
ajlm-2565	23	334	negatively	negatively	ADV
ajlm-2565	23	335	impact	impact	VERB
ajlm-2565	23	336	quality	quality	NOUN
ajlm-2565	23	337	of	of	ADP
ajlm-2565	23	338	life	life	NOUN
ajlm-2565	23	339	,	,	PUNCT
ajlm-2565	23	340	it	it	PRON
ajlm-2565	23	341	poses	pose	VERB
ajlm-2565	23	342	a	a	DET
ajlm-2565	23	343	severe	severe	ADJ
ajlm-2565	23	344	danger	danger	NOUN
ajlm-2565	23	345	to	to	ADP
ajlm-2565	23	346	public	public	ADJ
ajlm-2565	23	347	health	health	NOUN
ajlm-2565	23	348	and	and	CCONJ
ajlm-2565	23	349	the	the	DET
ajlm-2565	23	350	expense	expense	NOUN
ajlm-2565	23	351	of	of	ADP
ajlm-2565	23	352	healthcare	healthcare	PROPN
ajlm-2565	23	353	globally.23	globally.23	PROPN
ajlm-2565	23	354	following	follow	VERB
ajlm-2565	23	355	world	world	PROPN
ajlm-2565	23	356	health	health	NOUN
ajlm-2565	23	357	organization	organization	NOUN
ajlm-2565	23	358	recommendations	recommendation	NOUN
ajlm-2565	23	359	in	in	ADP
ajlm-2565	23	360	2018	2018	NUM
ajlm-2565	23	361	,	,	PUNCT
ajlm-2565	23	362	dolutegravir	dolutegravir	PROPN
ajlm-2565	23	363	-	-	PUNCT
ajlm-2565	23	364	based	base	VERB
ajlm-2565	23	365	antiretroviral	antiretroviral	ADJ
ajlm-2565	23	366	therapy	therapy	NOUN
ajlm-2565	23	367	(	(	PUNCT
ajlm-2565	23	368	art	art	NOUN
ajlm-2565	23	369	)	)	PUNCT
ajlm-2565	23	370	was	be	AUX
ajlm-2565	23	371	adopted	adopt	VERB
ajlm-2565	23	372	as	as	ADP
ajlm-2565	23	373	the	the	DET
ajlm-2565	23	374	first	first	ADJ
ajlm-2565	23	375	-	-	PUNCT
ajlm-2565	23	376	line	line	NOUN
ajlm-2565	23	377	treatment	treatment	NOUN
ajlm-2565	23	378	for	for	ADP
ajlm-2565	23	379	all	all	DET
ajlm-2565	23	380	people	people	NOUN
ajlm-2565	23	381	living	live	VERB
ajlm-2565	23	382	with	with	ADP
ajlm-2565	23	383	hiv	hiv	PROPN
ajlm-2565	23	384	in	in	ADP
ajlm-2565	23	385	uganda.28	uganda.28	NOUN
ajlm-2565	23	386	despite	despite	SCONJ
ajlm-2565	23	387	its	its	PRON
ajlm-2565	23	388	benefits	benefit	NOUN
ajlm-2565	23	389	,	,	PUNCT
ajlm-2565	23	390	recent	recent	ADJ
ajlm-2565	23	391	literature	literature	NOUN
ajlm-2565	23	392	indicates	indicate	VERB
ajlm-2565	23	393	a	a	DET
ajlm-2565	23	394	strong	strong	ADJ
ajlm-2565	23	395	association	association	NOUN
ajlm-2565	23	396	between	between	ADP
ajlm-2565	23	397	the	the	DET
ajlm-2565	23	398	initiation	initiation	NOUN
ajlm-2565	23	399	on	on	ADP
ajlm-2565	23	400	dolutegravir	dolutegravir	PROPN
ajlm-2565	23	401	-	-	PUNCT
ajlm-2565	23	402	based	base	VERB
ajlm-2565	23	403	art	art	NOUN
ajlm-2565	23	404	and	and	CCONJ
ajlm-2565	23	405	subsequent	subsequent	ADJ
ajlm-2565	23	406	weight	weight	NOUN
ajlm-2565	23	407	gain	gain	NOUN
ajlm-2565	23	408	and	and	CCONJ
ajlm-2565	23	409	obesity.29,30	obesity.29,30	NOUN
ajlm-2565	23	410	however	however	ADV
ajlm-2565	23	411	,	,	PUNCT
ajlm-2565	23	412	research	research	NOUN
ajlm-2565	23	413	about	about	ADP
ajlm-2565	23	414	the	the	DET
ajlm-2565	23	415	relationship	relationship	NOUN
ajlm-2565	23	416	of	of	ADP
ajlm-2565	23	417	obesity	obesity	NOUN
ajlm-2565	23	418	and	and	CCONJ
ajlm-2565	23	419	sua	sua	NOUN
ajlm-2565	23	420	in	in	ADP
ajlm-2565	23	421	the	the	DET
ajlm-2565	23	422	hiv	hiv	PROPN
ajlm-2565	23	423	patients	patient	NOUN
ajlm-2565	23	424	receiving	receive	VERB
ajlm-2565	23	425	antiretroviral	antiretroviral	ADJ
ajlm-2565	23	426	medication	medication	NOUN
ajlm-2565	23	427	is	be	AUX
ajlm-2565	23	428	scarce	scarce	ADJ
ajlm-2565	23	429	in	in	ADP
ajlm-2565	23	430	our	our	PRON
ajlm-2565	23	431	setting	setting	NOUN
ajlm-2565	23	432	.	.	PUNCT
ajlm-2565	24	1	therefore	therefore	ADV
ajlm-2565	24	2	,	,	PUNCT
ajlm-2565	24	3	the	the	DET
ajlm-2565	24	4	aim	aim	NOUN
ajlm-2565	24	5	of	of	ADP
ajlm-2565	24	6	our	our	PRON
ajlm-2565	24	7	study	study	NOUN
ajlm-2565	24	8	was	be	AUX
ajlm-2565	24	9	to	to	PART
ajlm-2565	24	10	evaluate	evaluate	VERB
ajlm-2565	24	11	the	the	DET
ajlm-2565	24	12	prevalence	prevalence	NOUN
ajlm-2565	24	13	of	of	ADP
ajlm-2565	24	14	hyperuricaemia	hyperuricaemia	NOUN
ajlm-2565	24	15	and	and	CCONJ
ajlm-2565	24	16	its	its	PRON
ajlm-2565	24	17	relationship	relationship	NOUN
ajlm-2565	24	18	with	with	ADP
ajlm-2565	24	19	obesity	obesity	NOUN
ajlm-2565	24	20	among	among	ADP
ajlm-2565	24	21	people	people	NOUN
ajlm-2565	24	22	with	with	ADP
ajlm-2565	24	23	hiv	hiv	PROPN
ajlm-2565	24	24	on	on	ADP
ajlm-2565	24	25	art	art	NOUN
ajlm-2565	24	26	.	.	PUNCT
ajlm-2565	25	1	methods	method	NOUN
ajlm-2565	25	2	ethical	ethical	ADJ
ajlm-2565	25	3	considerations	consideration	NOUN
ajlm-2565	25	4	ethical	ethical	ADJ
ajlm-2565	25	5	clearance	clearance	NOUN
ajlm-2565	25	6	was	be	AUX
ajlm-2565	25	7	obtained	obtain	VERB
ajlm-2565	25	8	from	from	ADP
ajlm-2565	25	9	the	the	DET
ajlm-2565	25	10	research	research	NOUN
ajlm-2565	25	11	ethics	ethic	NOUN
ajlm-2565	25	12	committee	committee	PROPN
ajlm-2565	25	13	of	of	ADP
ajlm-2565	25	14	mbarara	mbarara	PROPN
ajlm-2565	25	15	university	university	PROPN
ajlm-2565	25	16	of	of	ADP
ajlm-2565	25	17	science	science	NOUN
ajlm-2565	25	18	and	and	CCONJ
ajlm-2565	25	19	technology	technology	NOUN
ajlm-2565	25	20	(	(	PUNCT
ajlm-2565	25	21	reference	reference	NOUN
ajlm-2565	25	22	no	no	INTJ
ajlm-2565	25	23	.	.	PUNCT
ajlm-2565	25	24	:	:	PUNCT
ajlm-2565	25	25	must-2023	must-2023	NOUN
ajlm-2565	25	26	-	-	SYM
ajlm-2565	25	27	1039	1039	NUM
ajlm-2565	25	28	)	)	PUNCT
ajlm-2565	25	29	on	on	ADP
ajlm-2565	25	30	13	13	NUM
ajlm-2565	25	31	september	september	PROPN
ajlm-2565	25	32	2023	2023	NUM
ajlm-2565	25	33	for	for	ADP
ajlm-2565	25	34	the	the	DET
ajlm-2565	25	35	cross	cross	ADJ
ajlm-2565	25	36	-	-	ADJ
ajlm-2565	25	37	sectional	sectional	ADJ
ajlm-2565	25	38	study	study	NOUN
ajlm-2565	25	39	whose	whose	DET
ajlm-2565	25	40	data	datum	NOUN
ajlm-2565	25	41	set	set	VERB
ajlm-2565	25	42	was	be	AUX
ajlm-2565	25	43	used	use	VERB
ajlm-2565	25	44	in	in	ADP
ajlm-2565	25	45	the	the	DET
ajlm-2565	25	46	secondary	secondary	ADJ
ajlm-2565	25	47	data	datum	NOUN
ajlm-2565	25	48	analysis	analysis	NOUN
ajlm-2565	25	49	of	of	ADP
ajlm-2565	25	50	the	the	DET
ajlm-2565	25	51	current	current	ADJ
ajlm-2565	25	52	study	study	NOUN
ajlm-2565	25	53	.	.	PUNCT
ajlm-2565	26	1	further	further	ADJ
ajlm-2565	26	2	clearance	clearance	NOUN
ajlm-2565	26	3	to	to	PART
ajlm-2565	26	4	use	use	VERB
ajlm-2565	26	5	the	the	DET
ajlm-2565	26	6	primary	primary	ADJ
ajlm-2565	26	7	data	datum	NOUN
ajlm-2565	26	8	for	for	ADP
ajlm-2565	26	9	secondary	secondary	ADJ
ajlm-2565	26	10	data	datum	NOUN
ajlm-2565	26	11	analysis	analysis	NOUN
ajlm-2565	26	12	was	be	AUX
ajlm-2565	26	13	obtained	obtain	VERB
ajlm-2565	26	14	from	from	ADP
ajlm-2565	26	15	the	the	DET
ajlm-2565	26	16	research	research	NOUN
ajlm-2565	26	17	ethics	ethic	NOUN
ajlm-2565	26	18	committee	committee	PROPN
ajlm-2565	26	19	of	of	ADP
ajlm-2565	26	20	mbarara	mbarara	PROPN
ajlm-2565	26	21	university	university	PROPN
ajlm-2565	26	22	of	of	ADP
ajlm-2565	26	23	science	science	NOUN
ajlm-2565	26	24	and	and	CCONJ
ajlm-2565	26	25	technology	technology	NOUN
ajlm-2565	26	26	(	(	PUNCT
ajlm-2565	26	27	reference	reference	NOUN
ajlm-2565	26	28	no	no	INTJ
ajlm-2565	26	29	.	.	PUNCT
ajlm-2565	26	30	:	:	PUNCT
ajlm-2565	27	1	36/05	36/05	NUM
ajlm-2565	27	2	-	-	SYM
ajlm-2565	27	3	17	17	NUM
ajlm-2565	27	4	/	/	SYM
ajlm-2565	27	5	must-2023	must-2023	NOUN
ajlm-2565	27	6	-	-	PUNCT
ajlm-2565	27	7	1039	1039	NUM
ajlm-2565	27	8	)	)	PUNCT
ajlm-2565	27	9	.	.	PUNCT
ajlm-2565	28	1	in	in	ADP
ajlm-2565	28	2	addition	addition	NOUN
ajlm-2565	28	3	,	,	PUNCT
ajlm-2565	28	4	the	the	DET
ajlm-2565	28	5	principal	principal	ADJ
ajlm-2565	28	6	investigator	investigator	NOUN
ajlm-2565	28	7	and	and	CCONJ
ajlm-2565	28	8	the	the	DET
ajlm-2565	28	9	research	research	NOUN
ajlm-2565	28	10	assistants	assistant	NOUN
ajlm-2565	28	11	of	of	ADP
ajlm-2565	28	12	the	the	DET
ajlm-2565	28	13	primary	primary	ADJ
ajlm-2565	28	14	study	study	NOUN
ajlm-2565	28	15	obtained	obtain	VERB
ajlm-2565	28	16	informed	informed	ADJ
ajlm-2565	28	17	written	write	VERB
ajlm-2565	28	18	consent	consent	NOUN
ajlm-2565	28	19	from	from	ADP
ajlm-2565	28	20	each	each	DET
ajlm-2565	28	21	participant	participant	NOUN
ajlm-2565	28	22	before	before	ADP
ajlm-2565	28	23	enrollment	enrollment	NOUN
ajlm-2565	28	24	into	into	ADP
ajlm-2565	28	25	the	the	DET
ajlm-2565	28	26	study	study	NOUN
ajlm-2565	28	27	.	.	PUNCT
ajlm-2565	29	1	standard	standard	ADJ
ajlm-2565	29	2	clinical	clinical	ADJ
ajlm-2565	29	3	procedures	procedure	NOUN
ajlm-2565	29	4	and	and	CCONJ
ajlm-2565	29	5	regulations	regulation	NOUN
ajlm-2565	29	6	were	be	AUX
ajlm-2565	29	7	followed	follow	VERB
ajlm-2565	29	8	,	,	PUNCT
ajlm-2565	29	9	and	and	CCONJ
ajlm-2565	29	10	privacy	privacy	NOUN
ajlm-2565	29	11	,	,	PUNCT
ajlm-2565	29	12	anonymity	anonymity	NOUN
ajlm-2565	29	13	,	,	PUNCT
ajlm-2565	29	14	and	and	CCONJ
ajlm-2565	29	15	confidentiality	confidentiality	NOUN
ajlm-2565	29	16	were	be	AUX
ajlm-2565	29	17	protected	protect	VERB
ajlm-2565	29	18	during	during	ADP
ajlm-2565	29	19	data	data	NOUN
ajlm-2565	29	20	collection	collection	NOUN
ajlm-2565	29	21	and	and	CCONJ
ajlm-2565	29	22	handling	handling	NOUN
ajlm-2565	29	23	in	in	ADP
ajlm-2565	29	24	the	the	DET
ajlm-2565	29	25	primary	primary	ADJ
ajlm-2565	29	26	study	study	NOUN
ajlm-2565	29	27	.	.	PUNCT
ajlm-2565	30	1	the	the	DET
ajlm-2565	30	2	participants	participant	NOUN
ajlm-2565	30	3	were	be	AUX
ajlm-2565	30	4	selected	select	VERB
ajlm-2565	30	5	using	use	VERB
ajlm-2565	30	6	simple	simple	ADJ
ajlm-2565	30	7	random	random	ADJ
ajlm-2565	30	8	sampling	sampling	NOUN
ajlm-2565	30	9	and	and	CCONJ
ajlm-2565	30	10	allotted	allotted	ADJ
ajlm-2565	30	11	identification	identification	NOUN
ajlm-2565	30	12	numbers	number	NOUN
ajlm-2565	30	13	to	to	PART
ajlm-2565	30	14	replace	replace	VERB
ajlm-2565	30	15	names	name	NOUN
ajlm-2565	30	16	.	.	PUNCT
ajlm-2565	31	1	the	the	DET
ajlm-2565	31	2	questionnaires	questionnaire	NOUN
ajlm-2565	31	3	were	be	AUX
ajlm-2565	31	4	locked	lock	VERB
ajlm-2565	31	5	in	in	ADP
ajlm-2565	31	6	a	a	DET
ajlm-2565	31	7	cabin	cabin	NOUN
ajlm-2565	31	8	accessed	access	VERB
ajlm-2565	31	9	by	by	ADP
ajlm-2565	31	10	only	only	ADV
ajlm-2565	31	11	the	the	DET
ajlm-2565	31	12	principal	principal	ADJ
ajlm-2565	31	13	investigator	investigator	NOUN
ajlm-2565	31	14	.	.	PUNCT
ajlm-2565	32	1	the	the	DET
ajlm-2565	32	2	data	datum	NOUN
ajlm-2565	32	3	set	set	VERB
ajlm-2565	32	4	obtained	obtain	VERB
ajlm-2565	32	5	from	from	ADP
ajlm-2565	32	6	the	the	DET
ajlm-2565	32	7	primary	primary	ADJ
ajlm-2565	32	8	study	study	NOUN
ajlm-2565	32	9	was	be	AUX
ajlm-2565	32	10	used	use	VERB
ajlm-2565	32	11	purposely	purposely	ADV
ajlm-2565	32	12	for	for	ADP
ajlm-2565	32	13	secondary	secondary	ADJ
ajlm-2565	32	14	data	datum	NOUN
ajlm-2565	32	15	analysis	analysis	NOUN
ajlm-2565	32	16	based	base	VERB
ajlm-2565	32	17	on	on	ADP
ajlm-2565	32	18	the	the	DET
ajlm-2565	32	19	ethical	ethical	ADJ
ajlm-2565	32	20	clearance	clearance	NOUN
ajlm-2565	32	21	.	.	PUNCT
ajlm-2565	33	1	all	all	DET
ajlm-2565	33	2	data	datum	NOUN
ajlm-2565	33	3	were	be	AUX
ajlm-2565	33	4	handled	handle	VERB
ajlm-2565	33	5	according	accord	VERB
ajlm-2565	33	6	to	to	ADP
ajlm-2565	33	7	national	national	ADJ
ajlm-2565	33	8	and	and	CCONJ
ajlm-2565	33	9	international	international	ADJ
ajlm-2565	33	10	data	datum	NOUN
ajlm-2565	33	11	protection	protection	NOUN
ajlm-2565	33	12	regulations	regulation	NOUN
ajlm-2565	33	13	,	,	PUNCT
ajlm-2565	33	14	to	to	PART
ajlm-2565	33	15	ensure	ensure	VERB
ajlm-2565	33	16	that	that	SCONJ
ajlm-2565	33	17	the	the	DET
ajlm-2565	33	18	participants	participant	NOUN
ajlm-2565	33	19	’	’	PART
ajlm-2565	33	20	rights	right	NOUN
ajlm-2565	33	21	and	and	CCONJ
ajlm-2565	33	22	privacy	privacy	NOUN
ajlm-2565	33	23	were	be	AUX
ajlm-2565	33	24	respected	respect	VERB
ajlm-2565	33	25	.	.	PUNCT
ajlm-2565	34	1	study	study	NOUN
ajlm-2565	34	2	design	design	NOUN
ajlm-2565	34	3	,	,	PUNCT
ajlm-2565	34	4	setting	set	VERB
ajlm-2565	34	5	and	and	CCONJ
ajlm-2565	34	6	population	population	NOUN
ajlm-2565	34	7	this	this	DET
ajlm-2565	34	8	study	study	NOUN
ajlm-2565	34	9	was	be	AUX
ajlm-2565	34	10	a	a	DET
ajlm-2565	34	11	secondary	secondary	ADJ
ajlm-2565	34	12	data	data	NOUN
ajlm-2565	34	13	analysis	analysis	NOUN
ajlm-2565	34	14	of	of	ADP
ajlm-2565	34	15	a	a	DET
ajlm-2565	34	16	data	datum	NOUN
ajlm-2565	34	17	set	set	VERB
ajlm-2565	34	18	from	from	ADP
ajlm-2565	34	19	a	a	DET
ajlm-2565	34	20	cross	cross	ADJ
ajlm-2565	34	21	-	-	ADJ
ajlm-2565	34	22	sectional	sectional	ADJ
ajlm-2565	34	23	study	study	NOUN
ajlm-2565	34	24	conducted	conduct	VERB
ajlm-2565	34	25	among	among	ADP
ajlm-2565	34	26	hiv	hiv	PROPN
ajlm-2565	34	27	-	-	PUNCT
ajlm-2565	34	28	positive	positive	ADJ
ajlm-2565	34	29	participants	participant	NOUN
ajlm-2565	34	30	on	on	ADP
ajlm-2565	34	31	art	art	NOUN
ajlm-2565	34	32	from	from	ADP
ajlm-2565	34	33	21	21	NUM
ajlm-2565	34	34	september	september	PROPN
ajlm-2565	34	35	2023	2023	NUM
ajlm-2565	34	36	to	to	ADP
ajlm-2565	34	37	21	21	NUM
ajlm-2565	34	38	october	october	PROPN
ajlm-2565	34	39	2023	2023	NUM
ajlm-2565	34	40	at	at	ADP
ajlm-2565	34	41	mbarara	mbarara	PROPN
ajlm-2565	34	42	municipal	municipal	PROPN
ajlm-2565	34	43	council	council	PROPN
ajlm-2565	34	44	health	health	PROPN
ajlm-2565	34	45	centre	centre	PROPN
ajlm-2565	34	46	iv	iv	ADP
ajlm-2565	34	47	,	,	PUNCT
ajlm-2565	34	48	south	south	ADJ
ajlm-2565	34	49	-	-	PUNCT
ajlm-2565	34	50	western	western	ADJ
ajlm-2565	34	51	uganda	uganda	PROPN
ajlm-2565	34	52	.	.	PUNCT
ajlm-2565	35	1	the	the	DET
ajlm-2565	35	2	title	title	NOUN
ajlm-2565	35	3	of	of	ADP
ajlm-2565	35	4	the	the	DET
ajlm-2565	35	5	cross	cross	ADJ
ajlm-2565	35	6	-	-	ADJ
ajlm-2565	35	7	sectional	sectional	ADJ
ajlm-2565	35	8	study	study	NOUN
ajlm-2565	35	9	whose	whose	DET
ajlm-2565	35	10	data	datum	NOUN
ajlm-2565	35	11	set	set	NOUN
ajlm-2565	35	12	has	have	AUX
ajlm-2565	35	13	been	be	AUX
ajlm-2565	35	14	used	use	VERB
ajlm-2565	35	15	for	for	ADP
ajlm-2565	35	16	secondary	secondary	ADJ
ajlm-2565	35	17	analysis	analysis	NOUN
ajlm-2565	35	18	was	be	AUX
ajlm-2565	35	19	‘	'	PUNCT
ajlm-2565	35	20	correlation	correlation	NOUN
ajlm-2565	35	21	of	of	ADP
ajlm-2565	35	22	serum	serum	NOUN
ajlm-2565	35	23	uric	uric	ADJ
ajlm-2565	35	24	acid	acid	NOUN
ajlm-2565	35	25	/	/	SYM
ajlm-2565	35	26	serum	serum	NOUN
ajlm-2565	35	27	creatinine	creatinine	NOUN
ajlm-2565	35	28	ratio	ratio	NOUN
ajlm-2565	35	29	with	with	ADP
ajlm-2565	35	30	estimated	estimate	VERB
ajlm-2565	35	31	glomerular	glomerular	ADJ
ajlm-2565	35	32	filtration	filtration	NOUN
ajlm-2565	35	33	rate	rate	NOUN
ajlm-2565	35	34	in	in	ADP
ajlm-2565	35	35	predicting	predict	VERB
ajlm-2565	35	36	kidney	kidney	NOUN
ajlm-2565	35	37	dysfunction	dysfunction	NOUN
ajlm-2565	35	38	among	among	ADP
ajlm-2565	35	39	people	people	NOUN
ajlm-2565	35	40	living	live	VERB
ajlm-2565	35	41	with	with	ADP
ajlm-2565	35	42	hiv	hiv	PROPN
ajlm-2565	35	43	at	at	ADP
ajlm-2565	35	44	mbarara	mbarara	PROPN
ajlm-2565	35	45	municipal	municipal	PROPN
ajlm-2565	35	46	council	council	PROPN
ajlm-2565	35	47	health	health	PROPN
ajlm-2565	35	48	centre	centre	PROPN
ajlm-2565	35	49	iv	iv	X
ajlm-2565	35	50	,	,	PUNCT
ajlm-2565	35	51	uganda’.31	uganda’.31	ADP
ajlm-2565	35	52	the	the	DET
ajlm-2565	35	53	source	source	NOUN
ajlm-2565	35	54	population	population	NOUN
ajlm-2565	35	55	of	of	ADP
ajlm-2565	35	56	the	the	DET
ajlm-2565	35	57	cross	cross	ADJ
ajlm-2565	35	58	-	-	ADJ
ajlm-2565	35	59	sectional	sectional	ADJ
ajlm-2565	35	60	study	study	NOUN
ajlm-2565	35	61	was	be	AUX
ajlm-2565	35	62	all	all	PRON
ajlm-2565	35	63	adult	adult	VERB
ajlm-2565	35	64	hiv	hiv	NOUN
ajlm-2565	35	65	-	-	PUNCT
ajlm-2565	35	66	positive	positive	ADJ
ajlm-2565	35	67	patients	patient	NOUN
ajlm-2565	35	68	on	on	ADP
ajlm-2565	35	69	art	art	NOUN
ajlm-2565	35	70	,	,	PUNCT
ajlm-2565	35	71	while	while	SCONJ
ajlm-2565	35	72	those	those	DET
ajlm-2565	35	73	systematically	systematically	ADV
ajlm-2565	35	74	selected	select	VERB
ajlm-2565	35	75	hiv	hiv	PROPN
ajlm-2565	35	76	-	-	PUNCT
ajlm-2565	35	77	positive	positive	ADJ
ajlm-2565	35	78	patients	patient	NOUN
ajlm-2565	35	79	attending	attend	VERB
ajlm-2565	35	80	mbarara	mbarara	ADJ
ajlm-2565	35	81	municipal	municipal	ADJ
ajlm-2565	35	82	council	council	PROPN
ajlm-2565	35	83	health	health	PROPN
ajlm-2565	35	84	centre	centre	PROPN
ajlm-2565	35	85	iv	iv	NUM
ajlm-2565	35	86	art	art	NOUN
ajlm-2565	35	87	clinic	clinic	NOUN
ajlm-2565	35	88	during	during	ADP
ajlm-2565	35	89	the	the	DET
ajlm-2565	35	90	period	period	NOUN
ajlm-2565	35	91	of	of	ADP
ajlm-2565	35	92	data	datum	NOUN
ajlm-2565	35	93	collection	collection	NOUN
ajlm-2565	35	94	were	be	AUX
ajlm-2565	35	95	the	the	DET
ajlm-2565	35	96	study	study	NOUN
ajlm-2565	35	97	population	population	NOUN
ajlm-2565	35	98	.	.	PUNCT
ajlm-2565	36	1	sample	sample	NOUN
ajlm-2565	36	2	size	size	NOUN
ajlm-2565	36	3	and	and	CCONJ
ajlm-2565	36	4	sampling	sample	VERB
ajlm-2565	36	5	technique	technique	NOUN
ajlm-2565	36	6	the	the	DET
ajlm-2565	36	7	primary	primary	ADJ
ajlm-2565	36	8	study	study	NOUN
ajlm-2565	36	9	used	use	VERB
ajlm-2565	36	10	the	the	DET
ajlm-2565	36	11	kish	kish	NOUN
ajlm-2565	36	12	and	and	CCONJ
ajlm-2565	36	13	lesly	lesly	ADV
ajlm-2565	36	14	formula	formula	NOUN
ajlm-2565	36	15	to	to	PART
ajlm-2565	36	16	calculate	calculate	VERB
ajlm-2565	36	17	the	the	DET
ajlm-2565	36	18	sample	sample	NOUN
ajlm-2565	36	19	size	size	NOUN
ajlm-2565	36	20	.	.	PUNCT
ajlm-2565	37	1	the	the	DET
ajlm-2565	37	2	sample	sample	NOUN
ajlm-2565	37	3	size	size	NOUN
ajlm-2565	37	4	of	of	ADP
ajlm-2565	37	5	328	328	NUM
ajlm-2565	37	6	study	study	NOUN
ajlm-2565	37	7	participants	participant	NOUN
ajlm-2565	37	8	was	be	AUX
ajlm-2565	37	9	established	establish	VERB
ajlm-2565	37	10	in	in	ADP
ajlm-2565	37	11	the	the	DET
ajlm-2565	37	12	cross	cross	ADJ
ajlm-2565	37	13	-	-	ADJ
ajlm-2565	37	14	sectional	sectional	ADJ
ajlm-2565	37	15	study	study	NOUN
ajlm-2565	37	16	whose	whose	DET
ajlm-2565	37	17	major	major	ADJ
ajlm-2565	37	18	variable	variable	NOUN
ajlm-2565	37	19	was	be	AUX
ajlm-2565	37	20	kidney	kidney	NOUN
ajlm-2565	37	21	dysfunction	dysfunction	NOUN
ajlm-2565	37	22	.	.	PUNCT
ajlm-2565	38	1	a	a	DET
ajlm-2565	38	2	systematic	systematic	ADJ
ajlm-2565	38	3	sampling	sampling	NOUN
ajlm-2565	38	4	technique	technique	NOUN
ajlm-2565	38	5	was	be	AUX
ajlm-2565	38	6	used	use	VERB
ajlm-2565	38	7	to	to	PART
ajlm-2565	38	8	select	select	VERB
ajlm-2565	38	9	adult	adult	NOUN
ajlm-2565	38	10	hiv	hiv	NOUN
ajlm-2565	38	11	-	-	PUNCT
ajlm-2565	38	12	positive	positive	ADJ
ajlm-2565	38	13	patients	patient	NOUN
ajlm-2565	38	14	receiving	receive	VERB
ajlm-2565	38	15	art	art	NOUN
ajlm-2565	38	16	in	in	ADP
ajlm-2565	38	17	the	the	DET
ajlm-2565	38	18	clinic	clinic	NOUN
ajlm-2565	38	19	to	to	PART
ajlm-2565	38	20	participate	participate	VERB
ajlm-2565	38	21	in	in	ADP
ajlm-2565	38	22	the	the	DET
ajlm-2565	38	23	cross	cross	ADJ
ajlm-2565	38	24	-	-	ADJ
ajlm-2565	38	25	sectional	sectional	ADJ
ajlm-2565	38	26	study	study	NOUN
ajlm-2565	38	27	.	.	PUNCT
ajlm-2565	39	1	eligibility	eligibility	NOUN
ajlm-2565	39	2	criteria	criteria	VERB
ajlm-2565	39	3	the	the	DET
ajlm-2565	39	4	cross	cross	ADJ
ajlm-2565	39	5	-	-	ADJ
ajlm-2565	39	6	sectional	sectional	ADJ
ajlm-2565	39	7	study	study	NOUN
ajlm-2565	39	8	included	include	VERB
ajlm-2565	39	9	all	all	DET
ajlm-2565	39	10	adult	adult	NOUN
ajlm-2565	39	11	hiv	hiv	NOUN
ajlm-2565	39	12	-	-	PUNCT
ajlm-2565	39	13	positive	positive	ADJ
ajlm-2565	39	14	patients	patient	NOUN
ajlm-2565	39	15	who	who	PRON
ajlm-2565	39	16	were	be	AUX
ajlm-2565	39	17	aged	age	VERB
ajlm-2565	39	18	18	18	NUM
ajlm-2565	39	19	years	year	NOUN
ajlm-2565	39	20	and	and	CCONJ
ajlm-2565	39	21	above	above	ADV
ajlm-2565	39	22	,	,	PUNCT
ajlm-2565	39	23	and	and	CCONJ
ajlm-2565	39	24	who	who	PRON
ajlm-2565	39	25	had	have	AUX
ajlm-2565	39	26	been	be	AUX
ajlm-2565	39	27	on	on	ADP
ajlm-2565	39	28	art	art	NOUN
ajlm-2565	39	29	for	for	ADP
ajlm-2565	39	30	at	at	ADV
ajlm-2565	39	31	least	least	ADV
ajlm-2565	39	32	12	12	NUM
ajlm-2565	39	33	months	month	NOUN
ajlm-2565	39	34	,	,	PUNCT
ajlm-2565	39	35	using	use	VERB
ajlm-2565	39	36	a	a	DET
ajlm-2565	39	37	systematic	systematic	ADJ
ajlm-2565	39	38	selection	selection	NOUN
ajlm-2565	39	39	procedure	procedure	NOUN
ajlm-2565	39	40	.	.	PUNCT
ajlm-2565	40	1	however	however	ADV
ajlm-2565	40	2	,	,	PUNCT
ajlm-2565	40	3	the	the	DET
ajlm-2565	40	4	study	study	NOUN
ajlm-2565	40	5	excluded	exclude	VERB
ajlm-2565	40	6	adult	adult	NOUN
ajlm-2565	40	7	hiv	hiv	PROPN
ajlm-2565	40	8	-	-	PUNCT
ajlm-2565	40	9	positive	positive	ADJ
ajlm-2565	40	10	patients	patient	NOUN
ajlm-2565	40	11	receiving	receive	VERB
ajlm-2565	40	12	art	art	NOUN
ajlm-2565	40	13	who	who	PRON
ajlm-2565	40	14	had	have	AUX
ajlm-2565	40	15	known	know	VERB
ajlm-2565	40	16	kidney	kidney	NOUN
ajlm-2565	40	17	-	-	PUNCT
ajlm-2565	40	18	related	relate	VERB
ajlm-2565	40	19	illnesses	illness	NOUN
ajlm-2565	40	20	,	,	PUNCT
ajlm-2565	40	21	as	as	ADV
ajlm-2565	40	22	well	well	ADV
ajlm-2565	40	23	as	as	ADP
ajlm-2565	40	24	those	those	PRON
ajlm-2565	40	25	who	who	PRON
ajlm-2565	40	26	were	be	AUX
ajlm-2565	40	27	unable	unable	ADJ
ajlm-2565	40	28	to	to	PART
ajlm-2565	40	29	communicate	communicate	VERB
ajlm-2565	40	30	.	.	PUNCT
ajlm-2565	41	1	variables	variable	NOUN
ajlm-2565	41	2	and	and	CCONJ
ajlm-2565	41	3	equipment	equipment	VERB
ajlm-2565	41	4	the	the	DET
ajlm-2565	41	5	major	major	ADJ
ajlm-2565	41	6	outcome	outcome	NOUN
ajlm-2565	41	7	variable	variable	NOUN
ajlm-2565	41	8	in	in	ADP
ajlm-2565	41	9	the	the	DET
ajlm-2565	41	10	cross	cross	ADJ
ajlm-2565	41	11	-	-	ADJ
ajlm-2565	41	12	sectional	sectional	ADJ
ajlm-2565	41	13	study	study	NOUN
ajlm-2565	41	14	was	be	AUX
ajlm-2565	41	15	kidney	kidney	NOUN
ajlm-2565	41	16	dysfunction	dysfunction	NOUN
ajlm-2565	41	17	,	,	PUNCT
ajlm-2565	41	18	which	which	PRON
ajlm-2565	41	19	was	be	AUX
ajlm-2565	41	20	defined	define	VERB
ajlm-2565	41	21	as	as	ADP
ajlm-2565	41	22	an	an	DET
ajlm-2565	41	23	estimated	estimate	VERB
ajlm-2565	41	24	glomerular	glomerular	ADJ
ajlm-2565	41	25	filtration	filtration	NOUN
ajlm-2565	41	26	rate	rate	NOUN
ajlm-2565	41	27	(	(	PUNCT
ajlm-2565	41	28	egfr	egfr	X
ajlm-2565	41	29	)	)	PUNCT
ajlm-2565	41	30	<	<	X
ajlm-2565	42	1	90	90	NUM
ajlm-2565	42	2	ml	ml	NOUN
ajlm-2565	42	3	/	/	SYM
ajlm-2565	42	4	min	min	NOUN
ajlm-2565	42	5	,	,	PUNCT
ajlm-2565	42	6	and	and	CCONJ
ajlm-2565	42	7	the	the	DET
ajlm-2565	42	8	main	main	ADJ
ajlm-2565	42	9	exposure	exposure	NOUN
ajlm-2565	42	10	variable	variable	NOUN
ajlm-2565	42	11	was	be	AUX
ajlm-2565	42	12	sua	sua	NOUN
ajlm-2565	42	13	/	/	SYM
ajlm-2565	42	14	creatinine	creatinine	NOUN
ajlm-2565	42	15	ratio	ratio	NOUN
ajlm-2565	42	16	.	.	PUNCT
ajlm-2565	43	1	in	in	ADP
ajlm-2565	43	2	this	this	DET
ajlm-2565	43	3	secondary	secondary	ADJ
ajlm-2565	43	4	data	datum	NOUN
ajlm-2565	43	5	analysis	analysis	NOUN
ajlm-2565	43	6	study	study	NOUN
ajlm-2565	43	7	,	,	PUNCT
ajlm-2565	43	8	the	the	DET
ajlm-2565	43	9	main	main	ADJ
ajlm-2565	43	10	outcome	outcome	NOUN
ajlm-2565	43	11	variable	variable	NOUN
ajlm-2565	43	12	was	be	AUX
ajlm-2565	43	13	hyperuricaemia	hyperuricaemia	NOUN
ajlm-2565	43	14	.	.	PUNCT
ajlm-2565	44	1	body	body	NOUN
ajlm-2565	44	2	mass	mass	PROPN
ajlm-2565	44	3	index	index	NOUN
ajlm-2565	44	4	is	be	AUX
ajlm-2565	44	5	categorised	categorise	VERB
ajlm-2565	44	6	into	into	ADP
ajlm-2565	44	7	<	<	X
ajlm-2565	44	8	25	25	NUM
ajlm-2565	44	9	kg	kg	NOUN
ajlm-2565	44	10	/	/	SYM
ajlm-2565	44	11	m2	m2	PROPN
ajlm-2565	44	12	(	(	PUNCT
ajlm-2565	44	13	normal	normal	ADJ
ajlm-2565	44	14	weight	weight	NOUN
ajlm-2565	44	15	)	)	PUNCT
ajlm-2565	44	16	,	,	PUNCT
ajlm-2565	44	17	25	25	NUM
ajlm-2565	44	18	kg	kg	NOUN
ajlm-2565	44	19	/	/	SYM
ajlm-2565	44	20	m2	m2	PROPN
ajlm-2565	44	21	–	–	PUNCT
ajlm-2565	44	22	29.9	29.9	NUM
ajlm-2565	44	23	kg	kg	NOUN
ajlm-2565	44	24	/	/	SYM
ajlm-2565	44	25	m2	m2	PROPN
ajlm-2565	44	26	(	(	PUNCT
ajlm-2565	44	27	overweight	overweight	NOUN
ajlm-2565	44	28	)	)	PUNCT
ajlm-2565	44	29	,	,	PUNCT
ajlm-2565	44	30	and	and	CCONJ
ajlm-2565	44	31	≥	≥	NUM
ajlm-2565	44	32	30	30	NUM
ajlm-2565	44	33	kg	kg	NOUN
ajlm-2565	44	34	/	/	SYM
ajlm-2565	44	35	m2	m2	PROPN
ajlm-2565	44	36	(	(	PUNCT
ajlm-2565	44	37	obesity	obesity	NOUN
ajlm-2565	44	38	)	)	PUNCT
ajlm-2565	44	39	,	,	PUNCT
ajlm-2565	44	40	and	and	CCONJ
ajlm-2565	44	41	was	be	AUX
ajlm-2565	44	42	the	the	DET
ajlm-2565	44	43	major	major	ADJ
ajlm-2565	44	44	independent	independent	ADJ
ajlm-2565	44	45	variable	variable	NOUN
ajlm-2565	44	46	.	.	PUNCT
ajlm-2565	45	1	the	the	DET
ajlm-2565	45	2	other	other	ADJ
ajlm-2565	45	3	independent	independent	ADJ
ajlm-2565	45	4	variables	variable	NOUN
ajlm-2565	45	5	that	that	PRON
ajlm-2565	45	6	were	be	AUX
ajlm-2565	45	7	explored	explore	VERB
ajlm-2565	45	8	in	in	ADP
ajlm-2565	45	9	the	the	DET
ajlm-2565	45	10	data	datum	NOUN
ajlm-2565	45	11	set	set	VERB
ajlm-2565	45	12	for	for	ADP
ajlm-2565	45	13	their	their	PRON
ajlm-2565	45	14	relationship	relationship	NOUN
ajlm-2565	45	15	with	with	ADP
ajlm-2565	45	16	hyperuricaemia	hyperuricaemia	NOUN
ajlm-2565	45	17	included	include	VERB
ajlm-2565	45	18	social	social	ADJ
ajlm-2565	45	19	demographics	demographic	NOUN
ajlm-2565	45	20	(	(	PUNCT
ajlm-2565	45	21	gender	gender	NOUN
ajlm-2565	45	22	,	,	PUNCT
ajlm-2565	45	23	marital	marital	ADJ
ajlm-2565	45	24	status	status	NOUN
ajlm-2565	45	25	,	,	PUNCT
ajlm-2565	45	26	education	education	NOUN
ajlm-2565	45	27	level	level	NOUN
ajlm-2565	45	28	,	,	PUNCT
ajlm-2565	45	29	religion	religion	NOUN
ajlm-2565	45	30	,	,	PUNCT
ajlm-2565	45	31	employment	employment	NOUN
ajlm-2565	45	32	status	status	NOUN
ajlm-2565	45	33	,	,	PUNCT
ajlm-2565	45	34	residence	residence	NOUN
ajlm-2565	45	35	)	)	PUNCT
ajlm-2565	45	36	,	,	PUNCT
ajlm-2565	45	37	smoking	smoking	NOUN
ajlm-2565	45	38	status	status	NOUN
ajlm-2565	45	39	,	,	PUNCT
ajlm-2565	45	40	alcohol	alcohol	NOUN
ajlm-2565	45	41	consumption	consumption	NOUN
ajlm-2565	45	42	status	status	NOUN
ajlm-2565	45	43	,	,	PUNCT
ajlm-2565	45	44	blood	blood	NOUN
ajlm-2565	45	45	pressure	pressure	NOUN
ajlm-2565	45	46	(	(	PUNCT
ajlm-2565	45	47	bp	bp	PROPN
ajlm-2565	45	48	)	)	PUNCT
ajlm-2565	45	49	,	,	PUNCT
ajlm-2565	45	50	physical	physical	ADJ
ajlm-2565	45	51	activity	activity	NOUN
ajlm-2565	45	52	,	,	PUNCT
ajlm-2565	45	53	family	family	NOUN
ajlm-2565	45	54	history	history	NOUN
ajlm-2565	45	55	of	of	ADP
ajlm-2565	45	56	hypertension	hypertension	NOUN
ajlm-2565	45	57	,	,	PUNCT
ajlm-2565	45	58	family	family	NOUN
ajlm-2565	45	59	history	history	NOUN
ajlm-2565	45	60	of	of	ADP
ajlm-2565	45	61	kidney	kidney	NOUN
ajlm-2565	45	62	disease	disease	NOUN
ajlm-2565	45	63	,	,	PUNCT
ajlm-2565	45	64	family	family	NOUN
ajlm-2565	45	65	history	history	NOUN
ajlm-2565	45	66	of	of	ADP
ajlm-2565	45	67	cardiovascular	cardiovascular	ADJ
ajlm-2565	45	68	disease	disease	NOUN
ajlm-2565	45	69	,	,	PUNCT
ajlm-2565	45	70	duration	duration	NOUN
ajlm-2565	45	71	on	on	ADP
ajlm-2565	45	72	art	art	NOUN
ajlm-2565	45	73	,	,	PUNCT
ajlm-2565	45	74	viral	viral	ADJ
ajlm-2565	45	75	load	load	NOUN
ajlm-2565	45	76	,	,	PUNCT
ajlm-2565	45	77	egfr	egfr	NOUN
ajlm-2565	45	78	,	,	PUNCT
ajlm-2565	45	79	and	and	CCONJ
ajlm-2565	45	80	creatinine	creatinine	NOUN
ajlm-2565	45	81	level	level	NOUN
ajlm-2565	45	82	.	.	PUNCT
ajlm-2565	46	1	the	the	DET
ajlm-2565	46	2	information	information	NOUN
ajlm-2565	46	3	on	on	ADP
ajlm-2565	46	4	social	social	ADJ
ajlm-2565	46	5	demographics	demographic	NOUN
ajlm-2565	46	6	,	,	PUNCT
ajlm-2565	46	7	family	family	NOUN
ajlm-2565	46	8	background	background	NOUN
ajlm-2565	46	9	for	for	ADP
ajlm-2565	46	10	chronic	chronic	ADJ
ajlm-2565	46	11	diseases	disease	NOUN
ajlm-2565	46	12	(	(	PUNCT
ajlm-2565	46	13	hypertension	hypertension	NOUN
ajlm-2565	46	14	,	,	PUNCT
ajlm-2565	46	15	kidney	kidney	NOUN
ajlm-2565	46	16	disease	disease	NOUN
ajlm-2565	46	17	,	,	PUNCT
ajlm-2565	46	18	cardiovascular	cardiovascular	ADJ
ajlm-2565	46	19	diseases	disease	NOUN
ajlm-2565	46	20	)	)	PUNCT
ajlm-2565	46	21	,	,	PUNCT
ajlm-2565	46	22	and	and	CCONJ
ajlm-2565	46	23	behavioural	behavioural	ADJ
ajlm-2565	46	24	factors	factor	NOUN
ajlm-2565	46	25	was	be	AUX
ajlm-2565	46	26	collected	collect	VERB
ajlm-2565	46	27	by	by	ADP
ajlm-2565	46	28	trained	train	VERB
ajlm-2565	46	29	research	research	NOUN
ajlm-2565	46	30	assistants	assistant	NOUN
ajlm-2565	46	31	who	who	PRON
ajlm-2565	46	32	directly	directly	ADV
ajlm-2565	46	33	interviewed	interview	VERB
ajlm-2565	46	34	study	study	NOUN
ajlm-2565	46	35	participants	participant	NOUN
ajlm-2565	46	36	in	in	ADP
ajlm-2565	46	37	the	the	DET
ajlm-2565	46	38	local	local	ADJ
ajlm-2565	46	39	language	language	NOUN
ajlm-2565	46	40	using	use	VERB
ajlm-2565	46	41	a	a	DET
ajlm-2565	46	42	semi	semi	ADJ
ajlm-2565	46	43	-	-	ADJ
ajlm-2565	46	44	structured	structured	ADJ
ajlm-2565	46	45	questionnaire	questionnaire	NOUN
ajlm-2565	46	46	.	.	PUNCT
ajlm-2565	47	1	the	the	DET
ajlm-2565	47	2	trained	train	VERB
ajlm-2565	47	3	research	research	NOUN
ajlm-2565	47	4	assistants	assistant	NOUN
ajlm-2565	47	5	also	also	ADV
ajlm-2565	47	6	reviewed	review	VERB
ajlm-2565	47	7	the	the	DET
ajlm-2565	47	8	medical	medical	ADJ
ajlm-2565	47	9	records	record	NOUN
ajlm-2565	47	10	of	of	ADP
ajlm-2565	47	11	the	the	DET
ajlm-2565	47	12	consented	consented	ADJ
ajlm-2565	47	13	study	study	NOUN
ajlm-2565	47	14	participants	participant	NOUN
ajlm-2565	47	15	to	to	PART
ajlm-2565	47	16	obtain	obtain	VERB
ajlm-2565	47	17	data	datum	NOUN
ajlm-2565	47	18	regarding	regard	VERB
ajlm-2565	47	19	the	the	DET
ajlm-2565	47	20	duration	duration	NOUN
ajlm-2565	47	21	of	of	ADP
ajlm-2565	47	22	art	art	NOUN
ajlm-2565	47	23	,	,	PUNCT
ajlm-2565	47	24	recent	recent	ADJ
ajlm-2565	47	25	viral	viral	ADJ
ajlm-2565	47	26	load	load	NOUN
ajlm-2565	47	27	results	result	NOUN
ajlm-2565	47	28	,	,	PUNCT
ajlm-2565	47	29	and	and	CCONJ
ajlm-2565	47	30	medication	medication	NOUN
ajlm-2565	47	31	.	.	PUNCT
ajlm-2565	48	1	the	the	DET
ajlm-2565	48	2	measurement	measurement	NOUN
ajlm-2565	48	3	of	of	ADP
ajlm-2565	48	4	height	height	NOUN
ajlm-2565	48	5	and	and	CCONJ
ajlm-2565	48	6	weight	weight	NOUN
ajlm-2565	48	7	that	that	PRON
ajlm-2565	48	8	were	be	AUX
ajlm-2565	48	9	required	require	VERB
ajlm-2565	48	10	for	for	ADP
ajlm-2565	48	11	the	the	DET
ajlm-2565	48	12	calculation	calculation	NOUN
ajlm-2565	48	13	of	of	ADP
ajlm-2565	48	14	bmi	bmi	PROPN
ajlm-2565	48	15	,	,	PUNCT
ajlm-2565	48	16	waist	waist	NOUN
ajlm-2565	48	17	/	/	SYM
ajlm-2565	48	18	hip	hip	NOUN
ajlm-2565	48	19	circumferences	circumference	NOUN
ajlm-2565	48	20	needed	need	VERB
ajlm-2565	48	21	to	to	PART
ajlm-2565	48	22	calculate	calculate	VERB
ajlm-2565	48	23	waist	waist	NOUN
ajlm-2565	48	24	-	-	PUNCT
ajlm-2565	48	25	to	to	ADP
ajlm-2565	48	26	-	-	PUNCT
ajlm-2565	48	27	hip	hip	NOUN
ajlm-2565	48	28	ratio	ratio	NOUN
ajlm-2565	48	29	,	,	PUNCT
ajlm-2565	48	30	and	and	CCONJ
ajlm-2565	48	31	bp	bp	PROPN
ajlm-2565	48	32	were	be	AUX
ajlm-2565	48	33	also	also	ADV
ajlm-2565	48	34	performed	perform	VERB
ajlm-2565	48	35	by	by	ADP
ajlm-2565	48	36	the	the	DET
ajlm-2565	48	37	two	two	NUM
ajlm-2565	48	38	research	research	NOUN
ajlm-2565	48	39	assistants	assistant	NOUN
ajlm-2565	48	40	.	.	PUNCT
ajlm-2565	49	1	a	a	DET
ajlm-2565	49	2	digital	digital	ADJ
ajlm-2565	49	3	sphygmomanometer	sphygmomanometer	NOUN
ajlm-2565	49	4	was	be	AUX
ajlm-2565	49	5	used	use	VERB
ajlm-2565	49	6	to	to	PART
ajlm-2565	49	7	take	take	VERB
ajlm-2565	49	8	bp	bp	PROPN
ajlm-2565	49	9	measurements	measurement	NOUN
ajlm-2565	49	10	.	.	PUNCT
ajlm-2565	50	1	two	two	NUM
ajlm-2565	50	2	bp	bp	PROPN
ajlm-2565	50	3	readings	reading	NOUN
ajlm-2565	50	4	were	be	AUX
ajlm-2565	50	5	recorded	record	VERB
ajlm-2565	50	6	at	at	ADP
ajlm-2565	50	7	a	a	DET
ajlm-2565	50	8	5	5	NUM
ajlm-2565	50	9	min	min	NOUN
ajlm-2565	50	10	interval	interval	NOUN
ajlm-2565	50	11	,	,	PUNCT
ajlm-2565	50	12	and	and	CCONJ
ajlm-2565	50	13	their	their	PRON
ajlm-2565	50	14	mean	mean	ADJ
ajlm-2565	50	15	value	value	NOUN
ajlm-2565	50	16	was	be	AUX
ajlm-2565	50	17	taken	take	VERB
ajlm-2565	50	18	as	as	ADP
ajlm-2565	50	19	the	the	DET
ajlm-2565	50	20	bp	bp	PROPN
ajlm-2565	50	21	.	.	PUNCT
ajlm-2565	51	1	the	the	DET
ajlm-2565	51	2	weight	weight	NOUN
ajlm-2565	51	3	and	and	CCONJ
ajlm-2565	51	4	height	height	NOUN
ajlm-2565	51	5	of	of	ADP
ajlm-2565	51	6	the	the	DET
ajlm-2565	51	7	participants	participant	NOUN
ajlm-2565	51	8	were	be	AUX
ajlm-2565	51	9	measured	measure	VERB
ajlm-2565	51	10	using	use	VERB
ajlm-2565	51	11	a	a	DET
ajlm-2565	51	12	portable	portable	ADJ
ajlm-2565	51	13	weight	weight	NOUN
ajlm-2565	51	14	and	and	CCONJ
ajlm-2565	51	15	height	height	NOUN
ajlm-2565	51	16	scale	scale	NOUN
ajlm-2565	51	17	.	.	PUNCT
ajlm-2565	52	1	approximately	approximately	ADV
ajlm-2565	52	2	4	4	NUM
ajlm-2565	52	3	ml	ml	NOUN
ajlm-2565	52	4	of	of	ADP
ajlm-2565	52	5	venous	venous	ADJ
ajlm-2565	52	6	blood	blood	NOUN
ajlm-2565	52	7	was	be	AUX
ajlm-2565	52	8	collected	collect	VERB
ajlm-2565	52	9	from	from	ADP
ajlm-2565	52	10	each	each	DET
ajlm-2565	52	11	study	study	NOUN
ajlm-2565	52	12	participant	participant	NOUN
ajlm-2565	52	13	,	,	PUNCT
ajlm-2565	52	14	using	use	VERB
ajlm-2565	52	15	red	red	ADJ
ajlm-2565	52	16	top	top	NOUN
ajlm-2565	52	17	(	(	PUNCT
ajlm-2565	52	18	serum	serum	NOUN
ajlm-2565	52	19	)	)	PUNCT
ajlm-2565	52	20	vacutainer	vacutainer	ADJ
ajlm-2565	52	21	vacuum	vacuum	NOUN
ajlm-2565	52	22	tubes	tube	NOUN
ajlm-2565	52	23	,	,	PUNCT
ajlm-2565	52	24	by	by	ADP
ajlm-2565	52	25	the	the	DET
ajlm-2565	52	26	principal	principal	ADJ
ajlm-2565	52	27	investigator	investigator	NOUN
ajlm-2565	52	28	and	and	CCONJ
ajlm-2565	52	29	a	a	DET
ajlm-2565	52	30	laboratory	laboratory	NOUN
ajlm-2565	52	31	assistant	assistant	NOUN
ajlm-2565	52	32	attached	attach	VERB
ajlm-2565	52	33	to	to	ADP
ajlm-2565	52	34	the	the	DET
ajlm-2565	52	35	art	art	NOUN
ajlm-2565	52	36	clinic	clinic	NOUN
ajlm-2565	52	37	.	.	PUNCT
ajlm-2565	53	1	serum	serum	PROPN
ajlm-2565	53	2	was	be	AUX
ajlm-2565	53	3	separated	separate	VERB
ajlm-2565	53	4	by	by	ADP
ajlm-2565	53	5	centrifugation	centrifugation	NOUN
ajlm-2565	53	6	at	at	ADP
ajlm-2565	53	7	3000	3000	NUM
ajlm-2565	53	8	rpm	rpm	NOUN
ajlm-2565	53	9	for	for	ADP
ajlm-2565	53	10	4	4	NUM
ajlm-2565	53	11	min	min	NOUN
ajlm-2565	53	12	within	within	ADP
ajlm-2565	53	13	a	a	DET
ajlm-2565	53	14	period	period	NOUN
ajlm-2565	53	15	not	not	PART
ajlm-2565	53	16	more	more	ADJ
ajlm-2565	53	17	than	than	ADP
ajlm-2565	53	18	1	1	NUM
ajlm-2565	53	19	h	h	NOUN
ajlm-2565	53	20	after	after	ADP
ajlm-2565	53	21	blood	blood	NOUN
ajlm-2565	53	22	collection	collection	NOUN
ajlm-2565	53	23	.	.	PUNCT
ajlm-2565	54	1	the	the	DET
ajlm-2565	54	2	serum	serum	NOUN
ajlm-2565	54	3	concentrations	concentration	NOUN
ajlm-2565	54	4	of	of	ADP
ajlm-2565	54	5	uric	uric	ADJ
ajlm-2565	54	6	acid	acid	NOUN
ajlm-2565	54	7	and	and	CCONJ
ajlm-2565	54	8	creatinine	creatinine	NOUN
ajlm-2565	54	9	were	be	AUX
ajlm-2565	54	10	measured	measure	VERB
ajlm-2565	54	11	using	use	VERB
ajlm-2565	54	12	the	the	DET
ajlm-2565	54	13	cobas	cobas	PROPN
ajlm-2565	54	14	©	©	PROPN
ajlm-2565	54	15	111	111	NUM
ajlm-2565	54	16	analyser	analyser	NOUN
ajlm-2565	54	17	(	(	PUNCT
ajlm-2565	54	18	roche	roche	PROPN
ajlm-2565	54	19	diagnostics	diagnostic	NOUN
ajlm-2565	54	20	international	international	ADJ
ajlm-2565	54	21	,	,	PUNCT
ajlm-2565	54	22	rotkreuz	rotkreuz	PROPN
ajlm-2565	54	23	,	,	PUNCT
ajlm-2565	54	24	switzerland	switzerland	PROPN
ajlm-2565	54	25	)	)	PUNCT
ajlm-2565	54	26	at	at	ADP
ajlm-2565	54	27	the	the	DET
ajlm-2565	54	28	clinical	clinical	ADJ
ajlm-2565	54	29	chemistry	chemistry	NOUN
ajlm-2565	54	30	department	department	NOUN
ajlm-2565	54	31	laboratory	laboratory	NOUN
ajlm-2565	54	32	at	at	ADP
ajlm-2565	54	33	mbarara	mbarara	PROPN
ajlm-2565	54	34	city	city	PROPN
ajlm-2565	54	35	health	health	PROPN
ajlm-2565	54	36	centre	centre	PROPN
ajlm-2565	54	37	iv	iv	X
ajlm-2565	54	38	.	.	PUNCT
ajlm-2565	55	1	this	this	DET
ajlm-2565	55	2	instrument	instrument	NOUN
ajlm-2565	55	3	is	be	AUX
ajlm-2565	55	4	designed	design	VERB
ajlm-2565	55	5	to	to	PART
ajlm-2565	55	6	perform	perform	VERB
ajlm-2565	55	7	spectrophotometric	spectrophotometric	ADJ
ajlm-2565	55	8	measurements	measurement	NOUN
ajlm-2565	55	9	of	of	ADP
ajlm-2565	55	10	the	the	DET
ajlm-2565	55	11	analyte	analyte	NOUN
ajlm-2565	55	12	level	level	NOUN
ajlm-2565	55	13	at	at	ADP
ajlm-2565	55	14	a	a	DET
ajlm-2565	55	15	specific	specific	ADJ
ajlm-2565	55	16	set	set	NOUN
ajlm-2565	55	17	of	of	ADP
ajlm-2565	55	18	wavelengths	wavelength	NOUN
ajlm-2565	55	19	using	use	VERB
ajlm-2565	55	20	specific	specific	ADJ
ajlm-2565	55	21	reagents	reagent	NOUN
ajlm-2565	55	22	.	.	PUNCT
ajlm-2565	56	1	the	the	DET
ajlm-2565	56	2	analyser	analyser	NOUN
ajlm-2565	56	3	automatically	automatically	ADV
ajlm-2565	56	4	performs	perform	VERB
ajlm-2565	56	5	all	all	PRON
ajlm-2565	56	6	reagent	reagent	ADJ
ajlm-2565	56	7	and	and	CCONJ
ajlm-2565	56	8	sample	sample	NOUN
ajlm-2565	56	9	pipetting	pipetting	NOUN
ajlm-2565	56	10	,	,	PUNCT
ajlm-2565	56	11	incubation	incubation	NOUN
ajlm-2565	56	12	,	,	PUNCT
ajlm-2565	56	13	photometric	photometric	NOUN
ajlm-2565	56	14	measurements	measurement	NOUN
ajlm-2565	56	15	,	,	PUNCT
ajlm-2565	56	16	and	and	CCONJ
ajlm-2565	56	17	calculations	calculation	NOUN
ajlm-2565	56	18	.	.	PUNCT
ajlm-2565	57	1	calibration	calibration	NOUN
ajlm-2565	57	2	and	and	CCONJ
ajlm-2565	57	3	quality	quality	NOUN
ajlm-2565	57	4	control	control	NOUN
ajlm-2565	57	5	of	of	ADP
ajlm-2565	57	6	this	this	DET
ajlm-2565	57	7	chemistry	chemistry	NOUN
ajlm-2565	57	8	analyser	analyser	NOUN
ajlm-2565	57	9	were	be	AUX
ajlm-2565	57	10	performed	perform	VERB
ajlm-2565	57	11	before	before	SCONJ
ajlm-2565	57	12	the	the	DET
ajlm-2565	57	13	samples	sample	NOUN
ajlm-2565	57	14	were	be	AUX
ajlm-2565	57	15	run	run	VERB
ajlm-2565	57	16	.	.	PUNCT
ajlm-2565	58	1	the	the	DET
ajlm-2565	58	2	manufacturer	manufacturer	NOUN
ajlm-2565	58	3	’s	’s	PART
ajlm-2565	58	4	instructions	instruction	NOUN
ajlm-2565	58	5	for	for	ADP
ajlm-2565	58	6	the	the	DET
ajlm-2565	58	7	machine	machine	NOUN
ajlm-2565	58	8	and	and	CCONJ
ajlm-2565	58	9	the	the	DET
ajlm-2565	58	10	reagents	reagent	NOUN
ajlm-2565	58	11	were	be	AUX
ajlm-2565	58	12	strictly	strictly	ADV
ajlm-2565	58	13	followed	follow	VERB
ajlm-2565	58	14	.	.	PUNCT
ajlm-2565	59	1	in	in	ADP
ajlm-2565	59	2	order	order	NOUN
ajlm-2565	59	3	to	to	PART
ajlm-2565	59	4	contribute	contribute	VERB
ajlm-2565	59	5	to	to	ADP
ajlm-2565	59	6	the	the	DET
ajlm-2565	59	7	quality	quality	NOUN
ajlm-2565	59	8	control	control	NOUN
ajlm-2565	59	9	process	process	NOUN
ajlm-2565	59	10	,	,	PUNCT
ajlm-2565	59	11	10	10	NUM
ajlm-2565	59	12	%	%	NOUN
ajlm-2565	59	13	of	of	ADP
ajlm-2565	59	14	the	the	DET
ajlm-2565	59	15	samples	sample	NOUN
ajlm-2565	59	16	were	be	AUX
ajlm-2565	59	17	run	run	VERB
ajlm-2565	59	18	at	at	ADP
ajlm-2565	59	19	mbarara	mbarara	NOUN
ajlm-2565	59	20	regional	regional	ADJ
ajlm-2565	59	21	referral	referral	ADJ
ajlm-2565	59	22	hospital	hospital	NOUN
ajlm-2565	59	23	for	for	ADP
ajlm-2565	59	24	comparison	comparison	NOUN
ajlm-2565	59	25	,	,	PUNCT
ajlm-2565	59	26	using	use	VERB
ajlm-2565	59	27	the	the	DET
ajlm-2565	59	28	humastar	humastar	NOUN
ajlm-2565	59	29	200	200	NUM
ajlm-2565	59	30	(	(	PUNCT
ajlm-2565	59	31	human	human	ADJ
ajlm-2565	59	32	diagnostics	diagnostic	NOUN
ajlm-2565	59	33	worldwide	worldwide	ADV
ajlm-2565	59	34	,	,	PUNCT
ajlm-2565	59	35	wiesbaden	wiesbaden	PROPN
ajlm-2565	59	36	,	,	PUNCT
ajlm-2565	59	37	germany	germany	PROPN
ajlm-2565	59	38	)	)	PUNCT
ajlm-2565	59	39	.	.	PUNCT
ajlm-2565	60	1	there	there	PRON
ajlm-2565	60	2	was	be	VERB
ajlm-2565	60	3	no	no	DET
ajlm-2565	60	4	statistical	statistical	ADJ
ajlm-2565	60	5	difference	difference	NOUN
ajlm-2565	60	6	between	between	ADP
ajlm-2565	60	7	the	the	DET
ajlm-2565	60	8	results	result	NOUN
ajlm-2565	60	9	from	from	ADP
ajlm-2565	60	10	both	both	DET
ajlm-2565	60	11	laboratories	laboratory	NOUN
ajlm-2565	60	12	.	.	PUNCT
ajlm-2565	61	1	statistical	statistical	ADJ
ajlm-2565	61	2	analysis	analysis	NOUN
ajlm-2565	61	3	data	datum	NOUN
ajlm-2565	61	4	were	be	AUX
ajlm-2565	61	5	analyzed	analyze	VERB
ajlm-2565	61	6	using	use	VERB
ajlm-2565	61	7	stata	stata	PROPN
ajlm-2565	61	8	17.0	17.0	NUM
ajlm-2565	61	9	(	(	PUNCT
ajlm-2565	61	10	statacorp	statacorp	PROPN
ajlm-2565	61	11	llc	llc	PROPN
ajlm-2565	61	12	,	,	PUNCT
ajlm-2565	61	13	college	college	NOUN
ajlm-2565	61	14	station	station	NOUN
ajlm-2565	61	15	,	,	PUNCT
ajlm-2565	61	16	texas	texas	PROPN
ajlm-2565	61	17	,	,	PUNCT
ajlm-2565	61	18	united	united	PROPN
ajlm-2565	61	19	states	states	PROPN
ajlm-2565	61	20	)	)	PUNCT
ajlm-2565	61	21	.	.	PUNCT
ajlm-2565	62	1	creatinine	creatinine	NOUN
ajlm-2565	62	2	and	and	CCONJ
ajlm-2565	62	3	sua	sua	NOUN
ajlm-2565	62	4	:	:	PUNCT
ajlm-2565	62	5	creatinine	creatinine	NOUN
ajlm-2565	62	6	ratio	ratio	NOUN
ajlm-2565	62	7	were	be	AUX
ajlm-2565	62	8	tested	test	VERB
ajlm-2565	62	9	for	for	ADP
ajlm-2565	62	10	normality	normality	NOUN
ajlm-2565	62	11	using	use	VERB
ajlm-2565	62	12	the	the	DET
ajlm-2565	62	13	shapiro	shapiro	PROPN
ajlm-2565	62	14	-	-	PUNCT
ajlm-2565	62	15	wilk	wilk	NOUN
ajlm-2565	62	16	normality	normality	NOUN
ajlm-2565	62	17	test	test	NOUN
ajlm-2565	62	18	;	;	PUNCT
ajlm-2565	62	19	neither	neither	CCONJ
ajlm-2565	62	20	was	be	AUX
ajlm-2565	62	21	normally	normally	ADV
ajlm-2565	62	22	distributed	distribute	VERB
ajlm-2565	62	23	.	.	PUNCT
ajlm-2565	63	1	they	they	PRON
ajlm-2565	63	2	were	be	AUX
ajlm-2565	63	3	therefore	therefore	ADV
ajlm-2565	63	4	summarised	summarise	VERB
ajlm-2565	63	5	using	use	VERB
ajlm-2565	63	6	the	the	DET
ajlm-2565	63	7	median	median	NOUN
ajlm-2565	63	8	with	with	ADP
ajlm-2565	63	9	interquartile	interquartile	ADJ
ajlm-2565	63	10	range	range	NOUN
ajlm-2565	63	11	,	,	PUNCT
ajlm-2565	63	12	and	and	CCONJ
ajlm-2565	63	13	their	their	PRON
ajlm-2565	63	14	medians	median	NOUN
ajlm-2565	63	15	were	be	AUX
ajlm-2565	63	16	compared	compare	VERB
ajlm-2565	63	17	between	between	ADP
ajlm-2565	63	18	the	the	DET
ajlm-2565	63	19	participants	participant	NOUN
ajlm-2565	63	20	with	with	ADP
ajlm-2565	63	21	hyperuricaemia	hyperuricaemia	NOUN
ajlm-2565	63	22	and	and	CCONJ
ajlm-2565	63	23	those	those	PRON
ajlm-2565	63	24	without	without	ADP
ajlm-2565	63	25	hyperuricaemia	hyperuricaemia	NOUN
ajlm-2565	63	26	using	use	VERB
ajlm-2565	63	27	the	the	DET
ajlm-2565	63	28	wilcoxon	wilcoxon	ADJ
ajlm-2565	63	29	-	-	PUNCT
ajlm-2565	63	30	rank	rank	NOUN
ajlm-2565	63	31	sum	sum	NOUN
ajlm-2565	63	32	test	test	NOUN
ajlm-2565	63	33	.	.	PUNCT
ajlm-2565	64	1	uric	uric	ADJ
ajlm-2565	64	2	acid	acid	PROPN
ajlm-2565	64	3	levels	level	NOUN
ajlm-2565	64	4	were	be	AUX
ajlm-2565	64	5	categorised	categorise	VERB
ajlm-2565	64	6	into	into	ADP
ajlm-2565	64	7	hyperuricaemia	hyperuricaemia	ADJ
ajlm-2565	64	8	present	present	ADJ
ajlm-2565	64	9	(	(	PUNCT
ajlm-2565	64	10	uric	uric	ADJ
ajlm-2565	64	11	acid	acid	NOUN
ajlm-2565	64	12	>	>	X
ajlm-2565	64	13	7	7	NUM
ajlm-2565	64	14	mg	mg	PROPN
ajlm-2565	64	15	/	/	SYM
ajlm-2565	64	16	dl	dl	PROPN
ajlm-2565	64	17	in	in	ADP
ajlm-2565	64	18	men	man	NOUN
ajlm-2565	64	19	and	and	CCONJ
ajlm-2565	64	20	uric	uric	ADJ
ajlm-2565	64	21	acid	acid	PROPN
ajlm-2565	64	22	>	>	X
ajlm-2565	64	23	6	6	NUM
ajlm-2565	64	24	mg	mg	PROPN
ajlm-2565	64	25	/	/	SYM
ajlm-2565	64	26	dl	dl	PROPN
ajlm-2565	64	27	in	in	ADP
ajlm-2565	64	28	women	woman	NOUN
ajlm-2565	64	29	)	)	PUNCT
ajlm-2565	64	30	and	and	CCONJ
ajlm-2565	64	31	hyperuricaemia	hyperuricaemia	ADV
ajlm-2565	64	32	absent	absent	ADJ
ajlm-2565	64	33	.	.	PUNCT
ajlm-2565	65	1	the	the	DET
ajlm-2565	65	2	egfr	egfr	ADJ
ajlm-2565	65	3	rate	rate	NOUN
ajlm-2565	65	4	was	be	AUX
ajlm-2565	65	5	also	also	ADV
ajlm-2565	65	6	categorised	categorise	VERB
ajlm-2565	65	7	into	into	ADP
ajlm-2565	65	8	kidney	kidney	NOUN
ajlm-2565	65	9	dysfunction	dysfunction	NOUN
ajlm-2565	65	10	present	present	NOUN
ajlm-2565	65	11	(	(	PUNCT
ajlm-2565	65	12	egfr	egfr	VERB
ajlm-2565	65	13	<	<	X
ajlm-2565	65	14	90	90	NUM
ajlm-2565	65	15	ml	ml	NOUN
ajlm-2565	65	16	/	/	SYM
ajlm-2565	65	17	min	min	NOUN
ajlm-2565	65	18	)	)	PUNCT
ajlm-2565	65	19	and	and	CCONJ
ajlm-2565	65	20	kidney	kidney	NOUN
ajlm-2565	65	21	dysfunction	dysfunction	NOUN
ajlm-2565	65	22	absent	absent	ADJ
ajlm-2565	65	23	(	(	PUNCT
ajlm-2565	65	24	egfr	egfr	X
ajlm-2565	65	25	≥	≥	NUM
ajlm-2565	65	26	90	90	NUM
ajlm-2565	65	27	ml	ml	NOUN
ajlm-2565	65	28	/	/	SYM
ajlm-2565	65	29	min	min	NOUN
ajlm-2565	65	30	)	)	PUNCT
ajlm-2565	65	31	.	.	PUNCT
ajlm-2565	66	1	a	a	DET
ajlm-2565	66	2	categorical	categorical	ADJ
ajlm-2565	66	3	variable	variable	NOUN
ajlm-2565	66	4	,	,	PUNCT
ajlm-2565	66	5	hypertension	hypertension	NOUN
ajlm-2565	66	6	(	(	PUNCT
ajlm-2565	66	7	normal	normal	ADJ
ajlm-2565	66	8	bp	bp	PROPN
ajlm-2565	66	9	=	=	SYM
ajlm-2565	66	10	systolic	systolic	PROPN
ajlm-2565	66	11	bp	bp	PROPN
ajlm-2565	66	12	<	<	X
ajlm-2565	66	13	140	140	NUM
ajlm-2565	66	14	mmhg	mmhg	NOUN
ajlm-2565	66	15	and	and	CCONJ
ajlm-2565	66	16	diastolic	diastolic	ADJ
ajlm-2565	66	17	bp	bp	PROPN
ajlm-2565	66	18	<	<	X
ajlm-2565	66	19	90	90	NUM
ajlm-2565	66	20	mmhg	mmhg	NOUN
ajlm-2565	66	21	;	;	PUNCT
ajlm-2565	66	22	systolic	systolic	ADJ
ajlm-2565	66	23	hypertension	hypertension	NOUN
ajlm-2565	66	24	only	only	ADV
ajlm-2565	66	25	=	=	PUNCT
ajlm-2565	66	26	systolic	systolic	ADJ
ajlm-2565	66	27	bp	bp	PROPN
ajlm-2565	66	28	≥	≥	NUM
ajlm-2565	66	29	140	140	NUM
ajlm-2565	66	30	mmhg	mmhg	NOUN
ajlm-2565	66	31	and	and	CCONJ
ajlm-2565	66	32	diastolic	diastolic	PROPN
ajlm-2565	66	33	bp	bp	PROPN
ajlm-2565	66	34	<	<	X
ajlm-2565	66	35	90	90	NUM
ajlm-2565	66	36	mmhg	mmhg	NOUN
ajlm-2565	66	37	;	;	PUNCT
ajlm-2565	66	38	diastolic	diastolic	ADJ
ajlm-2565	66	39	hypertension	hypertension	NOUN
ajlm-2565	66	40	only	only	ADV
ajlm-2565	66	41	=	=	PUNCT
ajlm-2565	66	42	systolic	systolic	ADJ
ajlm-2565	66	43	bp	bp	PROPN
ajlm-2565	66	44	<	<	X
ajlm-2565	66	45	140	140	NUM
ajlm-2565	66	46	mmhg	mmhg	NOUN
ajlm-2565	66	47	and	and	CCONJ
ajlm-2565	66	48	diastolic	diastolic	PROPN
ajlm-2565	66	49	bp	bp	PROPN
ajlm-2565	66	50	≥	≥	PROPN
ajlm-2565	66	51	90	90	NUM
ajlm-2565	66	52	mmhg	mmhg	NOUN
ajlm-2565	66	53	;	;	PUNCT
ajlm-2565	66	54	and	and	CCONJ
ajlm-2565	66	55	both	both	CCONJ
ajlm-2565	66	56	systolic	systolic	ADJ
ajlm-2565	66	57	and	and	CCONJ
ajlm-2565	66	58	diastolic	diastolic	ADJ
ajlm-2565	66	59	hypertension	hypertension	NOUN
ajlm-2565	66	60	=	=	SYM
ajlm-2565	66	61	systolic	systolic	PROPN
ajlm-2565	66	62	bp	bp	PROPN
ajlm-2565	66	63	≥	≥	NUM
ajlm-2565	66	64	140	140	NUM
ajlm-2565	66	65	mmhg	mmhg	NOUN
ajlm-2565	66	66	and	and	CCONJ
ajlm-2565	66	67	diastolic	diastolic	PROPN
ajlm-2565	66	68	bp	bp	PROPN
ajlm-2565	66	69	≥	≥	PROPN
ajlm-2565	66	70	90	90	NUM
ajlm-2565	66	71	mmhg	mmhg	NOUN
ajlm-2565	66	72	)	)	PUNCT
ajlm-2565	66	73	,	,	PUNCT
ajlm-2565	66	74	was	be	AUX
ajlm-2565	66	75	generated	generate	VERB
ajlm-2565	66	76	from	from	ADP
ajlm-2565	66	77	both	both	CCONJ
ajlm-2565	66	78	continuous	continuous	ADJ
ajlm-2565	66	79	systolic	systolic	NOUN
ajlm-2565	66	80	and	and	CCONJ
ajlm-2565	66	81	diastolic	diastolic	ADJ
ajlm-2565	66	82	bp	bp	PROPN
ajlm-2565	66	83	variables	variable	NOUN
ajlm-2565	66	84	.	.	PUNCT
ajlm-2565	67	1	all	all	DET
ajlm-2565	67	2	categorical	categorical	ADJ
ajlm-2565	67	3	variables	variable	NOUN
ajlm-2565	67	4	were	be	AUX
ajlm-2565	67	5	summarised	summarise	VERB
ajlm-2565	67	6	using	use	VERB
ajlm-2565	67	7	frequencies	frequency	NOUN
ajlm-2565	67	8	and	and	CCONJ
ajlm-2565	67	9	percentages	percentage	NOUN
ajlm-2565	67	10	.	.	PUNCT
ajlm-2565	68	1	the	the	DET
ajlm-2565	68	2	prevalence	prevalence	NOUN
ajlm-2565	68	3	of	of	ADP
ajlm-2565	68	4	hyperuricaemia	hyperuricaemia	NOUN
ajlm-2565	68	5	,	,	PUNCT
ajlm-2565	68	6	together	together	ADV
ajlm-2565	68	7	with	with	ADP
ajlm-2565	68	8	its	its	PRON
ajlm-2565	68	9	95	95	NUM
ajlm-2565	68	10	%	%	NOUN
ajlm-2565	68	11	confidence	confidence	NOUN
ajlm-2565	68	12	interval	interval	NOUN
ajlm-2565	68	13	(	(	PUNCT
ajlm-2565	68	14	ci	ci	NOUN
ajlm-2565	68	15	)	)	PUNCT
ajlm-2565	68	16	,	,	PUNCT
ajlm-2565	68	17	was	be	AUX
ajlm-2565	68	18	obtained	obtain	VERB
ajlm-2565	68	19	by	by	ADP
ajlm-2565	68	20	dividing	divide	VERB
ajlm-2565	68	21	the	the	DET
ajlm-2565	68	22	number	number	NOUN
ajlm-2565	68	23	of	of	ADP
ajlm-2565	68	24	participants	participant	NOUN
ajlm-2565	68	25	with	with	ADP
ajlm-2565	68	26	hyperuricaemia	hyperuricaemia	NOUN
ajlm-2565	68	27	by	by	ADP
ajlm-2565	68	28	the	the	DET
ajlm-2565	68	29	total	total	ADJ
ajlm-2565	68	30	number	number	NOUN
ajlm-2565	68	31	of	of	ADP
ajlm-2565	68	32	participants	participant	NOUN
ajlm-2565	68	33	that	that	PRON
ajlm-2565	68	34	were	be	AUX
ajlm-2565	68	35	recruited	recruit	VERB
ajlm-2565	68	36	in	in	ADP
ajlm-2565	68	37	the	the	DET
ajlm-2565	68	38	study	study	NOUN
ajlm-2565	68	39	(	(	PUNCT
ajlm-2565	68	40	sample	sample	NOUN
ajlm-2565	68	41	size	size	NOUN
ajlm-2565	68	42	)	)	PUNCT
ajlm-2565	68	43	,	,	PUNCT
ajlm-2565	68	44	expressed	express	VERB
ajlm-2565	68	45	as	as	ADP
ajlm-2565	68	46	a	a	DET
ajlm-2565	68	47	percentage	percentage	NOUN
ajlm-2565	68	48	.	.	PUNCT
ajlm-2565	69	1	to	to	PART
ajlm-2565	69	2	assess	assess	VERB
ajlm-2565	69	3	the	the	DET
ajlm-2565	69	4	association	association	NOUN
ajlm-2565	69	5	between	between	ADP
ajlm-2565	69	6	categorised	categorise	VERB
ajlm-2565	69	7	bmi	bmi	NOUN
ajlm-2565	69	8	and	and	CCONJ
ajlm-2565	69	9	hyperuricaemia	hyperuricaemia	NOUN
ajlm-2565	69	10	,	,	PUNCT
ajlm-2565	69	11	we	we	PRON
ajlm-2565	69	12	used	use	VERB
ajlm-2565	69	13	logistic	logistic	ADJ
ajlm-2565	69	14	regression	regression	NOUN
ajlm-2565	69	15	.	.	PUNCT
ajlm-2565	70	1	hyperuricaemia	hyperuricaemia	PROPN
ajlm-2565	70	2	was	be	AUX
ajlm-2565	70	3	the	the	DET
ajlm-2565	70	4	binary	binary	ADJ
ajlm-2565	70	5	dependent	dependent	ADJ
ajlm-2565	70	6	variable	variable	NOUN
ajlm-2565	70	7	.	.	PUNCT
ajlm-2565	71	1	all	all	DET
ajlm-2565	71	2	independent	independent	ADJ
ajlm-2565	71	3	variables	variable	NOUN
ajlm-2565	71	4	,	,	PUNCT
ajlm-2565	71	5	including	include	VERB
ajlm-2565	71	6	the	the	DET
ajlm-2565	71	7	main	main	ADJ
ajlm-2565	71	8	independent	independent	ADJ
ajlm-2565	71	9	variable	variable	NOUN
ajlm-2565	71	10	(	(	PUNCT
ajlm-2565	71	11	categorised	categorise	VERB
ajlm-2565	71	12	bmi	bmi	NOUN
ajlm-2565	71	13	)	)	PUNCT
ajlm-2565	71	14	at	at	ADP
ajlm-2565	71	15	the	the	DET
ajlm-2565	71	16	bivariate	bivariate	ADJ
ajlm-2565	71	17	level	level	NOUN
ajlm-2565	71	18	,	,	PUNCT
ajlm-2565	71	19	were	be	AUX
ajlm-2565	71	20	compared	compare	VERB
ajlm-2565	71	21	with	with	ADP
ajlm-2565	71	22	hyperuricaemia	hyperuricaemia	X
ajlm-2565	71	23	(	(	PUNCT
ajlm-2565	71	24	uric	uric	ADJ
ajlm-2565	71	25	acid	acid	NOUN
ajlm-2565	71	26	levels	level	NOUN
ajlm-2565	71	27	that	that	PRON
ajlm-2565	71	28	were	be	AUX
ajlm-2565	71	29	dichotomised	dichotomise	VERB
ajlm-2565	71	30	into	into	ADP
ajlm-2565	71	31	high	high	ADJ
ajlm-2565	71	32	and	and	CCONJ
ajlm-2565	71	33	normal	normal	ADJ
ajlm-2565	71	34	levels	level	NOUN
ajlm-2565	71	35	)	)	PUNCT
ajlm-2565	71	36	.	.	PUNCT
ajlm-2565	72	1	the	the	DET
ajlm-2565	72	2	associations	association	NOUN
ajlm-2565	72	3	were	be	AUX
ajlm-2565	72	4	determined	determine	VERB
ajlm-2565	72	5	using	use	VERB
ajlm-2565	72	6	odds	odd	NOUN
ajlm-2565	72	7	ratios	ratio	NOUN
ajlm-2565	72	8	(	(	PUNCT
ajlm-2565	72	9	or	or	CCONJ
ajlm-2565	72	10	)	)	PUNCT
ajlm-2565	72	11	together	together	ADV
ajlm-2565	72	12	with	with	ADP
ajlm-2565	72	13	their	their	PRON
ajlm-2565	72	14	95	95	NUM
ajlm-2565	72	15	%	%	NOUN
ajlm-2565	72	16	ci	ci	NOUN
ajlm-2565	72	17	,	,	PUNCT
ajlm-2565	72	18	and	and	CCONJ
ajlm-2565	72	19	the	the	DET
ajlm-2565	72	20	statistically	statistically	ADV
ajlm-2565	72	21	significant	significant	ADJ
ajlm-2565	72	22	ors	or	NOUN
ajlm-2565	72	23	were	be	AUX
ajlm-2565	72	24	indicated	indicate	VERB
ajlm-2565	72	25	by	by	ADP
ajlm-2565	72	26	a	a	DET
ajlm-2565	72	27	p	p	NOUN
ajlm-2565	72	28	-	-	PUNCT
ajlm-2565	72	29	value	value	NOUN
ajlm-2565	72	30	of	of	ADP
ajlm-2565	72	31	<	<	X
ajlm-2565	72	32	0.2	0.2	NUM
ajlm-2565	72	33	at	at	ADP
ajlm-2565	72	34	the	the	DET
ajlm-2565	72	35	bivariate	bivariate	ADJ
ajlm-2565	72	36	level	level	NOUN
ajlm-2565	72	37	.	.	PUNCT
ajlm-2565	73	1	the	the	DET
ajlm-2565	73	2	variables	variable	NOUN
ajlm-2565	73	3	that	that	PRON
ajlm-2565	73	4	were	be	AUX
ajlm-2565	73	5	clinically	clinically	ADV
ajlm-2565	73	6	and/or	and/or	CCONJ
ajlm-2565	73	7	statistically	statistically	ADV
ajlm-2565	73	8	significant	significant	ADJ
ajlm-2565	73	9	at	at	ADP
ajlm-2565	73	10	this	this	DET
ajlm-2565	73	11	level	level	NOUN
ajlm-2565	73	12	were	be	AUX
ajlm-2565	73	13	also	also	ADV
ajlm-2565	73	14	included	include	VERB
ajlm-2565	73	15	in	in	ADP
ajlm-2565	73	16	the	the	DET
ajlm-2565	73	17	multivariable	multivariable	ADJ
ajlm-2565	73	18	model	model	NOUN
ajlm-2565	73	19	.	.	PUNCT
ajlm-2565	74	1	the	the	DET
ajlm-2565	74	2	hosmer	hosmer	NOUN
ajlm-2565	74	3	-	-	PUNCT
ajlm-2565	74	4	lemeshow	lemeshow	NOUN
ajlm-2565	74	5	test	test	NOUN
ajlm-2565	74	6	was	be	AUX
ajlm-2565	74	7	used	use	VERB
ajlm-2565	74	8	to	to	PART
ajlm-2565	74	9	test	test	VERB
ajlm-2565	74	10	the	the	DET
ajlm-2565	74	11	suitability	suitability	NOUN
ajlm-2565	74	12	of	of	ADP
ajlm-2565	74	13	the	the	DET
ajlm-2565	74	14	final	final	ADJ
ajlm-2565	74	15	model	model	NOUN
ajlm-2565	74	16	in	in	ADP
ajlm-2565	74	17	predicting	predict	VERB
ajlm-2565	74	18	the	the	DET
ajlm-2565	74	19	outcome	outcome	NOUN
ajlm-2565	74	20	variable	variable	NOUN
ajlm-2565	74	21	:	:	PUNCT
ajlm-2565	74	22	hyperuricaemia	hyperuricaemia	X
ajlm-2565	74	23	.	.	PUNCT
ajlm-2565	75	1	in	in	ADP
ajlm-2565	75	2	the	the	DET
ajlm-2565	75	3	final	final	ADJ
ajlm-2565	75	4	multivariable	multivariable	ADJ
ajlm-2565	75	5	model	model	NOUN
ajlm-2565	75	6	,	,	PUNCT
ajlm-2565	75	7	associations	association	NOUN
ajlm-2565	75	8	were	be	AUX
ajlm-2565	75	9	considered	consider	VERB
ajlm-2565	75	10	significant	significant	ADJ
ajlm-2565	75	11	at	at	ADP
ajlm-2565	75	12	a	a	DET
ajlm-2565	75	13	p	p	NOUN
ajlm-2565	75	14	-	-	PUNCT
ajlm-2565	75	15	value	value	NOUN
ajlm-2565	75	16	≤	≤	NOUN
ajlm-2565	75	17	0.05	0.05	NUM
ajlm-2565	75	18	.	.	PUNCT
ajlm-2565	76	1	to	to	PART
ajlm-2565	76	2	assess	assess	VERB
ajlm-2565	76	3	the	the	DET
ajlm-2565	76	4	predictive	predictive	ADJ
ajlm-2565	76	5	performance	performance	NOUN
ajlm-2565	76	6	of	of	ADP
ajlm-2565	76	7	bmi	bmi	NOUN
ajlm-2565	76	8	for	for	ADP
ajlm-2565	76	9	hyperuricaemia	hyperuricaemia	NOUN
ajlm-2565	76	10	,	,	PUNCT
ajlm-2565	76	11	we	we	PRON
ajlm-2565	76	12	used	use	VERB
ajlm-2565	76	13	a	a	DET
ajlm-2565	76	14	receiver	receiver	ADJ
ajlm-2565	76	15	operating	operate	VERB
ajlm-2565	76	16	characteristic	characteristic	ADJ
ajlm-2565	76	17	curve	curve	NOUN
ajlm-2565	76	18	.	.	PUNCT
ajlm-2565	77	1	predictive	predictive	ADJ
ajlm-2565	77	2	power	power	NOUN
ajlm-2565	77	3	was	be	AUX
ajlm-2565	77	4	evaluated	evaluate	VERB
ajlm-2565	77	5	using	use	VERB
ajlm-2565	77	6	the	the	DET
ajlm-2565	77	7	area	area	NOUN
ajlm-2565	77	8	under	under	ADP
ajlm-2565	77	9	the	the	DET
ajlm-2565	77	10	curve	curve	NOUN
ajlm-2565	77	11	(	(	PUNCT
ajlm-2565	77	12	auc	auc	NOUN
ajlm-2565	77	13	)	)	PUNCT
ajlm-2565	77	14	and	and	CCONJ
ajlm-2565	77	15	its	its	PRON
ajlm-2565	77	16	95	95	NUM
ajlm-2565	77	17	%	%	NOUN
ajlm-2565	77	18	ci	ci	NOUN
ajlm-2565	77	19	;	;	PUNCT
ajlm-2565	77	20	a	a	DET
ajlm-2565	77	21	value	value	NOUN
ajlm-2565	77	22	near	near	ADP
ajlm-2565	77	23	to	to	ADP
ajlm-2565	77	24	1	1	NUM
ajlm-2565	77	25	indicates	indicate	VERB
ajlm-2565	77	26	better	well	ADJ
ajlm-2565	77	27	performance	performance	NOUN
ajlm-2565	77	28	and	and	CCONJ
ajlm-2565	77	29	a	a	DET
ajlm-2565	77	30	95	95	NUM
ajlm-2565	77	31	%	%	NOUN
ajlm-2565	77	32	ci	ci	NOUN
ajlm-2565	77	33	that	that	PRON
ajlm-2565	77	34	included	include	VERB
ajlm-2565	77	35	0.5	0.5	NUM
ajlm-2565	77	36	indicates	indicate	VERB
ajlm-2565	77	37	a	a	DET
ajlm-2565	77	38	non	non	ADJ
ajlm-2565	77	39	-	-	ADJ
ajlm-2565	77	40	significant	significant	ADJ
ajlm-2565	77	41	ability	ability	NOUN
ajlm-2565	77	42	to	to	PART
ajlm-2565	77	43	discriminate	discriminate	VERB
ajlm-2565	77	44	between	between	ADP
ajlm-2565	77	45	those	those	PRON
ajlm-2565	77	46	with	with	ADP
ajlm-2565	77	47	hyperuricaemia	hyperuricaemia	NOUN
ajlm-2565	77	48	and	and	CCONJ
ajlm-2565	77	49	those	those	PRON
ajlm-2565	77	50	without	without	ADP
ajlm-2565	77	51	hyperuricaemia	hyperuricaemia	NOUN
ajlm-2565	77	52	.	.	PUNCT
ajlm-2565	78	1	we	we	PRON
ajlm-2565	78	2	used	use	VERB
ajlm-2565	78	3	the	the	DET
ajlm-2565	78	4	youden	youden	PROPN
ajlm-2565	78	5	index	index	NOUN
ajlm-2565	78	6	to	to	PART
ajlm-2565	78	7	estimate	estimate	VERB
ajlm-2565	78	8	the	the	DET
ajlm-2565	78	9	optimal	optimal	ADJ
ajlm-2565	78	10	cutoff	cutoff	NOUN
ajlm-2565	78	11	point	point	NOUN
ajlm-2565	78	12	of	of	ADP
ajlm-2565	78	13	bmi	bmi	NOUN
ajlm-2565	78	14	for	for	ADP
ajlm-2565	78	15	hyperuricaemia	hyperuricaemia	ADJ
ajlm-2565	78	16	prediction	prediction	NOUN
ajlm-2565	78	17	at	at	ADP
ajlm-2565	78	18	maximum	maximum	ADJ
ajlm-2565	78	19	sensitivity	sensitivity	NOUN
ajlm-2565	78	20	and	and	CCONJ
ajlm-2565	78	21	specificity	specificity	NOUN
ajlm-2565	78	22	.	.	PUNCT
ajlm-2565	79	1	results	result	VERB
ajlm-2565	79	2	characteristics	characteristic	NOUN
ajlm-2565	79	3	of	of	ADP
ajlm-2565	79	4	the	the	DET
ajlm-2565	79	5	study	study	NOUN
ajlm-2565	79	6	participants	participant	VERB
ajlm-2565	79	7	a	a	DET
ajlm-2565	79	8	total	total	NOUN
ajlm-2565	79	9	of	of	ADP
ajlm-2565	79	10	328	328	NUM
ajlm-2565	79	11	participants	participant	NOUN
ajlm-2565	79	12	were	be	AUX
ajlm-2565	79	13	recruited	recruit	VERB
ajlm-2565	79	14	in	in	ADP
ajlm-2565	79	15	this	this	DET
ajlm-2565	79	16	study	study	NOUN
ajlm-2565	79	17	,	,	PUNCT
ajlm-2565	79	18	of	of	ADP
ajlm-2565	79	19	which	which	PRON
ajlm-2565	79	20	97.3	97.3	NUM
ajlm-2565	79	21	%	%	NOUN
ajlm-2565	79	22	were	be	AUX
ajlm-2565	79	23	on	on	ADP
ajlm-2565	79	24	dolutegravir	dolutegravir	PROPN
ajlm-2565	79	25	-	-	PUNCT
ajlm-2565	79	26	based	base	VERB
ajlm-2565	79	27	art	art	NOUN
ajlm-2565	79	28	.	.	PUNCT
ajlm-2565	80	1	the	the	DET
ajlm-2565	80	2	median	median	ADJ
ajlm-2565	80	3	age	age	NOUN
ajlm-2565	80	4	of	of	ADP
ajlm-2565	80	5	the	the	DET
ajlm-2565	80	6	study	study	NOUN
ajlm-2565	80	7	participants	participant	NOUN
ajlm-2565	80	8	was	be	AUX
ajlm-2565	80	9	38	38	NUM
ajlm-2565	80	10	years	year	NOUN
ajlm-2565	80	11	,	,	PUNCT
ajlm-2565	80	12	with	with	ADP
ajlm-2565	80	13	an	an	DET
ajlm-2565	80	14	interquartile	interquartile	ADJ
ajlm-2565	80	15	range	range	NOUN
ajlm-2565	80	16	of	of	ADP
ajlm-2565	80	17	31	31	NUM
ajlm-2565	80	18	years	year	NOUN
ajlm-2565	80	19	–	–	PUNCT
ajlm-2565	80	20	47	47	NUM
ajlm-2565	80	21	years	year	NOUN
ajlm-2565	80	22	.	.	PUNCT
ajlm-2565	81	1	the	the	DET
ajlm-2565	81	2	majority	majority	NOUN
ajlm-2565	81	3	of	of	ADP
ajlm-2565	81	4	the	the	DET
ajlm-2565	81	5	study	study	NOUN
ajlm-2565	81	6	participants	participant	NOUN
ajlm-2565	81	7	were	be	AUX
ajlm-2565	81	8	women	woman	NOUN
ajlm-2565	81	9	(	(	PUNCT
ajlm-2565	81	10	230/328	230/328	NUM
ajlm-2565	81	11	;	;	PUNCT
ajlm-2565	81	12	70.1	70.1	NUM
ajlm-2565	81	13	%	%	NOUN
ajlm-2565	81	14	)	)	PUNCT
ajlm-2565	81	15	,	,	PUNCT
ajlm-2565	81	16	married	married	ADJ
ajlm-2565	81	17	or	or	CCONJ
ajlm-2565	81	18	cohabiting	cohabit	VERB
ajlm-2565	81	19	(	(	PUNCT
ajlm-2565	81	20	185/328	185/328	NUM
ajlm-2565	81	21	;	;	PUNCT
ajlm-2565	81	22	56.6	56.6	NUM
ajlm-2565	81	23	%	%	NOUN
ajlm-2565	81	24	)	)	PUNCT
ajlm-2565	81	25	,	,	PUNCT
ajlm-2565	81	26	had	have	AUX
ajlm-2565	81	27	completed	complete	VERB
ajlm-2565	81	28	the	the	DET
ajlm-2565	81	29	primary	primary	ADJ
ajlm-2565	81	30	level	level	NOUN
ajlm-2565	81	31	of	of	ADP
ajlm-2565	81	32	education	education	NOUN
ajlm-2565	81	33	(	(	PUNCT
ajlm-2565	81	34	179/328	179/328	NUM
ajlm-2565	81	35	;	;	PUNCT
ajlm-2565	81	36	54.6	54.6	NUM
ajlm-2565	81	37	%	%	NOUN
ajlm-2565	81	38	)	)	PUNCT
ajlm-2565	81	39	,	,	PUNCT
ajlm-2565	81	40	were	be	AUX
ajlm-2565	81	41	protestant	protestant	ADJ
ajlm-2565	81	42	by	by	ADP
ajlm-2565	81	43	religion	religion	NOUN
ajlm-2565	81	44	(	(	PUNCT
ajlm-2565	81	45	155/328	155/328	NUM
ajlm-2565	81	46	;	;	PUNCT
ajlm-2565	81	47	47.3	47.3	NUM
ajlm-2565	81	48	%	%	NOUN
ajlm-2565	81	49	)	)	PUNCT
ajlm-2565	81	50	,	,	PUNCT
ajlm-2565	81	51	and	and	CCONJ
ajlm-2565	81	52	unemployed	unemployed	ADJ
ajlm-2565	81	53	(	(	PUNCT
ajlm-2565	81	54	173/328	173/328	NUM
ajlm-2565	81	55	;	;	PUNCT
ajlm-2565	81	56	52.7	52.7	NUM
ajlm-2565	81	57	%	%	NOUN
ajlm-2565	81	58	)	)	PUNCT
ajlm-2565	81	59	(	(	PUNCT
ajlm-2565	81	60	table	table	NOUN
ajlm-2565	81	61	1	1	NUM
ajlm-2565	81	62	)	)	PUNCT
ajlm-2565	81	63	.	.	PUNCT
ajlm-2565	82	1	table	table	NOUN
ajlm-2565	82	2	1	1	NUM
ajlm-2565	82	3	:	:	PUNCT
ajlm-2565	82	4	 	 	SPACE
ajlm-2565	82	5	characteristics	characteristic	NOUN
ajlm-2565	82	6	of	of	ADP
ajlm-2565	82	7	study	study	NOUN
ajlm-2565	82	8	participants	participant	NOUN
ajlm-2565	82	9	stratified	stratify	VERB
ajlm-2565	82	10	by	by	ADP
ajlm-2565	82	11	hyperuricaemia	hyperuricaemia	ADJ
ajlm-2565	82	12	status	status	NOUN
ajlm-2565	82	13	among	among	ADP
ajlm-2565	82	14	hiv	hiv	PROPN
ajlm-2565	82	15	-	-	PUNCT
ajlm-2565	82	16	positive	positive	ADJ
ajlm-2565	82	17	patients	patient	NOUN
ajlm-2565	82	18	in	in	ADP
ajlm-2565	82	19	south	south	ADJ
ajlm-2565	82	20	-	-	PUNCT
ajlm-2565	82	21	western	western	ADJ
ajlm-2565	82	22	uganda	uganda	PROPN
ajlm-2565	82	23	,	,	PUNCT
ajlm-2565	82	24	april	april	PROPN
ajlm-2565	82	25	2024	2024	NUM
ajlm-2565	82	26	to	to	ADP
ajlm-2565	82	27	june	june	PROPN
ajlm-2565	82	28	2024	2024	NUM
ajlm-2565	82	29	.	.	PUNCT
ajlm-2565	83	1	prevalence	prevalence	NOUN
ajlm-2565	83	2	of	of	ADP
ajlm-2565	83	3	hyperuricaemia	hyperuricaemia	NOUN
ajlm-2565	83	4	out	out	ADP
ajlm-2565	83	5	of	of	ADP
ajlm-2565	83	6	the	the	DET
ajlm-2565	83	7	328	328	NUM
ajlm-2565	83	8	study	study	NOUN
ajlm-2565	83	9	participants	participant	NOUN
ajlm-2565	83	10	,	,	PUNCT
ajlm-2565	83	11	77	77	NUM
ajlm-2565	83	12	had	have	VERB
ajlm-2565	83	13	hyperuricaemia	hyperuricaemia	NOUN
ajlm-2565	83	14	,	,	PUNCT
ajlm-2565	83	15	giving	give	VERB
ajlm-2565	83	16	an	an	DET
ajlm-2565	83	17	overall	overall	ADJ
ajlm-2565	83	18	prevalence	prevalence	NOUN
ajlm-2565	83	19	of	of	ADP
ajlm-2565	83	20	23.48	23.48	NUM
ajlm-2565	83	21	%	%	NOUN
ajlm-2565	83	22	with	with	ADP
ajlm-2565	83	23	a	a	DET
ajlm-2565	83	24	95	95	NUM
ajlm-2565	83	25	%	%	NOUN
ajlm-2565	83	26	ci	ci	NOUN
ajlm-2565	83	27	of	of	ADP
ajlm-2565	83	28	19.19	19.19	NUM
ajlm-2565	83	29	%	%	NOUN
ajlm-2565	83	30	to	to	ADP
ajlm-2565	83	31	28.39	28.39	NUM
ajlm-2565	83	32	%	%	NOUN
ajlm-2565	83	33	,	,	PUNCT
ajlm-2565	83	34	as	as	SCONJ
ajlm-2565	83	35	indicated	indicate	VERB
ajlm-2565	83	36	in	in	ADP
ajlm-2565	83	37	figure	figure	NOUN
ajlm-2565	83	38	1	1	NUM
ajlm-2565	83	39	.	.	PUNCT
ajlm-2565	84	1	the	the	DET
ajlm-2565	84	2	prevalence	prevalence	NOUN
ajlm-2565	84	3	of	of	ADP
ajlm-2565	84	4	hyperuricaemia	hyperuricaemia	NOUN
ajlm-2565	84	5	was	be	AUX
ajlm-2565	84	6	significantly	significantly	ADV
ajlm-2565	84	7	higher	high	ADJ
ajlm-2565	84	8	among	among	ADP
ajlm-2565	84	9	the	the	DET
ajlm-2565	84	10	male	male	ADJ
ajlm-2565	84	11	participants	participant	NOUN
ajlm-2565	84	12	(	(	PUNCT
ajlm-2565	84	13	n	n	NOUN
ajlm-2565	84	14	=	=	SYM
ajlm-2565	84	15	31	31	NUM
ajlm-2565	84	16	;	;	PUNCT
ajlm-2565	84	17	31.6	31.6	NUM
ajlm-2565	84	18	%	%	NOUN
ajlm-2565	84	19	)	)	PUNCT
ajlm-2565	84	20	than	than	ADP
ajlm-2565	84	21	the	the	DET
ajlm-2565	84	22	female	female	ADJ
ajlm-2565	84	23	participants	participant	NOUN
ajlm-2565	84	24	(	(	PUNCT
ajlm-2565	84	25	n	n	NOUN
ajlm-2565	84	26	=	=	SYM
ajlm-2565	84	27	46	46	NUM
ajlm-2565	84	28	;	;	PUNCT
ajlm-2565	84	29	20.0	20.0	NUM
ajlm-2565	84	30	%	%	NOUN
ajlm-2565	84	31	)	)	PUNCT
ajlm-2565	84	32	,	,	PUNCT
ajlm-2565	84	33	p	p	NOUN
ajlm-2565	84	34	-	-	PUNCT
ajlm-2565	84	35	value	value	NOUN
ajlm-2565	84	36	0.023	0.023	NUM
ajlm-2565	84	37	.	.	PUNCT
ajlm-2565	85	1	we	we	PRON
ajlm-2565	85	2	also	also	ADV
ajlm-2565	85	3	observed	observe	VERB
ajlm-2565	85	4	a	a	DET
ajlm-2565	85	5	significantly	significantly	ADV
ajlm-2565	85	6	higher	high	ADJ
ajlm-2565	85	7	prevalence	prevalence	NOUN
ajlm-2565	85	8	of	of	ADP
ajlm-2565	85	9	hyperuricaemia	hyperuricaemia	NOUN
ajlm-2565	85	10	among	among	ADP
ajlm-2565	85	11	employed	employ	VERB
ajlm-2565	85	12	participants	participant	NOUN
ajlm-2565	85	13	(	(	PUNCT
ajlm-2565	85	14	n	n	NOUN
ajlm-2565	85	15	=	=	SYM
ajlm-2565	85	16	44	44	NUM
ajlm-2565	85	17	;	;	PUNCT
ajlm-2565	85	18	28.4	28.4	NUM
ajlm-2565	85	19	%	%	NOUN
ajlm-2565	85	20	)	)	PUNCT
ajlm-2565	85	21	in	in	ADP
ajlm-2565	85	22	comparison	comparison	NOUN
ajlm-2565	85	23	to	to	ADP
ajlm-2565	85	24	the	the	DET
ajlm-2565	85	25	unemployed	unemployed	ADJ
ajlm-2565	85	26	(	(	PUNCT
ajlm-2565	85	27	n	n	NOUN
ajlm-2565	85	28	=	=	SYM
ajlm-2565	85	29	33	33	NUM
ajlm-2565	85	30	;	;	PUNCT
ajlm-2565	85	31	19.1	19.1	NUM
ajlm-2565	85	32	%	%	NOUN
ajlm-2565	85	33	)	)	PUNCT
ajlm-2565	85	34	,	,	PUNCT
ajlm-2565	85	35	p	p	NOUN
ajlm-2565	85	36	-	-	PUNCT
ajlm-2565	85	37	value	value	NOUN
ajlm-2565	85	38	0.047	0.047	NUM
ajlm-2565	85	39	(	(	PUNCT
ajlm-2565	85	40	table	table	NOUN
ajlm-2565	85	41	1	1	NUM
ajlm-2565	85	42	)	)	PUNCT
ajlm-2565	85	43	.	.	PUNCT
ajlm-2565	86	1	figure	figure	VERB
ajlm-2565	86	2	1	1	NUM
ajlm-2565	86	3	:	:	PUNCT
ajlm-2565	86	4	a	a	DET
ajlm-2565	86	5	bar	bar	NOUN
ajlm-2565	86	6	graph	graph	NOUN
ajlm-2565	86	7	showing	show	VERB
ajlm-2565	86	8	prevalence	prevalence	NOUN
ajlm-2565	86	9	of	of	ADP
ajlm-2565	86	10	hyperuricaemia	hyperuricaemia	NOUN
ajlm-2565	86	11	among	among	ADP
ajlm-2565	86	12	hiv	hiv	PROPN
ajlm-2565	86	13	-	-	PUNCT
ajlm-2565	86	14	positive	positive	ADJ
ajlm-2565	86	15	patients	patient	NOUN
ajlm-2565	86	16	in	in	ADP
ajlm-2565	86	17	south	south	ADJ
ajlm-2565	86	18	-	-	PUNCT
ajlm-2565	86	19	western	western	ADJ
ajlm-2565	86	20	uganda	uganda	PROPN
ajlm-2565	86	21	,	,	PUNCT
ajlm-2565	86	22	april	april	PROPN
ajlm-2565	86	23	2024	2024	NUM
ajlm-2565	86	24	to	to	ADP
ajlm-2565	86	25	june	june	PROPN
ajlm-2565	86	26	2024	2024	NUM
ajlm-2565	86	27	.	.	PUNCT
ajlm-2565	87	1	association	association	NOUN
ajlm-2565	87	2	between	between	ADP
ajlm-2565	87	3	obesity	obesity	NOUN
ajlm-2565	87	4	and	and	CCONJ
ajlm-2565	87	5	hyperuricaemia	hyperuricaemia	ADJ
ajlm-2565	87	6	overweight	overweight	NOUN
ajlm-2565	87	7	(	(	PUNCT
ajlm-2565	87	8	adjusted	adjust	VERB
ajlm-2565	87	9	or	or	CCONJ
ajlm-2565	87	10	:	:	PUNCT
ajlm-2565	87	11	2.01	2.01	NUM
ajlm-2565	87	12	;	;	PUNCT
ajlm-2565	87	13	95	95	NUM
ajlm-2565	87	14	%	%	NOUN
ajlm-2565	87	15	ci	ci	NOUN
ajlm-2565	87	16	:	:	PUNCT
ajlm-2565	87	17	1.01–4.00	1.01–4.00	NUM
ajlm-2565	87	18	;	;	PUNCT
ajlm-2565	87	19	p	p	X
ajlm-2565	87	20	=	=	PROPN
ajlm-2565	87	21	0.046	0.046	NUM
ajlm-2565	87	22	)	)	PUNCT
ajlm-2565	87	23	,	,	PUNCT
ajlm-2565	87	24	obesity	obesity	NOUN
ajlm-2565	87	25	(	(	PUNCT
ajlm-2565	87	26	adjusted	adjusted	ADJ
ajlm-2565	87	27	or	or	CCONJ
ajlm-2565	87	28	:	:	PUNCT
ajlm-2565	87	29	2.50	2.50	NUM
ajlm-2565	87	30	;	;	PUNCT
ajlm-2565	87	31	95	95	NUM
ajlm-2565	87	32	%	%	NOUN
ajlm-2565	87	33	ci	ci	NOUN
ajlm-2565	87	34	:	:	PUNCT
ajlm-2565	87	35	1.09–5.73	1.09–5.73	NUM
ajlm-2565	87	36	,	,	PUNCT
ajlm-2565	87	37	p	p	X
ajlm-2565	87	38	=	=	NOUN
ajlm-2565	87	39	0.030	0.030	NUM
ajlm-2565	87	40	)	)	PUNCT
ajlm-2565	87	41	,	,	PUNCT
ajlm-2565	87	42	and	and	CCONJ
ajlm-2565	87	43	male	male	ADJ
ajlm-2565	87	44	gender	gender	NOUN
ajlm-2565	87	45	(	(	PUNCT
ajlm-2565	87	46	adjusted	adjusted	ADJ
ajlm-2565	87	47	or	or	CCONJ
ajlm-2565	87	48	:	:	PUNCT
ajlm-2565	87	49	2.31	2.31	NUM
ajlm-2565	87	50	;	;	PUNCT
ajlm-2565	87	51	95	95	NUM
ajlm-2565	87	52	%	%	NOUN
ajlm-2565	87	53	ci	ci	NOUN
ajlm-2565	87	54	:	:	PUNCT
ajlm-2565	87	55	1.07–5.01	1.07–5.01	NUM
ajlm-2565	87	56	;	;	PUNCT
ajlm-2565	87	57	p	p	X
ajlm-2565	87	58	=	=	NOUN
ajlm-2565	87	59	0.033	0.033	NUM
ajlm-2565	87	60	)	)	PUNCT
ajlm-2565	87	61	were	be	AUX
ajlm-2565	87	62	significantly	significantly	ADV
ajlm-2565	87	63	associated	associate	VERB
ajlm-2565	87	64	with	with	ADP
ajlm-2565	87	65	the	the	DET
ajlm-2565	87	66	prevalence	prevalence	NOUN
ajlm-2565	87	67	of	of	ADP
ajlm-2565	87	68	hyperuricaemia	hyperuricaemia	NOUN
ajlm-2565	87	69	among	among	ADP
ajlm-2565	87	70	hiv	hiv	PROPN
ajlm-2565	87	71	-	-	PUNCT
ajlm-2565	87	72	positive	positive	ADJ
ajlm-2565	87	73	patients	patient	NOUN
ajlm-2565	87	74	(	(	PUNCT
ajlm-2565	87	75	table	table	NOUN
ajlm-2565	87	76	2	2	NUM
ajlm-2565	87	77	)	)	PUNCT
ajlm-2565	87	78	.	.	PUNCT
ajlm-2565	88	1	table	table	NOUN
ajlm-2565	88	2	2	2	NUM
ajlm-2565	88	3	:	:	PUNCT
ajlm-2565	88	4	 	 	SPACE
ajlm-2565	88	5	factors	factor	NOUN
ajlm-2565	88	6	associated	associate	VERB
ajlm-2565	88	7	with	with	ADP
ajlm-2565	88	8	hyperuricaemia	hyperuricaemia	NOUN
ajlm-2565	88	9	among	among	ADP
ajlm-2565	88	10	hiv	hiv	PROPN
ajlm-2565	88	11	-	-	PUNCT
ajlm-2565	88	12	positive	positive	ADJ
ajlm-2565	88	13	patients	patient	NOUN
ajlm-2565	88	14	in	in	ADP
ajlm-2565	88	15	south	south	ADJ
ajlm-2565	88	16	-	-	PUNCT
ajlm-2565	88	17	western	western	ADJ
ajlm-2565	88	18	uganda	uganda	PROPN
ajlm-2565	88	19	,	,	PUNCT
ajlm-2565	88	20	april	april	PROPN
ajlm-2565	88	21	2024	2024	NUM
ajlm-2565	88	22	to	to	ADP
ajlm-2565	88	23	june	june	PROPN
ajlm-2565	88	24	2024	2024	NUM
ajlm-2565	88	25	.	.	PUNCT
ajlm-2565	89	1	predictive	predictive	ADJ
ajlm-2565	89	2	performance	performance	NOUN
ajlm-2565	89	3	of	of	ADP
ajlm-2565	89	4	body	body	NOUN
ajlm-2565	89	5	mass	mass	NOUN
ajlm-2565	89	6	index	index	NOUN
ajlm-2565	89	7	for	for	ADP
ajlm-2565	89	8	hyperuricaemia	hyperuricaemia	ADJ
ajlm-2565	89	9	body	body	PROPN
ajlm-2565	89	10	mass	mass	PROPN
ajlm-2565	89	11	index	index	NOUN
ajlm-2565	89	12	did	do	AUX
ajlm-2565	89	13	not	not	PART
ajlm-2565	89	14	show	show	VERB
ajlm-2565	89	15	a	a	DET
ajlm-2565	89	16	significant	significant	ADJ
ajlm-2565	89	17	predictive	predictive	ADJ
ajlm-2565	89	18	power	power	NOUN
ajlm-2565	89	19	for	for	ADP
ajlm-2565	89	20	identifying	identify	VERB
ajlm-2565	89	21	hyperuricaemia	hyperuricaemia	NOUN
ajlm-2565	89	22	,	,	PUNCT
ajlm-2565	89	23	as	as	SCONJ
ajlm-2565	89	24	the	the	DET
ajlm-2565	89	25	95	95	NUM
ajlm-2565	89	26	%	%	NOUN
ajlm-2565	89	27	ci	ci	NOUN
ajlm-2565	89	28	includes	include	VERB
ajlm-2565	89	29	a	a	DET
ajlm-2565	89	30	null	null	ADJ
ajlm-2565	89	31	value	value	NOUN
ajlm-2565	89	32	of	of	ADP
ajlm-2565	89	33	0.5	0.5	NUM
ajlm-2565	89	34	,	,	PUNCT
ajlm-2565	89	35	which	which	PRON
ajlm-2565	89	36	randomly	randomly	ADV
ajlm-2565	89	37	classifies	classify	VERB
ajlm-2565	89	38	participants	participant	NOUN
ajlm-2565	89	39	in	in	ADP
ajlm-2565	89	40	the	the	DET
ajlm-2565	89	41	two	two	NUM
ajlm-2565	89	42	groups	group	NOUN
ajlm-2565	89	43	(	(	PUNCT
ajlm-2565	89	44	table	table	NOUN
ajlm-2565	89	45	3	3	NUM
ajlm-2565	89	46	)	)	PUNCT
ajlm-2565	89	47	.	.	PUNCT
ajlm-2565	90	1	however	however	ADV
ajlm-2565	90	2	,	,	PUNCT
ajlm-2565	90	3	a	a	DET
ajlm-2565	90	4	significant	significant	ADJ
ajlm-2565	90	5	difference	difference	NOUN
ajlm-2565	90	6	in	in	ADP
ajlm-2565	90	7	the	the	DET
ajlm-2565	90	8	predictive	predictive	ADJ
ajlm-2565	90	9	performance	performance	NOUN
ajlm-2565	90	10	of	of	ADP
ajlm-2565	90	11	bmi	bmi	NOUN
ajlm-2565	90	12	for	for	ADP
ajlm-2565	90	13	hyperuricaemia	hyperuricaemia	NOUN
ajlm-2565	90	14	was	be	AUX
ajlm-2565	90	15	noted	note	VERB
ajlm-2565	90	16	between	between	ADP
ajlm-2565	90	17	male	male	ADJ
ajlm-2565	90	18	participants	participant	NOUN
ajlm-2565	90	19	(	(	PUNCT
ajlm-2565	90	20	auc	auc	X
ajlm-2565	90	21	=	=	SYM
ajlm-2565	90	22	0.4128	0.4128	NUM
ajlm-2565	90	23	)	)	PUNCT
ajlm-2565	90	24	and	and	CCONJ
ajlm-2565	90	25	female	female	ADJ
ajlm-2565	90	26	participants	participant	NOUN
ajlm-2565	90	27	(	(	PUNCT
ajlm-2565	90	28	auc	auc	NOUN
ajlm-2565	90	29	=	=	SYM
ajlm-2565	90	30	0.657	0.657	NUM
ajlm-2565	90	31	)	)	PUNCT
ajlm-2565	90	32	,	,	PUNCT
ajlm-2565	90	33	p	p	NOUN
ajlm-2565	90	34	-	-	PUNCT
ajlm-2565	90	35	value	value	NOUN
ajlm-2565	90	36	0.0029	0.0029	NUM
ajlm-2565	90	37	(	(	PUNCT
ajlm-2565	90	38	table	table	NOUN
ajlm-2565	90	39	3	3	NUM
ajlm-2565	90	40	and	and	CCONJ
ajlm-2565	90	41	figure	figure	NOUN
ajlm-2565	90	42	2	2	NUM
ajlm-2565	90	43	)	)	PUNCT
ajlm-2565	90	44	.	.	PUNCT
ajlm-2565	91	1	body	body	NOUN
ajlm-2565	91	2	mass	mass	PROPN
ajlm-2565	91	3	index	index	NOUN
ajlm-2565	91	4	showed	show	VERB
ajlm-2565	91	5	a	a	DET
ajlm-2565	91	6	significant	significant	ADJ
ajlm-2565	91	7	predictive	predictive	ADJ
ajlm-2565	91	8	performance	performance	NOUN
ajlm-2565	91	9	for	for	ADP
ajlm-2565	91	10	hyperuricaemia	hyperuricaemia	NOUN
ajlm-2565	91	11	among	among	ADP
ajlm-2565	91	12	female	female	ADJ
ajlm-2565	91	13	participants	participant	NOUN
ajlm-2565	91	14	(	(	PUNCT
ajlm-2565	91	15	auc	auc	ADV
ajlm-2565	91	16	:	:	PUNCT
ajlm-2565	91	17	0.657	0.657	NUM
ajlm-2565	91	18	;	;	PUNCT
ajlm-2565	91	19	95	95	NUM
ajlm-2565	91	20	%	%	NOUN
ajlm-2565	91	21	ci	ci	NOUN
ajlm-2565	91	22	:	:	PUNCT
ajlm-2565	91	23	0.568–0.746	0.568–0.746	NUM
ajlm-2565	91	24	)	)	PUNCT
ajlm-2565	91	25	,	,	PUNCT
ajlm-2565	91	26	while	while	SCONJ
ajlm-2565	91	27	the	the	DET
ajlm-2565	91	28	predictive	predictive	ADJ
ajlm-2565	91	29	performance	performance	NOUN
ajlm-2565	91	30	was	be	AUX
ajlm-2565	91	31	not	not	PART
ajlm-2565	91	32	significant	significant	ADJ
ajlm-2565	91	33	among	among	ADP
ajlm-2565	91	34	male	male	ADJ
ajlm-2565	91	35	participants	participant	NOUN
ajlm-2565	91	36	(	(	PUNCT
ajlm-2565	91	37	auc	auc	X
ajlm-2565	91	38	=	=	SYM
ajlm-2565	91	39	0.4128	0.4128	NUM
ajlm-2565	91	40	;	;	PUNCT
ajlm-2565	91	41	95	95	NUM
ajlm-2565	91	42	%	%	NOUN
ajlm-2565	91	43	ci	ci	NOUN
ajlm-2565	91	44	:	:	PUNCT
ajlm-2565	91	45	0.279–0.546	0.279–0.546	NUM
ajlm-2565	91	46	)	)	PUNCT
ajlm-2565	91	47	.	.	PUNCT
ajlm-2565	92	1	at	at	ADP
ajlm-2565	92	2	an	an	DET
ajlm-2565	92	3	optimal	optimal	ADJ
ajlm-2565	92	4	cutoff	cutoff	NOUN
ajlm-2565	92	5	point	point	NOUN
ajlm-2565	92	6	of	of	ADP
ajlm-2565	92	7	≥	≥	NOUN
ajlm-2565	92	8	26.806	26.806	NUM
ajlm-2565	92	9	kg	kg	NOUN
ajlm-2565	92	10	/	/	SYM
ajlm-2565	92	11	m2	m2	PROPN
ajlm-2565	92	12	,	,	PUNCT
ajlm-2565	92	13	bmi	bmi	PROPN
ajlm-2565	92	14	can	can	AUX
ajlm-2565	92	15	significantly	significantly	ADV
ajlm-2565	92	16	separate	separate	VERB
ajlm-2565	92	17	female	female	ADJ
ajlm-2565	92	18	participants	participant	NOUN
ajlm-2565	92	19	with	with	ADP
ajlm-2565	92	20	or	or	CCONJ
ajlm-2565	92	21	without	without	ADP
ajlm-2565	92	22	hyperuricaemia	hyperuricaemia	NOUN
ajlm-2565	92	23	at	at	ADP
ajlm-2565	92	24	both	both	CCONJ
ajlm-2565	92	25	a	a	DET
ajlm-2565	92	26	sensitivity	sensitivity	NOUN
ajlm-2565	92	27	and	and	CCONJ
ajlm-2565	92	28	specificity	specificity	NOUN
ajlm-2565	92	29	of	of	ADP
ajlm-2565	92	30	65	65	NUM
ajlm-2565	92	31	%	%	NOUN
ajlm-2565	92	32	(	(	PUNCT
ajlm-2565	92	33	table	table	NOUN
ajlm-2565	92	34	3	3	NUM
ajlm-2565	92	35	)	)	PUNCT
ajlm-2565	92	36	.	.	PUNCT
ajlm-2565	93	1	figure	figure	VERB
ajlm-2565	93	2	2	2	NUM
ajlm-2565	93	3	:	:	PUNCT
ajlm-2565	93	4	the	the	DET
ajlm-2565	93	5	receiver	receiver	NOUN
ajlm-2565	93	6	operating	operate	VERB
ajlm-2565	93	7	characteristic	characteristic	ADJ
ajlm-2565	93	8	curves	curve	NOUN
ajlm-2565	93	9	of	of	ADP
ajlm-2565	93	10	the	the	DET
ajlm-2565	93	11	body	body	NOUN
ajlm-2565	93	12	mass	mass	NOUN
ajlm-2565	93	13	index	index	NOUN
ajlm-2565	93	14	for	for	ADP
ajlm-2565	93	15	separating	separate	VERB
ajlm-2565	93	16	participants	participant	NOUN
ajlm-2565	93	17	with	with	ADP
ajlm-2565	93	18	and	and	CCONJ
ajlm-2565	93	19	without	without	ADP
ajlm-2565	93	20	hyperuricaemia	hyperuricaemia	NOUN
ajlm-2565	93	21	among	among	ADP
ajlm-2565	93	22	(	(	PUNCT
ajlm-2565	93	23	a	a	PRON
ajlm-2565	93	24	)	)	PUNCT
ajlm-2565	93	25	male	male	NOUN
ajlm-2565	93	26	and	and	CCONJ
ajlm-2565	93	27	(	(	PUNCT
ajlm-2565	93	28	b	b	NOUN
ajlm-2565	93	29	)	)	PUNCT
ajlm-2565	93	30	female	female	ADJ
ajlm-2565	93	31	hiv	hiv	NOUN
ajlm-2565	93	32	-	-	PUNCT
ajlm-2565	93	33	positive	positive	ADJ
ajlm-2565	93	34	patients	patient	NOUN
ajlm-2565	93	35	in	in	ADP
ajlm-2565	93	36	south	south	ADJ
ajlm-2565	93	37	-	-	PUNCT
ajlm-2565	93	38	western	western	ADJ
ajlm-2565	93	39	uganda	uganda	PROPN
ajlm-2565	93	40	,	,	PUNCT
ajlm-2565	93	41	april	april	PROPN
ajlm-2565	93	42	2024	2024	NUM
ajlm-2565	93	43	to	to	ADP
ajlm-2565	93	44	june	june	PROPN
ajlm-2565	93	45	2024	2024	NUM
ajlm-2565	93	46	.	.	PUNCT
ajlm-2565	94	1	table	table	NOUN
ajlm-2565	94	2	3	3	NUM
ajlm-2565	94	3	:	:	PUNCT
ajlm-2565	94	4	 	 	SPACE
ajlm-2565	94	5	predictive	predictive	ADJ
ajlm-2565	94	6	performance	performance	NOUN
ajlm-2565	94	7	of	of	ADP
ajlm-2565	94	8	body	body	NOUN
ajlm-2565	94	9	mass	mass	NOUN
ajlm-2565	94	10	index	index	NOUN
ajlm-2565	94	11	for	for	ADP
ajlm-2565	94	12	hyperuricaemia	hyperuricaemia	NOUN
ajlm-2565	94	13	among	among	ADP
ajlm-2565	94	14	hiv	hiv	PROPN
ajlm-2565	94	15	-	-	PUNCT
ajlm-2565	94	16	positive	positive	ADJ
ajlm-2565	94	17	patients	patient	NOUN
ajlm-2565	94	18	in	in	ADP
ajlm-2565	94	19	south	south	ADJ
ajlm-2565	94	20	-	-	PUNCT
ajlm-2565	94	21	western	western	ADJ
ajlm-2565	94	22	uganda	uganda	PROPN
ajlm-2565	94	23	,	,	PUNCT
ajlm-2565	94	24	april	april	PROPN
ajlm-2565	94	25	2024	2024	NUM
ajlm-2565	94	26	to	to	ADP
ajlm-2565	94	27	june	june	PROPN
ajlm-2565	94	28	2024	2024	NUM
ajlm-2565	94	29	.	.	PUNCT
ajlm-2565	95	1	discussion	discussion	NOUN
ajlm-2565	95	2	our	our	PRON
ajlm-2565	95	3	findings	finding	NOUN
ajlm-2565	95	4	indicate	indicate	VERB
ajlm-2565	95	5	for	for	ADP
ajlm-2565	95	6	the	the	DET
ajlm-2565	95	7	first	first	ADJ
ajlm-2565	95	8	time	time	NOUN
ajlm-2565	95	9	the	the	DET
ajlm-2565	95	10	relationship	relationship	NOUN
ajlm-2565	95	11	between	between	ADP
ajlm-2565	95	12	obesity	obesity	NOUN
ajlm-2565	95	13	and	and	CCONJ
ajlm-2565	95	14	hyperuricaemia	hyperuricaemia	NOUN
ajlm-2565	95	15	in	in	ADP
ajlm-2565	95	16	uganda	uganda	PROPN
ajlm-2565	95	17	.	.	PUNCT
ajlm-2565	96	1	in	in	ADP
ajlm-2565	96	2	our	our	PRON
ajlm-2565	96	3	study	study	NOUN
ajlm-2565	96	4	,	,	PUNCT
ajlm-2565	96	5	the	the	DET
ajlm-2565	96	6	overall	overall	ADJ
ajlm-2565	96	7	prevalence	prevalence	NOUN
ajlm-2565	96	8	of	of	ADP
ajlm-2565	96	9	hyperuricaemia	hyperuricaemia	NOUN
ajlm-2565	96	10	was	be	AUX
ajlm-2565	96	11	23.48	23.48	NUM
ajlm-2565	96	12	%	%	NOUN
ajlm-2565	96	13	(	(	PUNCT
ajlm-2565	96	14	95	95	NUM
ajlm-2565	96	15	%	%	NOUN
ajlm-2565	96	16	ci	ci	NOUN
ajlm-2565	96	17	:	:	PUNCT
ajlm-2565	96	18	19.19–28.39	19.19–28.39	NUM
ajlm-2565	96	19	)	)	PUNCT
ajlm-2565	96	20	,	,	PUNCT
ajlm-2565	96	21	which	which	PRON
ajlm-2565	96	22	falls	fall	VERB
ajlm-2565	96	23	within	within	ADP
ajlm-2565	96	24	the	the	DET
ajlm-2565	96	25	worldwide	worldwide	ADJ
ajlm-2565	96	26	prevalence	prevalence	NOUN
ajlm-2565	96	27	,	,	PUNCT
ajlm-2565	96	28	which	which	PRON
ajlm-2565	96	29	is	be	AUX
ajlm-2565	96	30	reported	report	VERB
ajlm-2565	96	31	to	to	PART
ajlm-2565	96	32	range	range	VERB
ajlm-2565	96	33	from	from	ADP
ajlm-2565	96	34	2.6	2.6	NUM
ajlm-2565	96	35	%	%	NOUN
ajlm-2565	96	36	to	to	ADP
ajlm-2565	96	37	36.0	36.0	NUM
ajlm-2565	96	38	%	%	NOUN
ajlm-2565	96	39	in	in	ADP
ajlm-2565	96	40	different	different	ADJ
ajlm-2565	96	41	populations	population	NOUN
ajlm-2565	96	42	by	by	ADP
ajlm-2565	96	43	a	a	DET
ajlm-2565	96	44	study	study	NOUN
ajlm-2565	96	45	carried	carry	VERB
ajlm-2565	96	46	out	out	ADP
ajlm-2565	96	47	in	in	ADP
ajlm-2565	96	48	bangkok	bangkok	PROPN
ajlm-2565	96	49	in	in	ADP
ajlm-2565	96	50	2011.32	2011.32	NUM
ajlm-2565	96	51	our	our	PRON
ajlm-2565	96	52	overall	overall	ADJ
ajlm-2565	96	53	prevalence	prevalence	NOUN
ajlm-2565	96	54	is	be	AUX
ajlm-2565	96	55	also	also	ADV
ajlm-2565	96	56	in	in	ADP
ajlm-2565	96	57	agreement	agreement	NOUN
ajlm-2565	96	58	with	with	ADP
ajlm-2565	96	59	the	the	DET
ajlm-2565	96	60	hyperuricaemia	hyperuricaemia	ADJ
ajlm-2565	96	61	prevalence	prevalence	NOUN
ajlm-2565	96	62	of	of	ADP
ajlm-2565	96	63	25.2	25.2	NUM
ajlm-2565	96	64	%	%	NOUN
ajlm-2565	96	65	reported	report	VERB
ajlm-2565	96	66	among	among	ADP
ajlm-2565	96	67	hiv	hiv	PROPN
ajlm-2565	96	68	-	-	PUNCT
ajlm-2565	96	69	positive	positive	ADJ
ajlm-2565	96	70	patients	patient	NOUN
ajlm-2565	96	71	receiving	receive	VERB
ajlm-2565	96	72	stable	stable	ADJ
ajlm-2565	96	73	highly	highly	ADV
ajlm-2565	96	74	active	active	ADJ
ajlm-2565	96	75	art	art	NOUN
ajlm-2565	96	76	in	in	ADP
ajlm-2565	96	77	perugia	perugia	NOUN
ajlm-2565	96	78	in	in	ADP
ajlm-2565	96	79	2018.33	2018.33	NUM
ajlm-2565	96	80	however	however	ADV
ajlm-2565	96	81	,	,	PUNCT
ajlm-2565	96	82	our	our	PRON
ajlm-2565	96	83	study	study	NOUN
ajlm-2565	96	84	prevalence	prevalence	NOUN
ajlm-2565	96	85	is	be	AUX
ajlm-2565	96	86	significantly	significantly	ADV
ajlm-2565	96	87	lower	low	ADJ
ajlm-2565	96	88	than	than	ADP
ajlm-2565	96	89	a	a	DET
ajlm-2565	96	90	2021	2021	NUM
ajlm-2565	96	91	study	study	NOUN
ajlm-2565	96	92	on	on	ADP
ajlm-2565	96	93	south	south	PROPN
ajlm-2565	96	94	indian	indian	ADJ
ajlm-2565	96	95	adult	adult	NOUN
ajlm-2565	96	96	patients	patient	NOUN
ajlm-2565	96	97	with	with	ADP
ajlm-2565	96	98	stable	stable	ADJ
ajlm-2565	96	99	coronary	coronary	ADJ
ajlm-2565	96	100	artery	artery	NOUN
ajlm-2565	96	101	disease	disease	NOUN
ajlm-2565	96	102	(	(	PUNCT
ajlm-2565	96	103	46.5%).34	46.5%).34	NUM
ajlm-2565	96	104	limited	limited	ADJ
ajlm-2565	96	105	studies	study	NOUN
ajlm-2565	96	106	done	do	VERB
ajlm-2565	96	107	in	in	ADP
ajlm-2565	96	108	africa	africa	PROPN
ajlm-2565	96	109	have	have	AUX
ajlm-2565	96	110	tried	try	VERB
ajlm-2565	96	111	to	to	PART
ajlm-2565	96	112	establish	establish	VERB
ajlm-2565	96	113	the	the	DET
ajlm-2565	96	114	prevalence	prevalence	NOUN
ajlm-2565	96	115	of	of	ADP
ajlm-2565	96	116	hyperuricaemia	hyperuricaemia	NOUN
ajlm-2565	96	117	among	among	ADP
ajlm-2565	96	118	hiv	hiv	PROPN
ajlm-2565	96	119	patients	patient	NOUN
ajlm-2565	96	120	.	.	PUNCT
ajlm-2565	97	1	a	a	DET
ajlm-2565	97	2	study	study	NOUN
ajlm-2565	97	3	done	do	VERB
ajlm-2565	97	4	in	in	ADP
ajlm-2565	97	5	zimbabwe	zimbabwe	NOUN
ajlm-2565	97	6	in	in	ADP
ajlm-2565	97	7	2017	2017	NUM
ajlm-2565	97	8	found	find	VERB
ajlm-2565	97	9	a	a	DET
ajlm-2565	97	10	prevalence	prevalence	NOUN
ajlm-2565	97	11	of	of	ADP
ajlm-2565	97	12	13.0	13.0	NUM
ajlm-2565	97	13	%	%	NOUN
ajlm-2565	97	14	,	,	PUNCT
ajlm-2565	97	15	which	which	PRON
ajlm-2565	97	16	was	be	AUX
ajlm-2565	97	17	lower	low	ADJ
ajlm-2565	97	18	than	than	ADP
ajlm-2565	97	19	our	our	PRON
ajlm-2565	97	20	finding.35	finding.35	NOUN
ajlm-2565	97	21	since	since	SCONJ
ajlm-2565	97	22	literature	literature	NOUN
ajlm-2565	97	23	is	be	AUX
ajlm-2565	97	24	scanty	scanty	ADJ
ajlm-2565	97	25	,	,	PUNCT
ajlm-2565	97	26	we	we	PRON
ajlm-2565	97	27	had	have	VERB
ajlm-2565	97	28	to	to	PART
ajlm-2565	97	29	compare	compare	VERB
ajlm-2565	97	30	our	our	PRON
ajlm-2565	97	31	results	result	NOUN
ajlm-2565	97	32	with	with	ADP
ajlm-2565	97	33	dissimilar	dissimilar	ADJ
ajlm-2565	97	34	studies	study	NOUN
ajlm-2565	97	35	that	that	PRON
ajlm-2565	97	36	did	do	AUX
ajlm-2565	97	37	not	not	PART
ajlm-2565	97	38	deal	deal	VERB
ajlm-2565	97	39	with	with	ADP
ajlm-2565	97	40	hiv	hiv	PROPN
ajlm-2565	97	41	patients	patient	NOUN
ajlm-2565	97	42	.	.	PUNCT
ajlm-2565	98	1	our	our	PRON
ajlm-2565	98	2	results	result	NOUN
ajlm-2565	98	3	are	be	AUX
ajlm-2565	98	4	in	in	ADP
ajlm-2565	98	5	agreement	agreement	NOUN
ajlm-2565	98	6	with	with	ADP
ajlm-2565	98	7	the	the	DET
ajlm-2565	98	8	20.5	20.5	NUM
ajlm-2565	98	9	%	%	NOUN
ajlm-2565	98	10	prevalence	prevalence	NOUN
ajlm-2565	98	11	reported	report	VERB
ajlm-2565	98	12	among	among	ADP
ajlm-2565	98	13	adults	adult	NOUN
ajlm-2565	98	14	in	in	ADP
ajlm-2565	98	15	nigeria	nigeria	PRON
ajlm-2565	98	16	in	in	ADP
ajlm-2565	98	17	2016,36	2016,36	NUM
ajlm-2565	98	18	and	and	CCONJ
ajlm-2565	98	19	the	the	DET
ajlm-2565	98	20	28.0	28.0	NUM
ajlm-2565	98	21	%	%	NOUN
ajlm-2565	98	22	prevalence	prevalence	NOUN
ajlm-2565	98	23	among	among	ADP
ajlm-2565	98	24	outpatients	outpatient	NOUN
ajlm-2565	98	25	at	at	ADP
ajlm-2565	98	26	bafoussam	bafoussam	PROPN
ajlm-2565	98	27	regional	regional	ADJ
ajlm-2565	98	28	hospital	hospital	NOUN
ajlm-2565	98	29	in	in	ADP
ajlm-2565	98	30	gabon	gabon	PROPN
ajlm-2565	98	31	in	in	ADP
ajlm-2565	98	32	2024,37	2024,37	PROPN
ajlm-2565	98	33	but	but	CCONJ
ajlm-2565	98	34	are	be	AUX
ajlm-2565	98	35	in	in	ADP
ajlm-2565	98	36	disagreement	disagreement	NOUN
ajlm-2565	98	37	with	with	ADP
ajlm-2565	98	38	the	the	DET
ajlm-2565	98	39	prevalence	prevalence	NOUN
ajlm-2565	98	40	of	of	ADP
ajlm-2565	98	41	31.0	31.0	NUM
ajlm-2565	98	42	%	%	NOUN
ajlm-2565	98	43	reported	report	VERB
ajlm-2565	98	44	by	by	ADP
ajlm-2565	98	45	a	a	DET
ajlm-2565	98	46	cross	cross	ADJ
ajlm-2565	98	47	-	-	ADJ
ajlm-2565	98	48	sectional	sectional	ADJ
ajlm-2565	98	49	study	study	NOUN
ajlm-2565	98	50	conducted	conduct	VERB
ajlm-2565	98	51	in	in	ADP
ajlm-2565	98	52	ethiopia	ethiopia	PROPN
ajlm-2565	98	53	among	among	ADP
ajlm-2565	98	54	adult	adult	NOUN
ajlm-2565	98	55	staff	staff	NOUN
ajlm-2565	98	56	members	member	NOUN
ajlm-2565	98	57	of	of	ADP
ajlm-2565	98	58	a	a	DET
ajlm-2565	98	59	public	public	ADJ
ajlm-2565	98	60	health	health	NOUN
ajlm-2565	98	61	institute.34	institute.34	NOUN
ajlm-2565	98	62	these	these	DET
ajlm-2565	98	63	discrepancies	discrepancy	NOUN
ajlm-2565	98	64	may	may	AUX
ajlm-2565	98	65	be	be	AUX
ajlm-2565	98	66	because	because	SCONJ
ajlm-2565	98	67	of	of	ADP
ajlm-2565	98	68	differences	difference	NOUN
ajlm-2565	98	69	in	in	ADP
ajlm-2565	98	70	ethnic	ethnic	ADJ
ajlm-2565	98	71	background	background	NOUN
ajlm-2565	98	72	and	and	CCONJ
ajlm-2565	98	73	study	study	NOUN
ajlm-2565	98	74	populations	population	NOUN
ajlm-2565	98	75	.	.	PUNCT
ajlm-2565	99	1	a	a	DET
ajlm-2565	99	2	significantly	significantly	ADV
ajlm-2565	99	3	higher	high	ADJ
ajlm-2565	99	4	prevalence	prevalence	NOUN
ajlm-2565	99	5	of	of	ADP
ajlm-2565	99	6	hyperuricaemia	hyperuricaemia	NOUN
ajlm-2565	99	7	was	be	AUX
ajlm-2565	99	8	observed	observe	VERB
ajlm-2565	99	9	among	among	ADP
ajlm-2565	99	10	male	male	ADJ
ajlm-2565	99	11	participants	participant	NOUN
ajlm-2565	99	12	than	than	ADP
ajlm-2565	99	13	female	female	ADJ
ajlm-2565	99	14	participants	participant	NOUN
ajlm-2565	99	15	,	,	PUNCT
ajlm-2565	99	16	as	as	SCONJ
ajlm-2565	99	17	was	be	AUX
ajlm-2565	99	18	also	also	ADV
ajlm-2565	99	19	reflected	reflect	VERB
ajlm-2565	99	20	in	in	ADP
ajlm-2565	99	21	previous	previous	ADJ
ajlm-2565	99	22	studies.38,39,40	studies.38,39,40	NOUN
ajlm-2565	99	23	our	our	PRON
ajlm-2565	99	24	study	study	NOUN
ajlm-2565	99	25	notes	note	VERB
ajlm-2565	99	26	a	a	DET
ajlm-2565	99	27	significant	significant	ADJ
ajlm-2565	99	28	association	association	NOUN
ajlm-2565	99	29	between	between	ADP
ajlm-2565	99	30	male	male	ADJ
ajlm-2565	99	31	gender	gender	NOUN
ajlm-2565	99	32	and	and	CCONJ
ajlm-2565	99	33	the	the	DET
ajlm-2565	99	34	presence	presence	NOUN
ajlm-2565	99	35	of	of	ADP
ajlm-2565	99	36	hyperuricaemia	hyperuricaemia	NOUN
ajlm-2565	99	37	among	among	ADP
ajlm-2565	99	38	hiv	hiv	PROPN
ajlm-2565	99	39	patients	patient	NOUN
ajlm-2565	99	40	on	on	ADP
ajlm-2565	99	41	art	art	NOUN
ajlm-2565	99	42	.	.	PUNCT
ajlm-2565	100	1	this	this	DET
ajlm-2565	100	2	association	association	NOUN
ajlm-2565	100	3	is	be	AUX
ajlm-2565	100	4	in	in	ADP
ajlm-2565	100	5	agreement	agreement	NOUN
ajlm-2565	100	6	with	with	ADP
ajlm-2565	100	7	the	the	DET
ajlm-2565	100	8	findings	finding	NOUN
ajlm-2565	100	9	of	of	ADP
ajlm-2565	100	10	a	a	DET
ajlm-2565	100	11	study	study	NOUN
ajlm-2565	100	12	conducted	conduct	VERB
ajlm-2565	100	13	in	in	ADP
ajlm-2565	100	14	kenya	kenya	PROPN
ajlm-2565	100	15	in	in	ADP
ajlm-2565	100	16	2018	2018	NUM
ajlm-2565	100	17	among	among	ADP
ajlm-2565	100	18	university	university	NOUN
ajlm-2565	100	19	workers	worker	NOUN
ajlm-2565	100	20	that	that	PRON
ajlm-2565	100	21	found	find	VERB
ajlm-2565	100	22	that	that	SCONJ
ajlm-2565	100	23	hyperuricaemia	hyperuricaemia	NOUN
ajlm-2565	100	24	was	be	AUX
ajlm-2565	100	25	threefold	threefold	ADV
ajlm-2565	100	26	higher	higher	ADV
ajlm-2565	100	27	in	in	ADP
ajlm-2565	100	28	male	male	ADJ
ajlm-2565	100	29	participants	participant	NOUN
ajlm-2565	100	30	(	(	PUNCT
ajlm-2565	100	31	adjusted	adjust	VERB
ajlm-2565	100	32	or	or	CCONJ
ajlm-2565	100	33	2.938	2.938	NUM
ajlm-2565	100	34	;	;	PUNCT
ajlm-2565	100	35	95	95	NUM
ajlm-2565	100	36	%	%	NOUN
ajlm-2565	100	37	ci	ci	NOUN
ajlm-2565	100	38	,	,	PUNCT
ajlm-2565	100	39	1.909–4.522	1.909–4.522	NOUN
ajlm-2565	100	40	,	,	PUNCT
ajlm-2565	100	41	p	p	X
ajlm-2565	100	42	<	<	X
ajlm-2565	100	43	0.01	0.01	NUM
ajlm-2565	100	44	)	)	PUNCT
ajlm-2565	100	45	than	than	ADP
ajlm-2565	100	46	female	female	ADJ
ajlm-2565	100	47	participants.39	participants.39	NOUN
ajlm-2565	100	48	a	a	DET
ajlm-2565	100	49	related	related	ADJ
ajlm-2565	100	50	study	study	NOUN
ajlm-2565	100	51	in	in	ADP
ajlm-2565	100	52	ethiopia	ethiopia	PROPN
ajlm-2565	100	53	in	in	ADP
ajlm-2565	100	54	2021	2021	NUM
ajlm-2565	100	55	,	,	PUNCT
ajlm-2565	100	56	though	though	SCONJ
ajlm-2565	100	57	in	in	ADP
ajlm-2565	100	58	a	a	DET
ajlm-2565	100	59	different	different	ADJ
ajlm-2565	100	60	study	study	NOUN
ajlm-2565	100	61	population	population	NOUN
ajlm-2565	100	62	,	,	PUNCT
ajlm-2565	100	63	also	also	ADV
ajlm-2565	100	64	observed	observe	VERB
ajlm-2565	100	65	a	a	DET
ajlm-2565	100	66	significant	significant	ADJ
ajlm-2565	100	67	association	association	NOUN
ajlm-2565	100	68	between	between	ADP
ajlm-2565	100	69	male	male	ADJ
ajlm-2565	100	70	gender	gender	NOUN
ajlm-2565	100	71	and	and	CCONJ
ajlm-2565	100	72	hyperuricaemia.34	hyperuricaemia.34	PRON
ajlm-2565	100	73	our	our	PRON
ajlm-2565	100	74	findings	finding	NOUN
ajlm-2565	100	75	in	in	ADP
ajlm-2565	100	76	respect	respect	NOUN
ajlm-2565	100	77	to	to	ADP
ajlm-2565	100	78	the	the	DET
ajlm-2565	100	79	odds	odd	NOUN
ajlm-2565	100	80	of	of	ADP
ajlm-2565	100	81	hyperuricaemia	hyperuricaemia	NOUN
ajlm-2565	100	82	(	(	PUNCT
ajlm-2565	100	83	which	which	PRON
ajlm-2565	100	84	were	be	AUX
ajlm-2565	100	85	2.01	2.01	NUM
ajlm-2565	100	86	times	time	NOUN
ajlm-2565	100	87	higher	high	ADJ
ajlm-2565	100	88	in	in	ADP
ajlm-2565	100	89	overweight	overweight	ADJ
ajlm-2565	100	90	participants	participant	NOUN
ajlm-2565	100	91	and	and	CCONJ
ajlm-2565	100	92	2.5	2.5	NUM
ajlm-2565	100	93	times	time	NOUN
ajlm-2565	100	94	higher	high	ADJ
ajlm-2565	100	95	in	in	ADP
ajlm-2565	100	96	obese	obese	ADJ
ajlm-2565	100	97	participants	participant	NOUN
ajlm-2565	100	98	than	than	SCONJ
ajlm-2565	100	99	in	in	ADP
ajlm-2565	100	100	participants	participant	NOUN
ajlm-2565	100	101	with	with	ADP
ajlm-2565	100	102	a	a	DET
ajlm-2565	100	103	bmi	bmi	NOUN
ajlm-2565	100	104	<	<	X
ajlm-2565	100	105	25	25	NUM
ajlm-2565	100	106	kg	kg	NOUN
ajlm-2565	100	107	/	/	SYM
ajlm-2565	100	108	m2	m2	PROPN
ajlm-2565	100	109	)	)	PUNCT
ajlm-2565	100	110	were	be	AUX
ajlm-2565	100	111	consistent	consistent	ADJ
ajlm-2565	100	112	with	with	ADP
ajlm-2565	100	113	results	result	NOUN
ajlm-2565	100	114	from	from	ADP
ajlm-2565	100	115	a	a	DET
ajlm-2565	100	116	zimbabwean	zimbabwean	ADJ
ajlm-2565	100	117	study	study	NOUN
ajlm-2565	100	118	in	in	ADP
ajlm-2565	100	119	2017	2017	NUM
ajlm-2565	100	120	that	that	PRON
ajlm-2565	100	121	showed	show	VERB
ajlm-2565	100	122	a	a	DET
ajlm-2565	100	123	significant	significant	ADJ
ajlm-2565	100	124	association	association	NOUN
ajlm-2565	100	125	between	between	ADP
ajlm-2565	100	126	hyperuricaemia	hyperuricaemia	NOUN
ajlm-2565	100	127	and	and	CCONJ
ajlm-2565	100	128	a	a	DET
ajlm-2565	100	129	bmi	bmi	NOUN
ajlm-2565	100	130	(	(	PUNCT
ajlm-2565	100	131	an	an	DET
ajlm-2565	100	132	indicator	indicator	NOUN
ajlm-2565	100	133	of	of	ADP
ajlm-2565	100	134	obesity	obesity	NOUN
ajlm-2565	100	135	)	)	PUNCT
ajlm-2565	100	136	>	>	X
ajlm-2565	101	1	30	30	NUM
ajlm-2565	101	2	kg	kg	NOUN
ajlm-2565	101	3	/	/	SYM
ajlm-2565	101	4	m2,35	m2,35	NOUN
ajlm-2565	101	5	and	and	CCONJ
ajlm-2565	101	6	a	a	DET
ajlm-2565	101	7	cross	cross	ADJ
ajlm-2565	101	8	-	-	ADJ
ajlm-2565	101	9	sectional	sectional	ADJ
ajlm-2565	101	10	study	study	NOUN
ajlm-2565	101	11	among	among	ADP
ajlm-2565	101	12	male	male	ADJ
ajlm-2565	101	13	adults	adult	NOUN
ajlm-2565	101	14	in	in	ADP
ajlm-2565	101	15	nigeria	nigeria	PROPN
ajlm-2565	101	16	in	in	ADP
ajlm-2565	101	17	2015.41	2015.41	NUM
ajlm-2565	101	18	these	these	DET
ajlm-2565	101	19	findings	finding	NOUN
ajlm-2565	101	20	were	be	AUX
ajlm-2565	101	21	also	also	ADV
ajlm-2565	101	22	in	in	ADP
ajlm-2565	101	23	agreement	agreement	NOUN
ajlm-2565	101	24	with	with	ADP
ajlm-2565	101	25	a	a	DET
ajlm-2565	101	26	study	study	NOUN
ajlm-2565	101	27	conducted	conduct	VERB
ajlm-2565	101	28	on	on	ADP
ajlm-2565	101	29	bangladeshi	bangladeshi	ADJ
ajlm-2565	101	30	adults	adult	NOUN
ajlm-2565	101	31	in	in	ADP
ajlm-2565	101	32	2018	2018	NUM
ajlm-2565	101	33	that	that	PRON
ajlm-2565	101	34	found	find	VERB
ajlm-2565	101	35	that	that	SCONJ
ajlm-2565	101	36	even	even	ADV
ajlm-2565	101	37	after	after	ADP
ajlm-2565	101	38	adjusting	adjust	VERB
ajlm-2565	101	39	for	for	ADP
ajlm-2565	101	40	lipid	lipid	NOUN
ajlm-2565	101	41	profile	profile	NOUN
ajlm-2565	101	42	,	,	PUNCT
ajlm-2565	101	43	age	age	NOUN
ajlm-2565	101	44	and	and	CCONJ
ajlm-2565	101	45	sex	sex	NOUN
ajlm-2565	101	46	,	,	PUNCT
ajlm-2565	101	47	the	the	DET
ajlm-2565	101	48	prevalence	prevalence	NOUN
ajlm-2565	101	49	of	of	ADP
ajlm-2565	101	50	obesity	obesity	NOUN
ajlm-2565	101	51	increased	increase	VERB
ajlm-2565	101	52	progressively	progressively	ADV
ajlm-2565	101	53	across	across	ADP
ajlm-2565	101	54	the	the	DET
ajlm-2565	101	55	sua	sua	NOUN
ajlm-2565	101	56	quartiles	quartile	NOUN
ajlm-2565	101	57	.	.	PUNCT
ajlm-2565	102	1	the	the	DET
ajlm-2565	102	2	sua	sua	PROPN
ajlm-2565	102	3	levels	level	NOUN
ajlm-2565	102	4	were	be	AUX
ajlm-2565	102	5	also	also	ADV
ajlm-2565	102	6	closely	closely	ADV
ajlm-2565	102	7	and	and	CCONJ
ajlm-2565	102	8	independently	independently	ADV
ajlm-2565	102	9	associated	associate	VERB
ajlm-2565	102	10	with	with	ADP
ajlm-2565	102	11	obesity.4	obesity.4	NOUN
ajlm-2565	102	12	another	another	DET
ajlm-2565	102	13	recent	recent	ADJ
ajlm-2565	102	14	nationwide	nationwide	ADJ
ajlm-2565	102	15	study	study	NOUN
ajlm-2565	102	16	in	in	ADP
ajlm-2565	102	17	china	china	PROPN
ajlm-2565	102	18	done	do	VERB
ajlm-2565	102	19	in	in	ADP
ajlm-2565	102	20	2024	2024	NUM
ajlm-2565	102	21	also	also	ADV
ajlm-2565	102	22	documented	document	VERB
ajlm-2565	102	23	a	a	DET
ajlm-2565	102	24	significant	significant	ADJ
ajlm-2565	102	25	association	association	NOUN
ajlm-2565	102	26	between	between	ADP
ajlm-2565	102	27	obesity	obesity	NOUN
ajlm-2565	102	28	indices	index	NOUN
ajlm-2565	102	29	,	,	PUNCT
ajlm-2565	102	30	including	include	VERB
ajlm-2565	102	31	bmi	bmi	NOUN
ajlm-2565	102	32	and	and	CCONJ
ajlm-2565	102	33	risk	risk	NOUN
ajlm-2565	102	34	of	of	ADP
ajlm-2565	102	35	hyperuricaemia.42	hyperuricaemia.42	X
ajlm-2565	102	36	also	also	ADV
ajlm-2565	102	37	,	,	PUNCT
ajlm-2565	102	38	in	in	ADP
ajlm-2565	102	39	line	line	NOUN
ajlm-2565	102	40	with	with	ADP
ajlm-2565	102	41	our	our	PRON
ajlm-2565	102	42	findings	finding	NOUN
ajlm-2565	102	43	,	,	PUNCT
ajlm-2565	102	44	numerous	numerous	ADJ
ajlm-2565	102	45	studies	study	NOUN
ajlm-2565	102	46	have	have	AUX
ajlm-2565	102	47	demonstrated	demonstrate	VERB
ajlm-2565	102	48	a	a	DET
ajlm-2565	102	49	positive	positive	ADJ
ajlm-2565	102	50	association	association	NOUN
ajlm-2565	102	51	between	between	ADP
ajlm-2565	102	52	sua	sua	NOUN
ajlm-2565	102	53	and	and	CCONJ
ajlm-2565	102	54	obesity	obesity	NOUN
ajlm-2565	102	55	in	in	ADP
ajlm-2565	102	56	various	various	ADJ
ajlm-2565	102	57	populations	population	NOUN
ajlm-2565	102	58	.	.	PUNCT
ajlm-2565	103	1	for	for	ADP
ajlm-2565	103	2	instance	instance	NOUN
ajlm-2565	103	3	,	,	PUNCT
ajlm-2565	103	4	a	a	DET
ajlm-2565	103	5	10	10	NUM
ajlm-2565	103	6	-	-	PUNCT
ajlm-2565	103	7	year	year	NOUN
ajlm-2565	103	8	follow	follow	NOUN
ajlm-2565	103	9	-	-	PUNCT
ajlm-2565	103	10	up	up	ADP
ajlm-2565	103	11	research	research	NOUN
ajlm-2565	103	12	study	study	NOUN
ajlm-2565	103	13	in	in	ADP
ajlm-2565	103	14	2007	2007	NUM
ajlm-2565	103	15	revealed	reveal	VERB
ajlm-2565	103	16	that	that	SCONJ
ajlm-2565	103	17	,	,	PUNCT
ajlm-2565	103	18	across	across	ADP
ajlm-2565	103	19	all	all	DET
ajlm-2565	103	20	race	race	NOUN
ajlm-2565	103	21	-	-	PUNCT
ajlm-2565	103	22	sex	sex	NOUN
ajlm-2565	103	23	-	-	PUNCT
ajlm-2565	103	24	groups	group	NOUN
ajlm-2565	103	25	,	,	PUNCT
ajlm-2565	103	26	rising	rise	VERB
ajlm-2565	103	27	sua	sua	NOUN
ajlm-2565	103	28	levels	level	NOUN
ajlm-2565	103	29	were	be	AUX
ajlm-2565	103	30	substantially	substantially	ADV
ajlm-2565	103	31	correlated	correlate	VERB
ajlm-2565	103	32	with	with	ADP
ajlm-2565	103	33	higher	high	ADJ
ajlm-2565	103	34	bmi.43	bmi.43	ADJ
ajlm-2565	103	35	studies	study	NOUN
ajlm-2565	103	36	from	from	ADP
ajlm-2565	103	37	different	different	ADJ
ajlm-2565	103	38	ethnicities	ethnicity	NOUN
ajlm-2565	103	39	also	also	ADV
ajlm-2565	103	40	found	find	VERB
ajlm-2565	103	41	a	a	DET
ajlm-2565	103	42	positive	positive	ADJ
ajlm-2565	103	43	relationship	relationship	NOUN
ajlm-2565	103	44	between	between	ADP
ajlm-2565	103	45	hyperuricaemia	hyperuricaemia	NOUN
ajlm-2565	103	46	and	and	CCONJ
ajlm-2565	103	47	obesity	obesity	NOUN
ajlm-2565	103	48	.	.	PUNCT
ajlm-2565	104	1	for	for	ADP
ajlm-2565	104	2	example	example	NOUN
ajlm-2565	104	3	,	,	PUNCT
ajlm-2565	104	4	tanaka	tanaka	PROPN
ajlm-2565	104	5	et	et	PROPN
ajlm-2565	104	6	al	al	PROPN
ajlm-2565	104	7	.	.	PROPN
ajlm-2565	104	8	established	establish	VERB
ajlm-2565	104	9	that	that	SCONJ
ajlm-2565	104	10	,	,	PUNCT
ajlm-2565	104	11	after	after	ADP
ajlm-2565	104	12	correcting	correct	VERB
ajlm-2565	104	13	for	for	ADP
ajlm-2565	104	14	genetic	genetic	ADJ
ajlm-2565	104	15	and	and	CCONJ
ajlm-2565	104	16	environmental	environmental	ADJ
ajlm-2565	104	17	variables	variable	NOUN
ajlm-2565	104	18	in	in	ADP
ajlm-2565	104	19	both	both	DET
ajlm-2565	104	20	genders	gender	NOUN
ajlm-2565	104	21	,	,	PUNCT
ajlm-2565	104	22	there	there	PRON
ajlm-2565	104	23	was	be	VERB
ajlm-2565	104	24	a	a	DET
ajlm-2565	104	25	significant	significant	ADJ
ajlm-2565	104	26	correlation	correlation	NOUN
ajlm-2565	104	27	between	between	ADP
ajlm-2565	104	28	bmi	bmi	PROPN
ajlm-2565	104	29	and	and	CCONJ
ajlm-2565	104	30	sua	sua	PROPN
ajlm-2565	104	31	levels	level	NOUN
ajlm-2565	104	32	in	in	ADP
ajlm-2565	104	33	japanese	japanese	ADJ
ajlm-2565	104	34	adult	adult	NOUN
ajlm-2565	104	35	twins	twin	NOUN
ajlm-2565	104	36	in	in	ADP
ajlm-2565	104	37	2015.26	2015.26	NUM
ajlm-2565	104	38	another	another	DET
ajlm-2565	104	39	study	study	NOUN
ajlm-2565	104	40	by	by	ADP
ajlm-2565	104	41	wang	wang	PROPN
ajlm-2565	104	42	et	et	PROPN
ajlm-2565	104	43	al	al	PROPN
ajlm-2565	104	44	.	.	PROPN
ajlm-2565	104	45	reported	report	VERB
ajlm-2565	104	46	that	that	SCONJ
ajlm-2565	104	47	,	,	PUNCT
ajlm-2565	104	48	among	among	ADP
ajlm-2565	104	49	healthy	healthy	ADJ
ajlm-2565	104	50	people	people	NOUN
ajlm-2565	104	51	in	in	ADP
ajlm-2565	104	52	the	the	DET
ajlm-2565	104	53	chinese	chinese	ADJ
ajlm-2565	104	54	province	province	NOUN
ajlm-2565	104	55	of	of	ADP
ajlm-2565	104	56	jiangsu	jiangsu	PROPN
ajlm-2565	104	57	in	in	ADP
ajlm-2565	104	58	2014	2014	NUM
ajlm-2565	104	59	,	,	PUNCT
ajlm-2565	104	60	there	there	PRON
ajlm-2565	104	61	was	be	VERB
ajlm-2565	104	62	a	a	DET
ajlm-2565	104	63	positive	positive	ADJ
ajlm-2565	104	64	correlation	correlation	NOUN
ajlm-2565	104	65	between	between	ADP
ajlm-2565	104	66	bmi	bmi	PROPN
ajlm-2565	104	67	and	and	CCONJ
ajlm-2565	104	68	sua	sua	NOUN
ajlm-2565	104	69	levels.20	levels.20	PROPN
ajlm-2565	104	70	more	more	ADV
ajlm-2565	104	71	recent	recent	ADJ
ajlm-2565	104	72	research	research	NOUN
ajlm-2565	104	73	has	have	AUX
ajlm-2565	104	74	also	also	ADV
ajlm-2565	104	75	shown	show	VERB
ajlm-2565	104	76	a	a	DET
ajlm-2565	104	77	strong	strong	ADJ
ajlm-2565	104	78	positive	positive	ADJ
ajlm-2565	104	79	correlation	correlation	NOUN
ajlm-2565	104	80	between	between	ADP
ajlm-2565	104	81	sua	sua	PROPN
ajlm-2565	104	82	levels	level	NOUN
ajlm-2565	104	83	and	and	CCONJ
ajlm-2565	104	84	obesity	obesity	NOUN
ajlm-2565	104	85	in	in	ADP
ajlm-2565	104	86	the	the	DET
ajlm-2565	104	87	chinese	chinese	ADJ
ajlm-2565	104	88	population	population	NOUN
ajlm-2565	104	89	in	in	ADP
ajlm-2565	104	90	2017	2017	NUM
ajlm-2565	104	91	and	and	CCONJ
ajlm-2565	104	92	2018,44,45,46	2018,44,45,46	NUM
ajlm-2565	104	93	japan	japan	PROPN
ajlm-2565	104	94	in	in	ADP
ajlm-2565	104	95	2006,47	2006,47	NUM
ajlm-2565	104	96	india	india	NOUN
ajlm-2565	104	97	in	in	ADP
ajlm-2565	104	98	2014,6,48	2014,6,48	NUM
ajlm-2565	104	99	pakistan	pakistan	NOUN
ajlm-2565	104	100	in	in	ADP
ajlm-2565	104	101	2009,49	2009,49	NUM
ajlm-2565	104	102	iraq	iraq	PROPN
ajlm-2565	104	103	in	in	ADP
ajlm-2565	104	104	2015,50	2015,50	NUM
ajlm-2565	104	105	and	and	CCONJ
ajlm-2565	104	106	the	the	DET
ajlm-2565	104	107	united	united	PROPN
ajlm-2565	104	108	states	states	PROPN
ajlm-2565	104	109	in	in	ADP
ajlm-2565	104	110	2004.51	2004.51	NUM
ajlm-2565	104	111	although	although	SCONJ
ajlm-2565	104	112	earlier	early	ADJ
ajlm-2565	104	113	research	research	NOUN
ajlm-2565	104	114	has	have	AUX
ajlm-2565	104	115	shown	show	VERB
ajlm-2565	104	116	a	a	DET
ajlm-2565	104	117	positive	positive	ADJ
ajlm-2565	104	118	association	association	NOUN
ajlm-2565	104	119	between	between	ADP
ajlm-2565	104	120	sua	sua	PROPN
ajlm-2565	104	121	levels	level	NOUN
ajlm-2565	104	122	and	and	CCONJ
ajlm-2565	104	123	obesity	obesity	NOUN
ajlm-2565	104	124	,	,	PUNCT
ajlm-2565	104	125	the	the	DET
ajlm-2565	104	126	exact	exact	ADJ
ajlm-2565	104	127	mechanism	mechanism	NOUN
ajlm-2565	104	128	by	by	ADP
ajlm-2565	104	129	which	which	PRON
ajlm-2565	104	130	obesity	obesity	NOUN
ajlm-2565	104	131	causes	cause	VERB
ajlm-2565	104	132	an	an	DET
ajlm-2565	104	133	increase	increase	NOUN
ajlm-2565	104	134	in	in	ADP
ajlm-2565	104	135	uric	uric	ADJ
ajlm-2565	104	136	acid	acid	NOUN
ajlm-2565	104	137	is	be	AUX
ajlm-2565	104	138	not	not	PART
ajlm-2565	104	139	yet	yet	ADV
ajlm-2565	104	140	thoroughly	thoroughly	ADV
ajlm-2565	104	141	understood	understand	VERB
ajlm-2565	104	142	.	.	PUNCT
ajlm-2565	105	1	the	the	DET
ajlm-2565	105	2	relationship	relationship	NOUN
ajlm-2565	105	3	between	between	ADP
ajlm-2565	105	4	obesity	obesity	NOUN
ajlm-2565	105	5	and	and	CCONJ
ajlm-2565	105	6	sua	sua	NOUN
ajlm-2565	105	7	may	may	AUX
ajlm-2565	105	8	be	be	AUX
ajlm-2565	105	9	explained	explain	VERB
ajlm-2565	105	10	using	use	VERB
ajlm-2565	105	11	two	two	NUM
ajlm-2565	105	12	factors	factor	NOUN
ajlm-2565	105	13	:	:	PUNCT
ajlm-2565	105	14	overproduction	overproduction	NOUN
ajlm-2565	105	15	and	and	CCONJ
ajlm-2565	105	16	poor	poor	ADJ
ajlm-2565	105	17	renal	renal	ADJ
ajlm-2565	105	18	excretion	excretion	NOUN
ajlm-2565	105	19	.	.	PUNCT
ajlm-2565	106	1	an	an	DET
ajlm-2565	106	2	investigation	investigation	NOUN
ajlm-2565	106	3	carried	carry	VERB
ajlm-2565	106	4	out	out	ADP
ajlm-2565	106	5	on	on	ADP
ajlm-2565	106	6	a	a	DET
ajlm-2565	106	7	japanese	japanese	ADJ
ajlm-2565	106	8	population	population	NOUN
ajlm-2565	106	9	who	who	PRON
ajlm-2565	106	10	had	have	VERB
ajlm-2565	106	11	visceral	visceral	ADJ
ajlm-2565	106	12	fat	fat	ADJ
ajlm-2565	106	13	obesity	obesity	NOUN
ajlm-2565	106	14	revealed	reveal	VERB
ajlm-2565	106	15	that	that	SCONJ
ajlm-2565	106	16	elevated	elevated	ADJ
ajlm-2565	106	17	uric	uric	ADJ
ajlm-2565	106	18	acid	acid	NOUN
ajlm-2565	106	19	levels	level	NOUN
ajlm-2565	106	20	are	be	AUX
ajlm-2565	106	21	significantly	significantly	ADV
ajlm-2565	106	22	impacted	impact	VERB
ajlm-2565	106	23	by	by	ADP
ajlm-2565	106	24	its	its	PRON
ajlm-2565	106	25	excessive	excessive	ADJ
ajlm-2565	106	26	synthesis	synthesis	NOUN
ajlm-2565	106	27	,	,	PUNCT
ajlm-2565	106	28	with	with	ADP
ajlm-2565	106	29	decreased	decrease	VERB
ajlm-2565	106	30	excretion	excretion	NOUN
ajlm-2565	106	31	and	and	CCONJ
ajlm-2565	106	32	clearance	clearance	NOUN
ajlm-2565	106	33	of	of	ADP
ajlm-2565	106	34	urates	urate	NOUN
ajlm-2565	106	35	in	in	ADP
ajlm-2565	106	36	the	the	DET
ajlm-2565	106	37	urine.52	urine.52	PROPN
ajlm-2565	106	38	furthermore	furthermore	ADV
ajlm-2565	106	39	,	,	PUNCT
ajlm-2565	106	40	the	the	DET
ajlm-2565	106	41	buildup	buildup	NOUN
ajlm-2565	106	42	of	of	ADP
ajlm-2565	106	43	visceral	visceral	ADJ
ajlm-2565	106	44	fat	fat	NOUN
ajlm-2565	106	45	causes	cause	VERB
ajlm-2565	106	46	an	an	DET
ajlm-2565	106	47	increased	increase	VERB
ajlm-2565	106	48	flow	flow	NOUN
ajlm-2565	106	49	of	of	ADP
ajlm-2565	106	50	free	free	ADJ
ajlm-2565	106	51	fatty	fatty	NOUN
ajlm-2565	106	52	acids	acid	NOUN
ajlm-2565	106	53	from	from	ADP
ajlm-2565	106	54	plasma	plasma	NOUN
ajlm-2565	106	55	into	into	ADP
ajlm-2565	106	56	the	the	DET
ajlm-2565	106	57	liver	liver	NOUN
ajlm-2565	106	58	and	and	CCONJ
ajlm-2565	106	59	hepatic	hepatic	ADJ
ajlm-2565	106	60	portal	portal	ADJ
ajlm-2565	106	61	vein	vein	NOUN
ajlm-2565	106	62	,	,	PUNCT
ajlm-2565	106	63	which	which	PRON
ajlm-2565	106	64	in	in	ADP
ajlm-2565	106	65	turn	turn	NOUN
ajlm-2565	106	66	promotes	promote	VERB
ajlm-2565	106	67	triglyceride	triglyceride	ADP
ajlm-2565	106	68	synthesis	synthesis	NOUN
ajlm-2565	106	69	and	and	CCONJ
ajlm-2565	106	70	subsequently	subsequently	ADV
ajlm-2565	106	71	increases	increase	VERB
ajlm-2565	106	72	the	the	DET
ajlm-2565	106	73	production	production	NOUN
ajlm-2565	106	74	of	of	ADP
ajlm-2565	106	75	uric	uric	ADJ
ajlm-2565	106	76	acid	acid	NOUN
ajlm-2565	106	77	by	by	ADP
ajlm-2565	106	78	activating	activate	VERB
ajlm-2565	106	79	the	the	DET
ajlm-2565	106	80	uric	uric	ADJ
ajlm-2565	106	81	acid	acid	NOUN
ajlm-2565	106	82	synthesis	synthesis	NOUN
ajlm-2565	106	83	pathway.53,54	pathway.53,54	NOUN
ajlm-2565	106	84	our	our	PRON
ajlm-2565	106	85	study	study	NOUN
ajlm-2565	106	86	also	also	ADV
ajlm-2565	106	87	indicates	indicate	VERB
ajlm-2565	106	88	a	a	DET
ajlm-2565	106	89	significantly	significantly	ADV
ajlm-2565	106	90	higher	high	ADJ
ajlm-2565	106	91	predictive	predictive	ADJ
ajlm-2565	106	92	performance	performance	NOUN
ajlm-2565	106	93	of	of	ADP
ajlm-2565	106	94	bmi	bmi	NOUN
ajlm-2565	106	95	for	for	ADP
ajlm-2565	106	96	hyperuricaemia	hyperuricaemia	NOUN
ajlm-2565	106	97	in	in	ADP
ajlm-2565	106	98	female	female	ADJ
ajlm-2565	106	99	participants	participant	NOUN
ajlm-2565	106	100	(	(	PUNCT
ajlm-2565	106	101	auc	auc	NOUN
ajlm-2565	106	102	=	=	SYM
ajlm-2565	106	103	0.657	0.657	NUM
ajlm-2565	106	104	)	)	PUNCT
ajlm-2565	106	105	than	than	ADP
ajlm-2565	106	106	in	in	ADP
ajlm-2565	106	107	male	male	ADJ
ajlm-2565	106	108	participants	participant	NOUN
ajlm-2565	106	109	(	(	PUNCT
ajlm-2565	106	110	auc	auc	NOUN
ajlm-2565	106	111	=	=	SYM
ajlm-2565	106	112	0.513	0.513	NUM
ajlm-2565	106	113	)	)	PUNCT
ajlm-2565	106	114	,	,	PUNCT
ajlm-2565	106	115	p	p	NOUN
ajlm-2565	106	116	-	-	PUNCT
ajlm-2565	106	117	value	value	NOUN
ajlm-2565	106	118	0.0029	0.0029	NUM
ajlm-2565	106	119	.	.	PUNCT
ajlm-2565	107	1	our	our	PRON
ajlm-2565	107	2	finding	finding	NOUN
ajlm-2565	107	3	is	be	AUX
ajlm-2565	107	4	consistent	consistent	ADJ
ajlm-2565	107	5	with	with	ADP
ajlm-2565	107	6	findings	finding	NOUN
ajlm-2565	107	7	from	from	ADP
ajlm-2565	107	8	a	a	DET
ajlm-2565	107	9	large	large	ADJ
ajlm-2565	107	10	taiwanese	taiwanese	ADJ
ajlm-2565	107	11	population	population	NOUN
ajlm-2565	107	12	study	study	NOUN
ajlm-2565	107	13	done	do	VERB
ajlm-2565	107	14	in	in	ADP
ajlm-2565	107	15	2023	2023	NUM
ajlm-2565	107	16	that	that	PRON
ajlm-2565	107	17	also	also	ADV
ajlm-2565	107	18	found	find	VERB
ajlm-2565	107	19	bmi	bmi	NOUN
ajlm-2565	107	20	to	to	PART
ajlm-2565	107	21	have	have	VERB
ajlm-2565	107	22	a	a	DET
ajlm-2565	107	23	higher	high	ADJ
ajlm-2565	107	24	predictive	predictive	ADJ
ajlm-2565	107	25	power	power	NOUN
ajlm-2565	107	26	for	for	ADP
ajlm-2565	107	27	hyperuricaemia	hyperuricaemia	NOUN
ajlm-2565	107	28	in	in	ADP
ajlm-2565	107	29	female	female	ADJ
ajlm-2565	107	30	participants	participant	NOUN
ajlm-2565	107	31	(	(	PUNCT
ajlm-2565	107	32	auc	auc	NOUN
ajlm-2565	107	33	=	=	SYM
ajlm-2565	107	34	0.728	0.728	NUM
ajlm-2565	107	35	)	)	PUNCT
ajlm-2565	107	36	than	than	ADP
ajlm-2565	107	37	in	in	ADP
ajlm-2565	107	38	male	male	ADJ
ajlm-2565	107	39	participants	participant	NOUN
ajlm-2565	107	40	(	(	PUNCT
ajlm-2565	107	41	auc	auc	NOUN
ajlm-2565	107	42	=	=	SYM
ajlm-2565	107	43	0.655).55	0.655).55	NOUN
ajlm-2565	107	44	limitations	limitation	VERB
ajlm-2565	107	45	the	the	DET
ajlm-2565	107	46	study	study	NOUN
ajlm-2565	107	47	is	be	AUX
ajlm-2565	107	48	a	a	DET
ajlm-2565	107	49	secondary	secondary	ADJ
ajlm-2565	107	50	data	data	NOUN
ajlm-2565	107	51	analysis	analysis	NOUN
ajlm-2565	107	52	;	;	PUNCT
ajlm-2565	107	53	hence	hence	ADV
ajlm-2565	107	54	,	,	PUNCT
ajlm-2565	107	55	we	we	PRON
ajlm-2565	107	56	had	have	VERB
ajlm-2565	107	57	limited	limit	VERB
ajlm-2565	107	58	control	control	NOUN
ajlm-2565	107	59	over	over	ADP
ajlm-2565	107	60	the	the	DET
ajlm-2565	107	61	data	data	NOUN
ajlm-2565	107	62	collection	collection	NOUN
ajlm-2565	107	63	process	process	NOUN
ajlm-2565	107	64	.	.	PUNCT
ajlm-2565	108	1	as	as	SCONJ
ajlm-2565	108	2	the	the	DET
ajlm-2565	108	3	study	study	NOUN
ajlm-2565	108	4	used	use	VERB
ajlm-2565	108	5	a	a	DET
ajlm-2565	108	6	data	datum	NOUN
ajlm-2565	108	7	set	set	VERB
ajlm-2565	108	8	from	from	ADP
ajlm-2565	108	9	a	a	DET
ajlm-2565	108	10	cross	cross	ADJ
ajlm-2565	108	11	-	-	ADJ
ajlm-2565	108	12	sectional	sectional	ADJ
ajlm-2565	108	13	study	study	NOUN
ajlm-2565	108	14	,	,	PUNCT
ajlm-2565	108	15	we	we	PRON
ajlm-2565	108	16	could	could	AUX
ajlm-2565	108	17	not	not	PART
ajlm-2565	108	18	establish	establish	VERB
ajlm-2565	108	19	the	the	DET
ajlm-2565	108	20	cause	cause	NOUN
ajlm-2565	108	21	-	-	PUNCT
ajlm-2565	108	22	effect	effect	NOUN
ajlm-2565	108	23	relationship	relationship	NOUN
ajlm-2565	108	24	.	.	PUNCT
ajlm-2565	109	1	the	the	DET
ajlm-2565	109	2	generalisability	generalisability	NOUN
ajlm-2565	109	3	of	of	ADP
ajlm-2565	109	4	our	our	PRON
ajlm-2565	109	5	findings	finding	NOUN
ajlm-2565	109	6	is	be	AUX
ajlm-2565	109	7	limited	limit	VERB
ajlm-2565	109	8	to	to	ADP
ajlm-2565	109	9	hiv	hiv	PROPN
ajlm-2565	109	10	-	-	PUNCT
ajlm-2565	109	11	positive	positive	ADJ
ajlm-2565	109	12	patients	patient	NOUN
ajlm-2565	109	13	on	on	ADP
ajlm-2565	109	14	dolutegravir	dolutegravir	NOUN
ajlm-2565	109	15	-	-	PUNCT
ajlm-2565	109	16	based	base	VERB
ajlm-2565	109	17	art	art	NOUN
ajlm-2565	109	18	,	,	PUNCT
ajlm-2565	109	19	and	and	CCONJ
ajlm-2565	109	20	the	the	DET
ajlm-2565	109	21	results	result	NOUN
ajlm-2565	109	22	may	may	AUX
ajlm-2565	109	23	not	not	PART
ajlm-2565	109	24	apply	apply	VERB
ajlm-2565	109	25	to	to	ADP
ajlm-2565	109	26	those	those	PRON
ajlm-2565	109	27	on	on	ADP
ajlm-2565	109	28	different	different	ADJ
ajlm-2565	109	29	art	art	NOUN
ajlm-2565	109	30	regimens	regimen	NOUN
ajlm-2565	109	31	or	or	CCONJ
ajlm-2565	109	32	other	other	ADJ
ajlm-2565	109	33	populations	population	NOUN
ajlm-2565	109	34	.	.	PUNCT
ajlm-2565	110	1	conclusion	conclusion	NOUN
ajlm-2565	110	2	our	our	PRON
ajlm-2565	110	3	findings	finding	NOUN
ajlm-2565	110	4	are	be	AUX
ajlm-2565	110	5	the	the	DET
ajlm-2565	110	6	first	first	ADJ
ajlm-2565	110	7	of	of	ADP
ajlm-2565	110	8	their	their	PRON
ajlm-2565	110	9	kind	kind	NOUN
ajlm-2565	110	10	to	to	PART
ajlm-2565	110	11	indicate	indicate	VERB
ajlm-2565	110	12	a	a	DET
ajlm-2565	110	13	relationship	relationship	NOUN
ajlm-2565	110	14	between	between	ADP
ajlm-2565	110	15	hyperuricaemia	hyperuricaemia	NOUN
ajlm-2565	110	16	and	and	CCONJ
ajlm-2565	110	17	obesity	obesity	NOUN
ajlm-2565	110	18	in	in	ADP
ajlm-2565	110	19	hiv	hiv	PROPN
ajlm-2565	110	20	patients	patient	NOUN
ajlm-2565	110	21	on	on	ADP
ajlm-2565	110	22	art	art	NOUN
ajlm-2565	110	23	in	in	ADP
ajlm-2565	110	24	uganda	uganda	PROPN
ajlm-2565	110	25	.	.	PUNCT
ajlm-2565	111	1	the	the	DET
ajlm-2565	111	2	high	high	ADJ
ajlm-2565	111	3	prevalence	prevalence	NOUN
ajlm-2565	111	4	of	of	ADP
ajlm-2565	111	5	hyperuricaemia	hyperuricaemia	NOUN
ajlm-2565	111	6	in	in	ADP
ajlm-2565	111	7	these	these	DET
ajlm-2565	111	8	patients	patient	NOUN
ajlm-2565	111	9	requires	require	VERB
ajlm-2565	111	10	the	the	DET
ajlm-2565	111	11	attention	attention	NOUN
ajlm-2565	111	12	of	of	ADP
ajlm-2565	111	13	policymakers	policymaker	NOUN
ajlm-2565	111	14	with	with	ADP
ajlm-2565	111	15	regard	regard	NOUN
ajlm-2565	111	16	to	to	ADP
ajlm-2565	111	17	the	the	DET
ajlm-2565	111	18	institution	institution	NOUN
ajlm-2565	111	19	of	of	ADP
ajlm-2565	111	20	routine	routine	ADJ
ajlm-2565	111	21	measurement	measurement	NOUN
ajlm-2565	111	22	of	of	ADP
ajlm-2565	111	23	sua	sua	NOUN
ajlm-2565	111	24	in	in	ADP
ajlm-2565	111	25	obese	obese	ADJ
ajlm-2565	111	26	and	and	CCONJ
ajlm-2565	111	27	overweight	overweight	ADJ
ajlm-2565	111	28	people	people	NOUN
ajlm-2565	111	29	to	to	PART
ajlm-2565	111	30	prevent	prevent	VERB
ajlm-2565	111	31	hyperuricaemia	hyperuricaemia	NOUN
ajlm-2565	111	32	and	and	CCONJ
ajlm-2565	111	33	its	its	PRON
ajlm-2565	111	34	related	related	ADJ
ajlm-2565	111	35	complications	complication	NOUN
ajlm-2565	111	36	.	.	PUNCT
ajlm-2565	112	1	a	a	DET
ajlm-2565	112	2	study	study	NOUN
ajlm-2565	112	3	that	that	PRON
ajlm-2565	112	4	does	do	AUX
ajlm-2565	112	5	not	not	PART
ajlm-2565	112	6	rely	rely	VERB
ajlm-2565	112	7	on	on	ADP
ajlm-2565	112	8	secondary	secondary	ADJ
ajlm-2565	112	9	data	datum	NOUN
ajlm-2565	112	10	should	should	AUX
ajlm-2565	112	11	be	be	AUX
ajlm-2565	112	12	carried	carry	VERB
ajlm-2565	112	13	out	out	ADP
ajlm-2565	112	14	country	country	NOUN
ajlm-2565	112	15	wide	wide	ADJ
ajlm-2565	112	16	to	to	PART
ajlm-2565	112	17	further	far	ADV
ajlm-2565	112	18	enhance	enhance	VERB
ajlm-2565	112	19	our	our	PRON
ajlm-2565	112	20	understanding	understanding	NOUN
ajlm-2565	112	21	of	of	ADP
ajlm-2565	112	22	the	the	DET
ajlm-2565	112	23	epidemiological	epidemiological	ADJ
ajlm-2565	112	24	spread	spread	NOUN
ajlm-2565	112	25	of	of	ADP
ajlm-2565	112	26	this	this	DET
ajlm-2565	112	27	relationship	relationship	NOUN
ajlm-2565	112	28	.	.	PUNCT
ajlm-2565	113	1	acknowledgements	acknowledgement	NOUN
ajlm-2565	113	2	this	this	DET
ajlm-2565	113	3	article	article	NOUN
ajlm-2565	113	4	is	be	AUX
ajlm-2565	113	5	a	a	DET
ajlm-2565	113	6	secondary	secondary	ADJ
ajlm-2565	113	7	analysis	analysis	NOUN
ajlm-2565	113	8	study	study	NOUN
ajlm-2565	113	9	of	of	ADP
ajlm-2565	113	10	s.a.l	s.a.l	NOUN
ajlm-2565	113	11	’s	’s	PART
ajlm-2565	113	12	thesis	thesis	NOUN
ajlm-2565	113	13	entitled	entitle	VERB
ajlm-2565	113	14	‘	'	PUNCT
ajlm-2565	113	15	correlation	correlation	NOUN
ajlm-2565	113	16	of	of	ADP
ajlm-2565	113	17	serum	serum	NOUN
ajlm-2565	113	18	uric	uric	ADJ
ajlm-2565	113	19	acid	acid	NOUN
ajlm-2565	113	20	/	/	SYM
ajlm-2565	113	21	serum	serum	NOUN
ajlm-2565	113	22	creatinine	creatinine	NOUN
ajlm-2565	113	23	ratio	ratio	NOUN
ajlm-2565	113	24	with	with	ADP
ajlm-2565	113	25	estimated	estimate	VERB
ajlm-2565	113	26	glomerular	glomerular	ADJ
ajlm-2565	113	27	filtration	filtration	NOUN
ajlm-2565	113	28	rate	rate	NOUN
ajlm-2565	113	29	in	in	ADP
ajlm-2565	113	30	predicting	predict	VERB
ajlm-2565	113	31	kidney	kidney	NOUN
ajlm-2565	113	32	dysfunction	dysfunction	NOUN
ajlm-2565	113	33	among	among	ADP
ajlm-2565	113	34	people	people	NOUN
ajlm-2565	113	35	living	live	VERB
ajlm-2565	113	36	with	with	ADP
ajlm-2565	113	37	hiv	hiv	PROPN
ajlm-2565	113	38	at	at	ADP
ajlm-2565	113	39	mbarara	mbarara	PROPN
ajlm-2565	113	40	municipal	municipal	ADJ
ajlm-2565	113	41	health	health	NOUN
ajlm-2565	113	42	centre	centre	PROPN
ajlm-2565	113	43	iv	iv	NUM
ajlm-2565	113	44	’	'	PUNCT
ajlm-2565	113	45	,	,	PUNCT
ajlm-2565	113	46	towards	towards	ADP
ajlm-2565	113	47	the	the	DET
ajlm-2565	113	48	degree	degree	NOUN
ajlm-2565	113	49	of	of	ADP
ajlm-2565	113	50	master	master	NOUN
ajlm-2565	113	51	of	of	ADP
ajlm-2565	113	52	medical	medical	ADJ
ajlm-2565	113	53	laboratory	laboratory	NOUN
ajlm-2565	113	54	science	science	NOUN
ajlm-2565	113	55	(	(	PUNCT
ajlm-2565	113	56	clinical	clinical	ADJ
ajlm-2565	113	57	chemistry	chemistry	NOUN
ajlm-2565	113	58	)	)	PUNCT
ajlm-2565	113	59	in	in	ADP
ajlm-2565	113	60	the	the	DET
ajlm-2565	113	61	department	department	NOUN
ajlm-2565	113	62	of	of	ADP
ajlm-2565	113	63	medical	medical	ADJ
ajlm-2565	113	64	laboratory	laboratory	NOUN
ajlm-2565	113	65	science	science	NOUN
ajlm-2565	113	66	,	,	PUNCT
ajlm-2565	113	67	mbarara	mbarara	PROPN
ajlm-2565	113	68	university	university	PROPN
ajlm-2565	113	69	of	of	ADP
ajlm-2565	113	70	science	science	NOUN
ajlm-2565	113	71	and	and	CCONJ
ajlm-2565	113	72	technology	technology	NOUN
ajlm-2565	113	73	,	,	PUNCT
ajlm-2565	113	74	uganda	uganda	PROPN
ajlm-2565	113	75	,	,	PUNCT
ajlm-2565	113	76	on	on	ADP
ajlm-2565	113	77	27	27	NUM
ajlm-2565	113	78	october	october	PROPN
ajlm-2565	113	79	2023	2023	NUM
ajlm-2565	113	80	,	,	PUNCT
ajlm-2565	113	81	with	with	ADP
ajlm-2565	113	82	supervisors	supervisor	NOUN
ajlm-2565	113	83	ritah	ritah	PROPN
ajlm-2565	113	84	kiconco	kiconco	PROPN
ajlm-2565	113	85	,	,	PUNCT
ajlm-2565	113	86	simon	simon	PROPN
ajlm-2565	113	87	peter	peter	PROPN
ajlm-2565	113	88	rugera	rugera	PROPN
ajlm-2565	113	89	,	,	PUNCT
ajlm-2565	113	90	and	and	CCONJ
ajlm-2565	113	91	rahma	rahma	PROPN
ajlm-2565	113	92	udu	udu	PROPN
ajlm-2565	113	93	.	.	PUNCT
ajlm-2565	114	1	competing	compete	VERB
ajlm-2565	114	2	interests	interest	NOUN
ajlm-2565	114	3	the	the	DET
ajlm-2565	114	4	authors	author	NOUN
ajlm-2565	114	5	reported	report	VERB
ajlm-2565	114	6	that	that	SCONJ
ajlm-2565	114	7	they	they	PRON
ajlm-2565	114	8	received	receive	VERB
ajlm-2565	114	9	funding	funding	NOUN
ajlm-2565	114	10	from	from	ADP
ajlm-2565	114	11	mbarara	mbarara	PROPN
ajlm-2565	114	12	university	university	PROPN
ajlm-2565	114	13	of	of	ADP
ajlm-2565	114	14	science	science	NOUN
ajlm-2565	114	15	and	and	CCONJ
ajlm-2565	114	16	technology	technology	NOUN
ajlm-2565	114	17	faculty	faculty	NOUN
ajlm-2565	114	18	of	of	ADP
ajlm-2565	114	19	medicine	medicine	NOUN
ajlm-2565	114	20	research	research	NOUN
ajlm-2565	114	21	fund	fund	PROPN
ajlm-2565	114	22	,	,	PUNCT
ajlm-2565	114	23	which	which	PRON
ajlm-2565	114	24	may	may	AUX
ajlm-2565	114	25	be	be	AUX
ajlm-2565	114	26	affected	affect	VERB
ajlm-2565	114	27	by	by	ADP
ajlm-2565	114	28	the	the	DET
ajlm-2565	114	29	research	research	NOUN
ajlm-2565	114	30	reported	report	VERB
ajlm-2565	114	31	in	in	ADP
ajlm-2565	114	32	the	the	DET
ajlm-2565	114	33	enclosed	enclose	VERB
ajlm-2565	114	34	publication	publication	NOUN
ajlm-2565	114	35	.	.	PUNCT
ajlm-2565	115	1	the	the	DET
ajlm-2565	115	2	authors	author	NOUN
ajlm-2565	115	3	have	have	AUX
ajlm-2565	115	4	disclosed	disclose	VERB
ajlm-2565	115	5	those	those	DET
ajlm-2565	115	6	interests	interest	NOUN
ajlm-2565	115	7	fully	fully	ADV
ajlm-2565	115	8	and	and	CCONJ
ajlm-2565	115	9	have	have	AUX
ajlm-2565	115	10	implemented	implement	VERB
ajlm-2565	115	11	an	an	DET
ajlm-2565	115	12	approved	approve	VERB
ajlm-2565	115	13	plan	plan	NOUN
ajlm-2565	115	14	for	for	ADP
ajlm-2565	115	15	managing	manage	VERB
ajlm-2565	115	16	any	any	DET
ajlm-2565	115	17	potential	potential	ADJ
ajlm-2565	115	18	conflicts	conflict	NOUN
ajlm-2565	115	19	arising	arise	VERB
ajlm-2565	115	20	from	from	ADP
ajlm-2565	115	21	their	their	PRON
ajlm-2565	115	22	involvement	involvement	NOUN
ajlm-2565	115	23	.	.	PUNCT
ajlm-2565	116	1	the	the	DET
ajlm-2565	116	2	terms	term	NOUN
ajlm-2565	116	3	of	of	ADP
ajlm-2565	116	4	these	these	DET
ajlm-2565	116	5	funding	funding	NOUN
ajlm-2565	116	6	arrangements	arrangement	NOUN
ajlm-2565	116	7	have	have	AUX
ajlm-2565	116	8	been	be	AUX
ajlm-2565	116	9	reviewed	review	VERB
ajlm-2565	116	10	and	and	CCONJ
ajlm-2565	116	11	approved	approve	VERB
ajlm-2565	116	12	by	by	ADP
ajlm-2565	116	13	the	the	DET
ajlm-2565	116	14	affiliated	affiliated	ADJ
ajlm-2565	116	15	university	university	NOUN
ajlm-2565	116	16	in	in	ADP
ajlm-2565	116	17	accordance	accordance	NOUN
ajlm-2565	116	18	with	with	ADP
ajlm-2565	116	19	its	its	PRON
ajlm-2565	116	20	policy	policy	NOUN
ajlm-2565	116	21	on	on	ADP
ajlm-2565	116	22	objectivity	objectivity	NOUN
ajlm-2565	116	23	in	in	ADP
ajlm-2565	116	24	research	research	NOUN
ajlm-2565	116	25	.	.	PUNCT
ajlm-2565	117	1	authors	author	NOUN
ajlm-2565	117	2	’	’	PART
ajlm-2565	117	3	contributions	contribution	NOUN
ajlm-2565	117	4	s.p.r	s.p.r	NOUN
ajlm-2565	117	5	.	.	PUNCT
ajlm-2565	117	6	,	,	PUNCT
ajlm-2565	117	7	c.n.b	c.n.b	NOUN
ajlm-2565	117	8	.	.	PUNCT
ajlm-2565	117	9	,	,	PUNCT
ajlm-2565	117	10	and	and	CCONJ
ajlm-2565	117	11	s.a.l	s.a.l	PROPN
ajlm-2565	117	12	.	.	PUNCT
ajlm-2565	117	13	contributed	contribute	VERB
ajlm-2565	117	14	to	to	ADP
ajlm-2565	117	15	the	the	DET
ajlm-2565	117	16	conceptualisation	conceptualisation	NOUN
ajlm-2565	117	17	of	of	ADP
ajlm-2565	117	18	the	the	DET
ajlm-2565	117	19	study	study	NOUN
ajlm-2565	117	20	,	,	PUNCT
ajlm-2565	117	21	data	datum	NOUN
ajlm-2565	117	22	analysis	analysis	NOUN
ajlm-2565	117	23	,	,	PUNCT
ajlm-2565	117	24	and	and	CCONJ
ajlm-2565	117	25	result	result	VERB
ajlm-2565	117	26	interpretation	interpretation	NOUN
ajlm-2565	117	27	.	.	PUNCT
ajlm-2565	118	1	c.n.b	c.n.b	NOUN
ajlm-2565	118	2	.	.	PUNCT
ajlm-2565	118	3	,	,	PUNCT
ajlm-2565	118	4	s.a.l	s.a.l	PROPN
ajlm-2565	118	5	.	.	PROPN
ajlm-2565	118	6	,	,	PUNCT
ajlm-2565	118	7	h.m	h.m	PROPN
ajlm-2565	118	8	.	.	PROPN
ajlm-2565	118	9	,	,	PUNCT
ajlm-2565	118	10	j.t	j.t	PROPN
ajlm-2565	118	11	.	.	PROPN
ajlm-2565	118	12	,	,	PUNCT
ajlm-2565	118	13	r.k	r.k	PROPN
ajlm-2565	118	14	.	.	PROPN
ajlm-2565	118	15	and	and	CCONJ
ajlm-2565	118	16	s.p.r	s.p.r	NOUN
ajlm-2565	118	17	.	.	PUNCT
ajlm-2565	118	18	,	,	PUNCT
ajlm-2565	118	19	and	and	CCONJ
ajlm-2565	118	20	r.u	r.u	PROPN
ajlm-2565	118	21	.	.	PROPN
ajlm-2565	118	22	contributed	contribute	VERB
ajlm-2565	118	23	to	to	ADP
ajlm-2565	118	24	the	the	DET
ajlm-2565	118	25	methodology	methodology	NOUN
ajlm-2565	118	26	.	.	PUNCT
ajlm-2565	119	1	s.p.r	s.p.r	NOUN
ajlm-2565	119	2	.	.	PUNCT
ajlm-2565	119	3	,	,	PUNCT
ajlm-2565	119	4	r.k	r.k	PROPN
ajlm-2565	119	5	.	.	PROPN
ajlm-2565	119	6	,	,	PUNCT
ajlm-2565	119	7	c.n.b	c.n.b	NOUN
ajlm-2565	119	8	.	.	PUNCT
ajlm-2565	119	9	,	,	PUNCT
ajlm-2565	119	10	s.a.l	s.a.l	PROPN
ajlm-2565	119	11	.	.	PROPN
ajlm-2565	119	12	,	,	PUNCT
ajlm-2565	119	13	j.t	j.t	PROPN
ajlm-2565	119	14	.	.	PROPN
ajlm-2565	119	15	,	,	PUNCT
ajlm-2565	119	16	and	and	CCONJ
ajlm-2565	119	17	h.m	h.m	PROPN
ajlm-2565	119	18	.	.	PROPN
ajlm-2565	119	19	contributed	contribute	VERB
ajlm-2565	119	20	to	to	ADP
ajlm-2565	119	21	the	the	DET
ajlm-2565	119	22	writing	writing	NOUN
ajlm-2565	119	23	of	of	ADP
ajlm-2565	119	24	the	the	DET
ajlm-2565	119	25	original	original	ADJ
ajlm-2565	119	26	draft	draft	NOUN
ajlm-2565	119	27	article	article	NOUN
ajlm-2565	119	28	.	.	PUNCT
ajlm-2565	120	1	c.n.b	c.n.b	NOUN
ajlm-2565	120	2	.	.	PUNCT
ajlm-2565	120	3	,	,	PUNCT
ajlm-2565	120	4	s.a.l	s.a.l	PROPN
ajlm-2565	120	5	.	.	PROPN
ajlm-2565	120	6	,	,	PUNCT
ajlm-2565	120	7	h.m	h.m	PROPN
ajlm-2565	120	8	.	.	PROPN
ajlm-2565	120	9	,	,	PUNCT
ajlm-2565	120	10	j.t	j.t	PROPN
ajlm-2565	120	11	.	.	PROPN
ajlm-2565	120	12	,	,	PUNCT
ajlm-2565	120	13	r.k	r.k	PROPN
ajlm-2565	120	14	.	.	PROPN
ajlm-2565	120	15	and	and	CCONJ
ajlm-2565	120	16	s.p.r	s.p.r	NOUN
ajlm-2565	120	17	.	.	PUNCT
ajlm-2565	120	18	,	,	PUNCT
ajlm-2565	120	19	and	and	CCONJ
ajlm-2565	120	20	r.u	r.u	PROPN
ajlm-2565	120	21	.	.	PROPN
ajlm-2565	120	22	contributed	contribute	VERB
ajlm-2565	120	23	to	to	ADP
ajlm-2565	120	24	the	the	DET
ajlm-2565	120	25	writing	writing	NOUN
ajlm-2565	120	26	,	,	PUNCT
ajlm-2565	120	27	review	review	NOUN
ajlm-2565	120	28	and	and	CCONJ
ajlm-2565	120	29	editing	editing	NOUN
ajlm-2565	120	30	.	.	PUNCT
ajlm-2565	121	1	s.p.r	s.p.r	NOUN
ajlm-2565	121	2	.	.	PUNCT
ajlm-2565	121	3	,	,	PUNCT
ajlm-2565	121	4	c.n.b	c.n.b	NOUN
ajlm-2565	121	5	.	.	PUNCT
ajlm-2565	121	6	,	,	PUNCT
ajlm-2565	121	7	and	and	CCONJ
ajlm-2565	121	8	r.k	r.k	PROPN
ajlm-2565	121	9	.	.	PROPN
ajlm-2565	121	10	contributed	contribute	VERB
ajlm-2565	121	11	to	to	ADP
ajlm-2565	121	12	supervision	supervision	NOUN
ajlm-2565	121	13	and	and	CCONJ
ajlm-2565	121	14	project	project	PROPN
ajlm-2565	121	15	administration	administration	NOUN
ajlm-2565	121	16	.	.	PUNCT
ajlm-2565	122	1	s.p.r	s.p.r	NOUN
ajlm-2565	122	2	.	.	PROPN
ajlm-2565	122	3	,	,	PUNCT
ajlm-2565	122	4	h.m	h.m	PROPN
ajlm-2565	122	5	.	.	PROPN
ajlm-2565	122	6	,	,	PUNCT
ajlm-2565	122	7	j.t	j.t	PROPN
ajlm-2565	122	8	.	.	PROPN
ajlm-2565	122	9	,	,	PUNCT
ajlm-2565	122	10	r.u	r.u	PROPN
ajlm-2565	122	11	.	.	PROPN
ajlm-2565	122	12	,	,	PUNCT
ajlm-2565	122	13	r.k	r.k	PROPN
ajlm-2565	122	14	.	.	PROPN
ajlm-2565	122	15	,	,	PUNCT
ajlm-2565	122	16	s.a.l	s.a.l	ADJ
ajlm-2565	122	17	.	.	PUNCT
ajlm-2565	122	18	,	,	PUNCT
ajlm-2565	122	19	and	and	CCONJ
ajlm-2565	122	20	c.n.b	c.n.b	NOUN
ajlm-2565	122	21	.	.	PUNCT
ajlm-2565	123	1	have	have	AUX
ajlm-2565	123	2	read	read	VERB
ajlm-2565	123	3	and	and	CCONJ
ajlm-2565	123	4	agreed	agree	VERB
ajlm-2565	123	5	to	to	ADP
ajlm-2565	123	6	the	the	DET
ajlm-2565	123	7	publication	publication	NOUN
ajlm-2565	123	8	of	of	ADP
ajlm-2565	123	9	the	the	DET
ajlm-2565	123	10	article	article	NOUN
ajlm-2565	123	11	.	.	PUNCT
ajlm-2565	124	1	sources	source	NOUN
ajlm-2565	124	2	of	of	ADP
ajlm-2565	124	3	support	support	NOUN
ajlm-2565	124	4	this	this	DET
ajlm-2565	124	5	research	research	NOUN
ajlm-2565	124	6	received	receive	VERB
ajlm-2565	124	7	funding	funding	NOUN
ajlm-2565	124	8	from	from	ADP
ajlm-2565	124	9	the	the	DET
ajlm-2565	124	10	mbarara	mbarara	NOUN
ajlm-2565	124	11	university	university	PROPN
ajlm-2565	124	12	of	of	ADP
ajlm-2565	124	13	science	science	NOUN
ajlm-2565	124	14	and	and	CCONJ
ajlm-2565	124	15	technology	technology	NOUN
ajlm-2565	124	16	faculty	faculty	NOUN
ajlm-2565	124	17	of	of	ADP
ajlm-2565	124	18	medicine	medicine	NOUN
ajlm-2565	124	19	research	research	NOUN
ajlm-2565	124	20	fund	fund	NOUN
ajlm-2565	124	21	to	to	PART
ajlm-2565	124	22	analyse	analyse	VERB
ajlm-2565	124	23	primary	primary	ADJ
ajlm-2565	124	24	data	datum	NOUN
ajlm-2565	124	25	and	and	CCONJ
ajlm-2565	124	26	write	write	VERB
ajlm-2565	124	27	the	the	DET
ajlm-2565	124	28	article	article	NOUN
ajlm-2565	124	29	.	.	PUNCT
ajlm-2565	125	1	data	datum	NOUN
ajlm-2565	125	2	availability	availability	NOUN
ajlm-2565	125	3	the	the	DET
ajlm-2565	125	4	data	datum	NOUN
ajlm-2565	125	5	set	set	VERB
ajlm-2565	125	6	used	use	VERB
ajlm-2565	125	7	in	in	ADP
ajlm-2565	125	8	this	this	DET
ajlm-2565	125	9	study	study	NOUN
ajlm-2565	125	10	is	be	AUX
ajlm-2565	125	11	available	available	ADJ
ajlm-2565	125	12	from	from	ADP
ajlm-2565	125	13	the	the	DET
ajlm-2565	125	14	corresponding	corresponding	ADJ
ajlm-2565	125	15	author	author	NOUN
ajlm-2565	125	16	,	,	PUNCT
ajlm-2565	125	17	s.p.r	s.p.r	NOUN
ajlm-2565	125	18	.	.	PUNCT
ajlm-2565	125	19	,	,	PUNCT
ajlm-2565	125	20	upon	upon	SCONJ
ajlm-2565	125	21	request	request	NOUN
ajlm-2565	125	22	.	.	PUNCT
ajlm-2565	126	1	disclaimer	disclaimer	VERB
ajlm-2565	126	2	the	the	DET
ajlm-2565	126	3	views	view	NOUN
ajlm-2565	126	4	and	and	CCONJ
ajlm-2565	126	5	opinions	opinion	NOUN
ajlm-2565	126	6	expressed	express	VERB
ajlm-2565	126	7	in	in	ADP
ajlm-2565	126	8	this	this	DET
ajlm-2565	126	9	article	article	NOUN
ajlm-2565	126	10	are	be	AUX
ajlm-2565	126	11	those	those	PRON
ajlm-2565	126	12	of	of	ADP
ajlm-2565	126	13	the	the	DET
ajlm-2565	126	14	authors	author	NOUN
ajlm-2565	126	15	and	and	CCONJ
ajlm-2565	126	16	are	be	AUX
ajlm-2565	126	17	the	the	DET
ajlm-2565	126	18	product	product	NOUN
ajlm-2565	126	19	of	of	ADP
ajlm-2565	126	20	professional	professional	ADJ
ajlm-2565	126	21	research	research	NOUN
ajlm-2565	126	22	.	.	PUNCT
ajlm-2565	127	1	the	the	DET
ajlm-2565	127	2	article	article	NOUN
ajlm-2565	127	3	does	do	AUX
ajlm-2565	127	4	not	not	PART
ajlm-2565	127	5	necessarily	necessarily	ADV
ajlm-2565	127	6	reflect	reflect	VERB
ajlm-2565	127	7	the	the	DET
ajlm-2565	127	8	official	official	ADJ
ajlm-2565	127	9	policy	policy	NOUN
ajlm-2565	127	10	or	or	CCONJ
ajlm-2565	127	11	position	position	NOUN
ajlm-2565	127	12	of	of	ADP
ajlm-2565	127	13	any	any	DET
ajlm-2565	127	14	affiliated	affiliated	ADJ
ajlm-2565	127	15	institution	institution	NOUN
ajlm-2565	127	16	,	,	PUNCT
ajlm-2565	127	17	funder	funder	NOUN
ajlm-2565	127	18	,	,	PUNCT
ajlm-2565	127	19	agency	agency	NOUN
ajlm-2565	127	20	,	,	PUNCT
ajlm-2565	127	21	or	or	CCONJ
ajlm-2565	127	22	that	that	PRON
ajlm-2565	127	23	of	of	ADP
ajlm-2565	127	24	the	the	DET
ajlm-2565	127	25	publisher	publisher	NOUN
ajlm-2565	127	26	.	.	PUNCT
ajlm-2565	128	1	the	the	DET
ajlm-2565	128	2	authors	author	NOUN
ajlm-2565	128	3	are	be	AUX
ajlm-2565	128	4	responsible	responsible	ADJ
ajlm-2565	128	5	for	for	ADP
ajlm-2565	128	6	this	this	DET
ajlm-2565	128	7	article	article	NOUN
ajlm-2565	128	8	’s	’s	PART
ajlm-2565	128	9	results	result	NOUN
ajlm-2565	128	10	,	,	PUNCT
ajlm-2565	128	11	findings	finding	NOUN
ajlm-2565	128	12	,	,	PUNCT
ajlm-2565	128	13	and	and	CCONJ
ajlm-2565	128	14	content	content	NOUN
ajlm-2565	128	15	.	.	PUNCT
ajlm-2565	129	1	references	reference	NOUN
ajlm-2565	129	2	glantzounis	glantzounis	VERB
ajlm-2565	129	3	g	g	NOUN
ajlm-2565	129	4	,	,	PUNCT
ajlm-2565	129	5	tsimoyiannis	tsimoyiannis	PROPN
ajlm-2565	129	6	e	e	NOUN
ajlm-2565	129	7	,	,	PUNCT
ajlm-2565	129	8	kappas	kappa	VERB
ajlm-2565	129	9	a	a	PRON
ajlm-2565	129	10	,	,	PUNCT
ajlm-2565	129	11	galaris	galaris	PROPN
ajlm-2565	129	12	d.	d.	PROPN
ajlm-2565	129	13	uric	uric	PROPN
ajlm-2565	129	14	acid	acid	PROPN
ajlm-2565	129	15	and	and	CCONJ
ajlm-2565	129	16	oxidative	oxidative	ADJ
ajlm-2565	129	17	stress	stress	NOUN
ajlm-2565	129	18	.	.	PUNCT
ajlm-2565	130	1	curr	curr	PROPN
ajlm-2565	130	2	pharm	pharm	PROPN
ajlm-2565	130	3	des	des	PROPN
ajlm-2565	130	4	.	.	PROPN
ajlm-2565	130	5	2005;11(32):4145–4151	2005;11(32):4145–4151	NUM
ajlm-2565	130	6	.	.	PUNCT
ajlm-2565	131	1	https://doi.org/10.2174/138161205774913255	https://doi.org/10.2174/138161205774913255	PROPN
ajlm-2565	131	2	miao	miao	PROPN
ajlm-2565	131	3	z	z	PROPN
ajlm-2565	131	4	,	,	PUNCT
ajlm-2565	131	5	yan	yan	PROPN
ajlm-2565	131	6	s	s	PROPN
ajlm-2565	131	7	,	,	PUNCT
ajlm-2565	131	8	wang	wang	PROPN
ajlm-2565	131	9	j	j	PROPN
ajlm-2565	131	10	,	,	PUNCT
ajlm-2565	131	11	et	et	PROPN
ajlm-2565	131	12	al	al	PROPN
ajlm-2565	131	13	.	.	PROPN
ajlm-2565	132	1	insulin	insulin	NOUN
ajlm-2565	132	2	resistance	resistance	NOUN
ajlm-2565	132	3	acts	act	VERB
ajlm-2565	132	4	as	as	ADP
ajlm-2565	132	5	an	an	DET
ajlm-2565	132	6	independent	independent	ADJ
ajlm-2565	132	7	risk	risk	NOUN
ajlm-2565	132	8	factor	factor	NOUN
ajlm-2565	132	9	exacerbating	exacerbate	VERB
ajlm-2565	132	10	high	high	ADJ
ajlm-2565	132	11	-	-	PUNCT
ajlm-2565	132	12	purine	purine	NOUN
ajlm-2565	132	13	diet	diet	NOUN
ajlm-2565	132	14	induced	induce	VERB
ajlm-2565	132	15	renal	renal	ADJ
ajlm-2565	132	16	injury	injury	NOUN
ajlm-2565	132	17	and	and	CCONJ
ajlm-2565	132	18	knee	knee	NOUN
ajlm-2565	132	19	joint	joint	ADJ
ajlm-2565	132	20	gouty	gouty	ADJ
ajlm-2565	132	21	lesions	lesion	NOUN
ajlm-2565	132	22	.	.	PUNCT
ajlm-2565	133	1	inflamm	inflamm	PROPN
ajlm-2565	133	2	res	re	NOUN
ajlm-2565	133	3	.	.	PUNCT
ajlm-2565	134	1	2009;58(10):659–668	2009;58(10):659–668	NUM
ajlm-2565	134	2	.	.	PUNCT
ajlm-2565	134	3	https://doi.org/10.1007/s00011-009-0031-9	https://doi.org/10.1007/s00011-009-0031-9	PROPN
ajlm-2565	135	1	schlesinger	schlesinger	PROPN
ajlm-2565	135	2	n.	n.	PROPN
ajlm-2565	135	3	dietary	dietary	ADJ
ajlm-2565	135	4	factors	factor	NOUN
ajlm-2565	135	5	and	and	CCONJ
ajlm-2565	135	6	hyperuricaemia	hyperuricaemia	NOUN
ajlm-2565	135	7	.	.	PUNCT
ajlm-2565	136	1	curr	curr	PROPN
ajlm-2565	136	2	pharm	pharm	PROPN
ajlm-2565	136	3	des	des	PROPN
ajlm-2565	136	4	.	.	PROPN
ajlm-2565	136	5	2005;11(32):4133–4138	2005;11(32):4133–4138	NUM
ajlm-2565	136	6	.	.	PUNCT
ajlm-2565	137	1	https://doi.org/10.2174/138161205774913273	https://doi.org/10.2174/138161205774913273	PROPN
ajlm-2565	137	2	ali	ali	PROPN
ajlm-2565	137	3	n	n	CCONJ
ajlm-2565	137	4	,	,	PUNCT
ajlm-2565	137	5	perveen	perveen	VERB
ajlm-2565	137	6	r	r	NOUN
ajlm-2565	137	7	,	,	PUNCT
ajlm-2565	137	8	rahman	rahman	PROPN
ajlm-2565	137	9	s	s	PROPN
ajlm-2565	137	10	,	,	PUNCT
ajlm-2565	137	11	et	et	PROPN
ajlm-2565	137	12	al	al	PROPN
ajlm-2565	137	13	.	.	PUNCT
ajlm-2565	138	1	prevalence	prevalence	NOUN
ajlm-2565	138	2	of	of	ADP
ajlm-2565	138	3	hyperuricemia	hyperuricemia	NOUN
ajlm-2565	138	4	and	and	CCONJ
ajlm-2565	138	5	the	the	DET
ajlm-2565	138	6	relationship	relationship	NOUN
ajlm-2565	138	7	between	between	ADP
ajlm-2565	138	8	serum	serum	NOUN
ajlm-2565	138	9	uric	uric	ADJ
ajlm-2565	138	10	acid	acid	NOUN
ajlm-2565	138	11	and	and	CCONJ
ajlm-2565	138	12	obesity	obesity	NOUN
ajlm-2565	138	13	:	:	PUNCT
ajlm-2565	138	14	a	a	DET
ajlm-2565	138	15	study	study	NOUN
ajlm-2565	138	16	on	on	ADP
ajlm-2565	138	17	bangladeshi	bangladeshi	ADJ
ajlm-2565	138	18	adults	adult	NOUN
ajlm-2565	138	19	.	.	PUNCT
ajlm-2565	139	1	plos	plos	PROPN
ajlm-2565	139	2	one	one	NUM
ajlm-2565	139	3	.	.	PUNCT
ajlm-2565	140	1	2018;13(11):e0206850	2018;13(11):e0206850	NOUN
ajlm-2565	140	2	.	.	PUNCT
ajlm-2565	141	1	https://doi.org/10.1371/journal.pone.0206850	https://doi.org/10.1371/journal.pone.0206850	PROPN
ajlm-2565	141	2	kuo	kuo	PROPN
ajlm-2565	141	3	c	c	PROPN
ajlm-2565	141	4	-	-	PUNCT
ajlm-2565	141	5	f	f	PROPN
ajlm-2565	141	6	,	,	PUNCT
ajlm-2565	141	7	grainge	grainge	PROPN
ajlm-2565	141	8	mj	mj	PROPN
ajlm-2565	141	9	,	,	PUNCT
ajlm-2565	141	10	zhang	zhang	PROPN
ajlm-2565	141	11	w	w	PROPN
ajlm-2565	141	12	,	,	PUNCT
ajlm-2565	141	13	doherty	doherty	PROPN
ajlm-2565	141	14	m.	m.	PROPN
ajlm-2565	141	15	global	global	ADJ
ajlm-2565	141	16	epidemiology	epidemiology	NOUN
ajlm-2565	141	17	of	of	ADP
ajlm-2565	141	18	gout	gout	NOUN
ajlm-2565	141	19	:	:	PUNCT
ajlm-2565	141	20	prevalence	prevalence	NOUN
ajlm-2565	141	21	,	,	PUNCT
ajlm-2565	141	22	incidence	incidence	NOUN
ajlm-2565	141	23	and	and	CCONJ
ajlm-2565	141	24	risk	risk	NOUN
ajlm-2565	141	25	factors	factor	NOUN
ajlm-2565	141	26	.	.	PUNCT
ajlm-2565	142	1	nat	nat	PROPN
ajlm-2565	142	2	rev	rev	PROPN
ajlm-2565	142	3	rheumatol	rheumatol	NOUN
ajlm-2565	142	4	.	.	PUNCT
ajlm-2565	143	1	2015;11(11):649–662	2015;11(11):649–662	NUM
ajlm-2565	143	2	.	.	PUNCT
ajlm-2565	144	1	https://doi.org/10.1038/nrrheum.2015.91	https://doi.org/10.1038/nrrheum.2015.91	PROPN
ajlm-2565	144	2	kanwar	kanwar	PROPN
ajlm-2565	144	3	g	g	PROPN
ajlm-2565	144	4	,	,	PUNCT
ajlm-2565	144	5	kabra	kabra	PROPN
ajlm-2565	144	6	r.	r.	PROPN
ajlm-2565	144	7	serum	serum	PROPN
ajlm-2565	144	8	uric	uric	ADJ
ajlm-2565	144	9	acid	acid	NOUN
ajlm-2565	144	10	level	level	NOUN
ajlm-2565	144	11	and	and	CCONJ
ajlm-2565	144	12	obesity	obesity	NOUN
ajlm-2565	144	13	:	:	PUNCT
ajlm-2565	144	14	an	an	DET
ajlm-2565	144	15	association	association	NOUN
ajlm-2565	144	16	.	.	PUNCT
ajlm-2565	145	1	int	int	PROPN
ajlm-2565	146	1	j	j	PROPN
ajlm-2565	146	2	healthc	healthc	PROPN
ajlm-2565	146	3	sci	sci	PROPN
ajlm-2565	146	4	.	.	PUNCT
ajlm-2565	146	5	2016;4(1):52–55	2016;4(1):52–55	PROPN
ajlm-2565	146	6	.	.	PUNCT
ajlm-2565	147	1	zhu	zhu	PROPN
ajlm-2565	147	2	y	y	PROPN
ajlm-2565	147	3	,	,	PUNCT
ajlm-2565	147	4	pandya	pandya	PROPN
ajlm-2565	147	5	bj	bj	NOUN
ajlm-2565	147	6	,	,	PUNCT
ajlm-2565	147	7	choi	choi	PROPN
ajlm-2565	147	8	hk	hk	PROPN
ajlm-2565	147	9	.	.	PUNCT
ajlm-2565	148	1	prevalence	prevalence	NOUN
ajlm-2565	148	2	of	of	ADP
ajlm-2565	148	3	gout	gout	NOUN
ajlm-2565	148	4	and	and	CCONJ
ajlm-2565	148	5	hyperuricemia	hyperuricemia	NOUN
ajlm-2565	148	6	in	in	ADP
ajlm-2565	148	7	the	the	DET
ajlm-2565	148	8	us	us	PROPN
ajlm-2565	148	9	general	general	ADJ
ajlm-2565	148	10	population	population	NOUN
ajlm-2565	148	11	:	:	PUNCT
ajlm-2565	148	12	the	the	DET
ajlm-2565	148	13	national	national	ADJ
ajlm-2565	148	14	health	health	PROPN
ajlm-2565	148	15	and	and	CCONJ
ajlm-2565	148	16	nutrition	nutrition	NOUN
ajlm-2565	148	17	examination	examination	NOUN
ajlm-2565	148	18	survey	survey	PROPN
ajlm-2565	148	19	2007–2008	2007–2008	NOUN
ajlm-2565	148	20	.	.	PUNCT
ajlm-2565	149	1	arthritis	arthritis	NOUN
ajlm-2565	149	2	rheum	rheum	NOUN
ajlm-2565	149	3	.	.	PUNCT
ajlm-2565	150	1	2011;63(10):3136–3141	2011;63(10):3136–3141	X
ajlm-2565	150	2	.	.	PUNCT
ajlm-2565	151	1	https://doi.org/10.1002/art.30520	https://doi.org/10.1002/art.30520	PROPN
ajlm-2565	151	2	chen	chen	PROPN
ajlm-2565	151	3	l	l	PROPN
ajlm-2565	151	4	-	-	PROPN
ajlm-2565	151	5	y	y	PROPN
ajlm-2565	151	6	,	,	PUNCT
ajlm-2565	151	7	zhu	zhu	PROPN
ajlm-2565	151	8	w	w	PROPN
ajlm-2565	151	9	-	-	PUNCT
ajlm-2565	151	10	h	h	PROPN
ajlm-2565	151	11	,	,	PUNCT
ajlm-2565	151	12	chen	chen	PROPN
ajlm-2565	151	13	z	z	PROPN
ajlm-2565	151	14	-	-	PUNCT
ajlm-2565	151	15	w	w	PROPN
ajlm-2565	151	16	,	,	PUNCT
ajlm-2565	151	17	et	et	PROPN
ajlm-2565	151	18	al	al	PROPN
ajlm-2565	151	19	.	.	PROPN
ajlm-2565	151	20	relationship	relationship	NOUN
ajlm-2565	151	21	between	between	ADP
ajlm-2565	151	22	hyperuricemia	hyperuricemia	NOUN
ajlm-2565	151	23	and	and	CCONJ
ajlm-2565	151	24	metabolic	metabolic	NOUN
ajlm-2565	151	25	syndrome	syndrome	NOUN
ajlm-2565	151	26	.	.	PUNCT
ajlm-2565	152	1	j	j	PROPN
ajlm-2565	152	2	zhejiang	zhejiang	PROPN
ajlm-2565	152	3	univ	univ	PROPN
ajlm-2565	152	4	sci	sci	PROPN
ajlm-2565	152	5	b.	b.	PROPN
ajlm-2565	152	6	2007;8(8):593–598	2007;8(8):593–598	NUM
ajlm-2565	152	7	.	.	PROPN
ajlm-2565	152	8	https://doi.org/10.1631/jzus.2007.b0593	https://doi.org/10.1631/jzus.2007.b0593	X
ajlm-2565	152	9	conen	conen	PROPN
ajlm-2565	152	10	d	d	NOUN
ajlm-2565	152	11	,	,	PUNCT
ajlm-2565	152	12	wietlisbach	wietlisbach	PROPN
ajlm-2565	152	13	v	v	NOUN
ajlm-2565	152	14	,	,	PUNCT
ajlm-2565	152	15	bovet	bovet	NOUN
ajlm-2565	152	16	p	p	NOUN
ajlm-2565	152	17	,	,	PUNCT
ajlm-2565	152	18	et	et	PROPN
ajlm-2565	152	19	al	al	PROPN
ajlm-2565	152	20	.	.	PUNCT
ajlm-2565	153	1	prevalence	prevalence	NOUN
ajlm-2565	153	2	of	of	ADP
ajlm-2565	153	3	hyperuricemia	hyperuricemia	NOUN
ajlm-2565	153	4	and	and	CCONJ
ajlm-2565	153	5	relation	relation	NOUN
ajlm-2565	153	6	of	of	ADP
ajlm-2565	153	7	serum	serum	NOUN
ajlm-2565	153	8	uric	uric	ADJ
ajlm-2565	153	9	acid	acid	NOUN
ajlm-2565	153	10	with	with	ADP
ajlm-2565	153	11	cardiovascular	cardiovascular	ADJ
ajlm-2565	153	12	risk	risk	NOUN
ajlm-2565	153	13	factors	factor	NOUN
ajlm-2565	153	14	in	in	ADP
ajlm-2565	153	15	a	a	DET
ajlm-2565	153	16	developing	develop	VERB
ajlm-2565	153	17	country	country	NOUN
ajlm-2565	153	18	.	.	PUNCT
ajlm-2565	154	1	bmc	bmc	ADJ
ajlm-2565	154	2	public	public	ADJ
ajlm-2565	154	3	health	health	NOUN
ajlm-2565	154	4	.	.	PUNCT
ajlm-2565	155	1	2004;4:1–9	2004;4:1–9	X
ajlm-2565	155	2	.	.	PUNCT
ajlm-2565	155	3	https://doi.org/10.1186/1471-2458-4-9	https://doi.org/10.1186/1471-2458-4-9	PROPN
ajlm-2565	155	4	ogura	ogura	PROPN
ajlm-2565	155	5	t	t	PROPN
ajlm-2565	155	6	,	,	PUNCT
ajlm-2565	155	7	matsuura	matsuura	PROPN
ajlm-2565	155	8	k	k	PROPN
ajlm-2565	155	9	,	,	PUNCT
ajlm-2565	155	10	matsumoto	matsumoto	PROPN
ajlm-2565	155	11	y	y	PROPN
ajlm-2565	155	12	,	,	PUNCT
ajlm-2565	155	13	et	et	PROPN
ajlm-2565	155	14	al	al	PROPN
ajlm-2565	155	15	.	.	PUNCT
ajlm-2565	156	1	recent	recent	ADJ
ajlm-2565	156	2	trends	trend	NOUN
ajlm-2565	156	3	of	of	ADP
ajlm-2565	156	4	hyperuricemia	hyperuricemia	NOUN
ajlm-2565	156	5	and	and	CCONJ
ajlm-2565	156	6	obesity	obesity	NOUN
ajlm-2565	156	7	in	in	ADP
ajlm-2565	156	8	japanese	japanese	ADJ
ajlm-2565	156	9	male	male	ADJ
ajlm-2565	156	10	adolescents	adolescent	NOUN
ajlm-2565	156	11	,	,	PUNCT
ajlm-2565	156	12	1991	1991	NUM
ajlm-2565	156	13	through	through	ADP
ajlm-2565	156	14	2002	2002	NUM
ajlm-2565	156	15	.	.	PUNCT
ajlm-2565	157	1	metabolism	metabolism	NOUN
ajlm-2565	157	2	.	.	PUNCT
ajlm-2565	158	1	2004;53(4):448–453	2004;53(4):448–453	NUM
ajlm-2565	158	2	.	.	NOUN
ajlm-2565	158	3	https://doi.org/10.1016/j.metabol.2003.11.017	https://doi.org/10.1016/j.metabol.2003.11.017	PRON
ajlm-2565	158	4	choi	choi	PROPN
ajlm-2565	158	5	hk	hk	PROPN
ajlm-2565	158	6	,	,	PUNCT
ajlm-2565	158	7	mccormick	mccormick	PROPN
ajlm-2565	158	8	n	n	PROPN
ajlm-2565	158	9	,	,	PUNCT
ajlm-2565	158	10	lu	lu	PROPN
ajlm-2565	158	11	n	n	NUM
ajlm-2565	158	12	,	,	PUNCT
ajlm-2565	158	13	rai	rai	X
ajlm-2565	158	14	sk	sk	PROPN
ajlm-2565	158	15	,	,	PUNCT
ajlm-2565	158	16	yokose	yokose	NOUN
ajlm-2565	158	17	c	c	NOUN
ajlm-2565	158	18	,	,	PUNCT
ajlm-2565	158	19	zhang	zhang	PROPN
ajlm-2565	158	20	y.	y.	PROPN
ajlm-2565	158	21	population	population	PROPN
ajlm-2565	158	22	impact	impact	NOUN
ajlm-2565	158	23	attributable	attributable	ADJ
ajlm-2565	158	24	to	to	ADP
ajlm-2565	158	25	modifiable	modifiable	ADJ
ajlm-2565	158	26	risk	risk	NOUN
ajlm-2565	158	27	factors	factor	NOUN
ajlm-2565	158	28	for	for	ADP
ajlm-2565	158	29	hyperuricemia	hyperuricemia	NOUN
ajlm-2565	158	30	.	.	PUNCT
ajlm-2565	159	1	arthritis	arthritis	NOUN
ajlm-2565	159	2	rheumatol	rheumatol	NOUN
ajlm-2565	159	3	.	.	PUNCT
ajlm-2565	160	1	2020;72(1):157–165	2020;72(1):157–165	X
ajlm-2565	160	2	.	.	X
ajlm-2565	161	1	https://doi.org/10.1002/art.41067	https://doi.org/10.1002/art.41067	NOUN
ajlm-2565	161	2	wang	wang	PROPN
ajlm-2565	161	3	x	x	PROPN
ajlm-2565	161	4	-	-	PROPN
ajlm-2565	161	5	y	y	PROPN
ajlm-2565	161	6	,	,	PUNCT
ajlm-2565	161	7	li	li	PROPN
ajlm-2565	161	8	n	n	PROPN
ajlm-2565	161	9	,	,	PUNCT
ajlm-2565	161	10	guo	guo	PROPN
ajlm-2565	161	11	j	j	PROPN
ajlm-2565	161	12	-	-	PUNCT
ajlm-2565	161	13	t	t	PROPN
ajlm-2565	161	14	,	,	PUNCT
ajlm-2565	161	15	leng	leng	PROPN
ajlm-2565	161	16	s.	s.	PROPN
ajlm-2565	161	17	analysis	analysis	NOUN
ajlm-2565	161	18	on	on	ADP
ajlm-2565	161	19	the	the	DET
ajlm-2565	161	20	associated	associated	ADJ
ajlm-2565	161	21	factors	factor	NOUN
ajlm-2565	161	22	of	of	ADP
ajlm-2565	161	23	hyperuricemia	hyperuricemia	NOUN
ajlm-2565	161	24	:	:	PUNCT
ajlm-2565	161	25	based	base	VERB
ajlm-2565	161	26	on	on	ADP
ajlm-2565	161	27	classification	classification	NOUN
ajlm-2565	161	28	tree	tree	NOUN
ajlm-2565	161	29	model	model	NOUN
ajlm-2565	161	30	.	.	PUNCT
ajlm-2565	162	1	chin	chin	PROPN
ajlm-2565	162	2	j	j	PROPN
ajlm-2565	162	3	dis	dis	PROPN
ajlm-2565	162	4	control	control	PROPN
ajlm-2565	162	5	prev	prev	PROPN
ajlm-2565	162	6	.	.	PUNCT
ajlm-2565	163	1	2019;23(11):1364–1369	2019;23(11):1364–1369	X
ajlm-2565	163	2	.	.	PUNCT
ajlm-2565	164	1	remedios	remedios	PROPN
ajlm-2565	164	2	c	c	PROPN
ajlm-2565	164	3	,	,	PUNCT
ajlm-2565	164	4	shah	shah	PROPN
ajlm-2565	164	5	m	m	PROPN
ajlm-2565	164	6	,	,	PUNCT
ajlm-2565	164	7	bhasker	bhasker	PROPN
ajlm-2565	164	8	ag	ag	PROPN
ajlm-2565	164	9	,	,	PUNCT
ajlm-2565	164	10	lakdawala	lakdawala	PROPN
ajlm-2565	164	11	m.	m.	NOUN
ajlm-2565	165	1	hyperuricemia	hyperuricemia	NOUN
ajlm-2565	165	2	:	:	PUNCT
ajlm-2565	165	3	a	a	DET
ajlm-2565	165	4	reality	reality	NOUN
ajlm-2565	165	5	in	in	ADP
ajlm-2565	165	6	the	the	DET
ajlm-2565	165	7	indian	indian	ADJ
ajlm-2565	165	8	obese	obese	PROPN
ajlm-2565	165	9	.	.	PUNCT
ajlm-2565	166	1	obes	obes	PROPN
ajlm-2565	166	2	surg	surg	NOUN
ajlm-2565	166	3	.	.	PUNCT
ajlm-2565	167	1	2012;22(6):945–948	2012;22(6):945–948	X
ajlm-2565	167	2	.	.	PROPN
ajlm-2565	167	3	https://doi.org/10.1007/s11695-012-0655-7	https://doi.org/10.1007/s11695-012-0655-7	NUM
ajlm-2565	167	4	skoczyńska	skoczyńska	PROPN
ajlm-2565	167	5	m	m	PROPN
ajlm-2565	167	6	,	,	PUNCT
ajlm-2565	167	7	chowaniec	chowaniec	PROPN
ajlm-2565	167	8	m	m	PROPN
ajlm-2565	167	9	,	,	PUNCT
ajlm-2565	167	10	szymczak	szymczak	ADV
ajlm-2565	167	11	a	a	PRON
ajlm-2565	167	12	,	,	PUNCT
ajlm-2565	167	13	langner	langner	NOUN
ajlm-2565	167	14	-	-	PUNCT
ajlm-2565	167	15	hetmańczuk	hetmańczuk	PROPN
ajlm-2565	167	16	a	a	PROPN
ajlm-2565	167	17	,	,	PUNCT
ajlm-2565	167	18	maciążek	maciążek	VERB
ajlm-2565	167	19	-	-	PUNCT
ajlm-2565	167	20	chyra	chyra	PROPN
ajlm-2565	167	21	b	b	PROPN
ajlm-2565	167	22	,	,	PUNCT
ajlm-2565	167	23	wiland	wiland	PROPN
ajlm-2565	167	24	p.	p.	NOUN
ajlm-2565	167	25	pathophysiology	pathophysiology	NOUN
ajlm-2565	167	26	of	of	ADP
ajlm-2565	167	27	hyperuricemia	hyperuricemia	NOUN
ajlm-2565	167	28	and	and	CCONJ
ajlm-2565	167	29	its	its	PRON
ajlm-2565	167	30	clinical	clinical	ADJ
ajlm-2565	167	31	significance	significance	NOUN
ajlm-2565	167	32	–	–	PUNCT
ajlm-2565	167	33	a	a	DET
ajlm-2565	167	34	narrative	narrative	NOUN
ajlm-2565	167	35	review	review	NOUN
ajlm-2565	167	36	.	.	PUNCT
ajlm-2565	168	1	reumatologia	reumatologia	PROPN
ajlm-2565	168	2	.	.	PUNCT
ajlm-2565	169	1	2020;58(5):312–323	2020;58(5):312–323	X
ajlm-2565	169	2	.	.	PUNCT
ajlm-2565	170	1	https://doi.org/10.5114/reum.2020.100140	https://doi.org/10.5114/reum.2020.100140	PROPN
ajlm-2565	170	2	dehghan	dehghan	PROPN
ajlm-2565	170	3	a	a	PRON
ajlm-2565	170	4	,	,	PUNCT
ajlm-2565	170	5	van	van	PROPN
ajlm-2565	170	6	hoek	hoek	PROPN
ajlm-2565	170	7	m	m	PROPN
ajlm-2565	170	8	,	,	PUNCT
ajlm-2565	170	9	sijbrands	sijbrand	VERB
ajlm-2565	170	10	ej	ej	PROPN
ajlm-2565	170	11	,	,	PUNCT
ajlm-2565	170	12	hofman	hofman	PROPN
ajlm-2565	170	13	a	a	PRON
ajlm-2565	170	14	,	,	PUNCT
ajlm-2565	170	15	witteman	witteman	PROPN
ajlm-2565	170	16	jc	jc	PROPN
ajlm-2565	170	17	.	.	PROPN
ajlm-2565	170	18	high	high	PROPN
ajlm-2565	170	19	serum	serum	PROPN
ajlm-2565	170	20	uric	uric	ADJ
ajlm-2565	170	21	acid	acid	NOUN
ajlm-2565	170	22	as	as	ADP
ajlm-2565	170	23	a	a	DET
ajlm-2565	170	24	novel	novel	ADJ
ajlm-2565	170	25	risk	risk	NOUN
ajlm-2565	170	26	factor	factor	NOUN
ajlm-2565	170	27	for	for	ADP
ajlm-2565	170	28	type	type	NOUN
ajlm-2565	170	29	2	2	NUM
ajlm-2565	170	30	diabetes	diabetes	NOUN
ajlm-2565	170	31	.	.	PUNCT
ajlm-2565	171	1	diabetes	diabetes	NOUN
ajlm-2565	171	2	care	care	NOUN
ajlm-2565	171	3	.	.	PUNCT
ajlm-2565	172	1	2008;31(2):361–362	2008;31(2):361–362	NUM
ajlm-2565	172	2	.	.	PUNCT
ajlm-2565	173	1	https://doi.org/10.2337/dc07-1276	https://doi.org/10.2337/dc07-1276	PROPN
ajlm-2565	173	2	grayson	grayson	PROPN
ajlm-2565	173	3	pc	pc	PROPN
ajlm-2565	173	4	,	,	PUNCT
ajlm-2565	173	5	kim	kim	PROPN
ajlm-2565	173	6	sy	sy	PROPN
ajlm-2565	173	7	,	,	PUNCT
ajlm-2565	173	8	lavalley	lavalley	PROPN
ajlm-2565	173	9	m	m	PROPN
ajlm-2565	173	10	,	,	PUNCT
ajlm-2565	173	11	choi	choi	PROPN
ajlm-2565	173	12	hk	hk	PROPN
ajlm-2565	173	13	.	.	PUNCT
ajlm-2565	174	1	hyperuricemia	hyperuricemia	NOUN
ajlm-2565	174	2	and	and	CCONJ
ajlm-2565	174	3	incident	incident	NOUN
ajlm-2565	174	4	hypertension	hypertension	NOUN
ajlm-2565	174	5	:	:	PUNCT
ajlm-2565	174	6	a	a	DET
ajlm-2565	174	7	systematic	systematic	ADJ
ajlm-2565	174	8	review	review	NOUN
ajlm-2565	174	9	and	and	CCONJ
ajlm-2565	174	10	meta	meta	ADJ
ajlm-2565	174	11	-	-	PUNCT
ajlm-2565	174	12	analysis	analysis	NOUN
ajlm-2565	174	13	.	.	PUNCT
ajlm-2565	175	1	arthritis	arthritis	NOUN
ajlm-2565	175	2	care	care	NOUN
ajlm-2565	175	3	res	re	NOUN
ajlm-2565	175	4	.	.	PUNCT
ajlm-2565	176	1	2011;63(1):102–110	2011;63(1):102–110	X
ajlm-2565	176	2	.	.	PUNCT
ajlm-2565	177	1	https://doi.org/10.1002/acr.20344	https://doi.org/10.1002/acr.20344	PROPN
ajlm-2565	177	2	wang	wang	PROPN
ajlm-2565	177	3	j	j	PROPN
ajlm-2565	177	4	,	,	PUNCT
ajlm-2565	177	5	qin	qin	PROPN
ajlm-2565	177	6	t	t	PROPN
ajlm-2565	177	7	,	,	PUNCT
ajlm-2565	177	8	chen	chen	PROPN
ajlm-2565	177	9	j	j	PROPN
ajlm-2565	177	10	,	,	PUNCT
ajlm-2565	177	11	et	et	PROPN
ajlm-2565	177	12	al	al	PROPN
ajlm-2565	177	13	.	.	PUNCT
ajlm-2565	177	14	hyperuricemia	hyperuricemia	PROPN
ajlm-2565	177	15	and	and	CCONJ
ajlm-2565	177	16	risk	risk	NOUN
ajlm-2565	177	17	of	of	ADP
ajlm-2565	177	18	incident	incident	NOUN
ajlm-2565	177	19	hypertension	hypertension	NOUN
ajlm-2565	177	20	:	:	PUNCT
ajlm-2565	177	21	a	a	DET
ajlm-2565	177	22	systematic	systematic	ADJ
ajlm-2565	177	23	review	review	NOUN
ajlm-2565	177	24	and	and	CCONJ
ajlm-2565	177	25	meta	meta	ADJ
ajlm-2565	177	26	-	-	PUNCT
ajlm-2565	177	27	analysis	analysis	NOUN
ajlm-2565	177	28	of	of	ADP
ajlm-2565	177	29	observational	observational	ADJ
ajlm-2565	177	30	studies	study	NOUN
ajlm-2565	177	31	.	.	PUNCT
ajlm-2565	178	1	plos	plos	PROPN
ajlm-2565	178	2	one	one	NUM
ajlm-2565	178	3	.	.	PUNCT
ajlm-2565	179	1	2014;9(12):e114259	2014;9(12):e114259	NOUN
ajlm-2565	179	2	.	.	PUNCT
ajlm-2565	180	1	https://doi.org/10.1371/journal.pone.0114259	https://doi.org/10.1371/journal.pone.0114259	NOUN
ajlm-2565	180	2	zhu	zhu	PROPN
ajlm-2565	180	3	p	p	NOUN
ajlm-2565	180	4	,	,	PUNCT
ajlm-2565	180	5	liu	liu	PROPN
ajlm-2565	180	6	y	y	PROPN
ajlm-2565	180	7	,	,	PUNCT
ajlm-2565	180	8	han	han	PROPN
ajlm-2565	180	9	l	l	PROPN
ajlm-2565	180	10	,	,	PUNCT
ajlm-2565	180	11	xu	xu	PROPN
ajlm-2565	180	12	g	g	PROPN
ajlm-2565	180	13	,	,	PUNCT
ajlm-2565	180	14	ran	run	VERB
ajlm-2565	180	15	j	j	PROPN
ajlm-2565	180	16	-	-	PUNCT
ajlm-2565	180	17	m.	m.	NOUN
ajlm-2565	180	18	serum	serum	PROPN
ajlm-2565	180	19	uric	uric	PROPN
ajlm-2565	180	20	acid	acid	PROPN
ajlm-2565	180	21	is	be	AUX
ajlm-2565	180	22	associated	associate	VERB
ajlm-2565	180	23	with	with	ADP
ajlm-2565	180	24	incident	incident	NOUN
ajlm-2565	180	25	chronic	chronic	ADJ
ajlm-2565	180	26	kidney	kidney	NOUN
ajlm-2565	180	27	disease	disease	NOUN
ajlm-2565	180	28	in	in	ADP
ajlm-2565	180	29	middle	middle	ADJ
ajlm-2565	180	30	-	-	PUNCT
ajlm-2565	180	31	aged	aged	ADJ
ajlm-2565	180	32	populations	population	NOUN
ajlm-2565	180	33	:	:	PUNCT
ajlm-2565	180	34	a	a	DET
ajlm-2565	180	35	meta	meta	ADJ
ajlm-2565	180	36	-	-	PUNCT
ajlm-2565	180	37	analysis	analysis	NOUN
ajlm-2565	180	38	of	of	ADP
ajlm-2565	180	39	15	15	NUM
ajlm-2565	180	40	cohort	cohort	NOUN
ajlm-2565	180	41	studies	study	NOUN
ajlm-2565	180	42	.	.	PUNCT
ajlm-2565	181	1	plos	plos	PROPN
ajlm-2565	181	2	one	one	NUM
ajlm-2565	181	3	.	.	PUNCT
ajlm-2565	182	1	2014;9(6):e100801	2014;9(6):e100801	NUM
ajlm-2565	182	2	.	.	PUNCT
ajlm-2565	183	1	https://doi.org/10.1371/journal.pone.0100801	https://doi.org/10.1371/journal.pone.0100801	PROPN
ajlm-2565	183	2	hsu	hsu	PROPN
ajlm-2565	183	3	c	c	PROPN
ajlm-2565	183	4	-	-	PUNCT
ajlm-2565	183	5	y	y	PROPN
ajlm-2565	183	6	,	,	PUNCT
ajlm-2565	183	7	iribarren	iribarren	VERB
ajlm-2565	183	8	c	c	PROPN
ajlm-2565	183	9	,	,	PUNCT
ajlm-2565	183	10	mcculloch	mcculloch	PROPN
ajlm-2565	183	11	ce	ce	PROPN
ajlm-2565	183	12	,	,	PUNCT
ajlm-2565	183	13	darbinian	darbinian	PROPN
ajlm-2565	183	14	j	j	PROPN
ajlm-2565	183	15	,	,	PUNCT
ajlm-2565	183	16	go	go	VERB
ajlm-2565	183	17	as	as	ADP
ajlm-2565	183	18	.	.	PUNCT
ajlm-2565	184	1	risk	risk	NOUN
ajlm-2565	184	2	factors	factor	NOUN
ajlm-2565	184	3	for	for	ADP
ajlm-2565	184	4	end	end	NOUN
ajlm-2565	184	5	-	-	PUNCT
ajlm-2565	184	6	stage	stage	NOUN
ajlm-2565	184	7	renal	renal	ADJ
ajlm-2565	184	8	disease	disease	NOUN
ajlm-2565	184	9	:	:	PUNCT
ajlm-2565	184	10	25	25	NUM
ajlm-2565	184	11	-	-	PUNCT
ajlm-2565	184	12	year	year	NOUN
ajlm-2565	184	13	follow	follow	NOUN
ajlm-2565	184	14	-	-	PUNCT
ajlm-2565	184	15	up	up	NOUN
ajlm-2565	184	16	.	.	PUNCT
ajlm-2565	185	1	arch	arch	ADJ
ajlm-2565	185	2	intern	intern	NOUN
ajlm-2565	185	3	med	med	PROPN
ajlm-2565	185	4	.	.	PUNCT
ajlm-2565	186	1	2009;169(4):342–350	2009;169(4):342–350	PROPN
ajlm-2565	186	2	.	.	PUNCT
ajlm-2565	187	1	https://doi.org/10.1001/archinternmed.2008.605	https://doi.org/10.1001/archinternmed.2008.605	PROPN
ajlm-2565	187	2	wang	wang	PROPN
ajlm-2565	187	3	h	h	PROPN
ajlm-2565	187	4	,	,	PUNCT
ajlm-2565	187	5	lizhen	lizhen	PROPN
ajlm-2565	187	6	w	w	PROPN
ajlm-2565	187	7	,	,	PUNCT
ajlm-2565	187	8	xie	xie	PROPN
ajlm-2565	188	1	r	r	PROPN
ajlm-2565	188	2	,	,	PUNCT
ajlm-2565	188	3	et	et	PROPN
ajlm-2565	188	4	al	al	PROPN
ajlm-2565	188	5	.	.	PROPN
ajlm-2565	188	6	association	association	PROPN
ajlm-2565	188	7	of	of	ADP
ajlm-2565	188	8	serum	serum	PROPN
ajlm-2565	188	9	uric	uric	ADJ
ajlm-2565	188	10	acid	acid	NOUN
ajlm-2565	188	11	with	with	ADP
ajlm-2565	188	12	body	body	NOUN
ajlm-2565	188	13	mass	mass	PROPN
ajlm-2565	188	14	index	index	NOUN
ajlm-2565	188	15	:	:	PUNCT
ajlm-2565	188	16	a	a	DET
ajlm-2565	188	17	cross	cross	ADJ
ajlm-2565	188	18	-	-	ADJ
ajlm-2565	188	19	sectional	sectional	ADJ
ajlm-2565	188	20	study	study	NOUN
ajlm-2565	188	21	from	from	ADP
ajlm-2565	188	22	jiangsu	jiangsu	PROPN
ajlm-2565	188	23	province	province	PROPN
ajlm-2565	188	24	,	,	PUNCT
ajlm-2565	188	25	china	china	PROPN
ajlm-2565	188	26	.	.	PUNCT
ajlm-2565	189	1	iran	iran	PROPN
ajlm-2565	189	2	j	j	PROPN
ajlm-2565	189	3	public	public	ADJ
ajlm-2565	189	4	health	health	NOUN
ajlm-2565	189	5	.	.	PUNCT
ajlm-2565	190	1	2014;43(11):1503–1509	2014;43(11):1503–1509	X
ajlm-2565	190	2	.	.	PUNCT
ajlm-2565	191	1	billiet	billiet	PROPN
ajlm-2565	191	2	l	l	PROPN
ajlm-2565	191	3	,	,	PUNCT
ajlm-2565	191	4	doaty	doaty	PROPN
ajlm-2565	191	5	s	s	PROPN
ajlm-2565	191	6	,	,	PUNCT
ajlm-2565	191	7	katz	katz	PROPN
ajlm-2565	191	8	jd	jd	PROPN
ajlm-2565	191	9	,	,	PUNCT
ajlm-2565	191	10	velasquez	velasquez	PROPN
ajlm-2565	191	11	mt	mt	PROPN
ajlm-2565	191	12	.	.	PROPN
ajlm-2565	191	13	review	review	PROPN
ajlm-2565	191	14	of	of	ADP
ajlm-2565	191	15	hyperuricemia	hyperuricemia	NOUN
ajlm-2565	191	16	as	as	ADP
ajlm-2565	191	17	new	new	ADJ
ajlm-2565	191	18	marker	marker	NOUN
ajlm-2565	191	19	for	for	ADP
ajlm-2565	191	20	metabolic	metabolic	NOUN
ajlm-2565	191	21	syndrome	syndrome	NOUN
ajlm-2565	191	22	.	.	PUNCT
ajlm-2565	192	1	isrn	isrn	NOUN
ajlm-2565	192	2	rheumatol	rheumatol	VERB
ajlm-2565	192	3	.	.	PUNCT
ajlm-2565	193	1	2014;2014:852954	2014;2014:852954	NOUN
ajlm-2565	193	2	.	.	PUNCT
ajlm-2565	194	1	https://doi.org/10.1155/2014/852954	https://doi.org/10.1155/2014/852954	PROPN
ajlm-2565	194	2	eckel	eckel	PROPN
ajlm-2565	194	3	rh	rh	PROPN
ajlm-2565	194	4	,	,	PUNCT
ajlm-2565	194	5	grundy	grundy	PROPN
ajlm-2565	194	6	sm	sm	PROPN
ajlm-2565	194	7	,	,	PUNCT
ajlm-2565	194	8	zimmet	zimmet	NOUN
ajlm-2565	194	9	pz	pz	NOUN
ajlm-2565	194	10	.	.	PUNCT
ajlm-2565	195	1	the	the	DET
ajlm-2565	195	2	metabolic	metabolic	NOUN
ajlm-2565	195	3	syndrome	syndrome	NOUN
ajlm-2565	195	4	.	.	PUNCT
ajlm-2565	196	1	lancet	lancet	PROPN
ajlm-2565	196	2	.	.	PUNCT
ajlm-2565	197	1	2005;365(9468):1415–1428	2005;365(9468):1415–1428	NOUN
ajlm-2565	197	2	.	.	PUNCT
ajlm-2565	198	1	https://doi.org/10.1016/s0140-6736(05)66378-7	https://doi.org/10.1016/s0140-6736(05)66378-7	PROPN
ajlm-2565	198	2	blüher	blüher	PROPN
ajlm-2565	198	3	m.	m.	NOUN
ajlm-2565	198	4	obesity	obesity	NOUN
ajlm-2565	198	5	:	:	PUNCT
ajlm-2565	198	6	global	global	ADJ
ajlm-2565	198	7	epidemiology	epidemiology	NOUN
ajlm-2565	198	8	and	and	CCONJ
ajlm-2565	198	9	pathogenesis	pathogenesis	NOUN
ajlm-2565	198	10	.	.	PUNCT
ajlm-2565	199	1	nat	nat	PROPN
ajlm-2565	199	2	rev	rev	PROPN
ajlm-2565	199	3	endocrinol	endocrinol	NOUN
ajlm-2565	199	4	.	.	PUNCT
ajlm-2565	200	1	2019;15(5):288–298	2019;15(5):288–298	X
ajlm-2565	200	2	.	.	PUNCT
ajlm-2565	200	3	https://doi.org/10.1038/s41574-019-0176-8	https://doi.org/10.1038/s41574-019-0176-8	PRON
ajlm-2565	201	1	who	who	PRON
ajlm-2565	201	2	.	.	PUNCT
ajlm-2565	202	1	obesity	obesity	NOUN
ajlm-2565	202	2	and	and	CCONJ
ajlm-2565	202	3	overweight	overweight	ADJ
ajlm-2565	203	1	[	[	X
ajlm-2565	203	2	homepage	homepage	NOUN
ajlm-2565	203	3	on	on	ADP
ajlm-2565	203	4	the	the	DET
ajlm-2565	203	5	internet	internet	NOUN
ajlm-2565	203	6	]	]	PUNCT
ajlm-2565	203	7	.	.	PUNCT
ajlm-2565	204	1	2024	2024	NUM
ajlm-2565	205	1	[	[	X
ajlm-2565	205	2	cited	cite	VERB
ajlm-2565	205	3	2024	2024	NUM
ajlm-2565	205	4	mar	mar	PROPN
ajlm-2565	205	5	01	01	NUM
ajlm-2565	205	6	]	]	PUNCT
ajlm-2565	205	7	.	.	PUNCT
ajlm-2565	206	1	available	available	ADJ
ajlm-2565	206	2	from	from	ADP
ajlm-2565	206	3	:	:	PUNCT
ajlm-2565	206	4	https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight#:~:text=worldwide%20adult%20obesity%20has%20more,16%25%20were%20living%20with%20obesity	https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight#:~:text=worldwide%20adult%20obesity%20has%20more,16%25%20were%20living%20with%20obesity	PROPN
ajlm-2565	206	5	zhang	zhang	PROPN
ajlm-2565	206	6	j	j	PROPN
ajlm-2565	206	7	,	,	PUNCT
ajlm-2565	206	8	zhang	zhang	PROPN
ajlm-2565	206	9	y	y	PROPN
ajlm-2565	206	10	,	,	PUNCT
ajlm-2565	206	11	deng	deng	PROPN
ajlm-2565	206	12	w	w	PROPN
ajlm-2565	206	13	,	,	PUNCT
ajlm-2565	206	14	chen	chen	PROPN
ajlm-2565	206	15	b.	b.	PROPN
ajlm-2565	206	16	elevated	elevated	PROPN
ajlm-2565	206	17	serum	serum	PROPN
ajlm-2565	206	18	uric	uric	PROPN
ajlm-2565	206	19	acid	acid	PROPN
ajlm-2565	206	20	is	be	AUX
ajlm-2565	206	21	associated	associate	VERB
ajlm-2565	206	22	with	with	ADP
ajlm-2565	206	23	angiotensinogen	angiotensinogen	NOUN
ajlm-2565	206	24	in	in	ADP
ajlm-2565	206	25	obese	obese	ADJ
ajlm-2565	206	26	patients	patient	NOUN
ajlm-2565	206	27	with	with	ADP
ajlm-2565	206	28	untreated	untreated	ADJ
ajlm-2565	206	29	hypertension	hypertension	NOUN
ajlm-2565	206	30	.	.	PUNCT
ajlm-2565	207	1	j	j	PROPN
ajlm-2565	207	2	clin	clin	PROPN
ajlm-2565	207	3	hypertens	hyperten	NOUN
ajlm-2565	207	4	.	.	PUNCT
ajlm-2565	208	1	2014;16(8):569–574	2014;16(8):569–574	X
ajlm-2565	208	2	.	.	PUNCT
ajlm-2565	209	1	https://doi.org/10.1111/jch.12353	https://doi.org/10.1111/jch.12353	PROPN
ajlm-2565	209	2	tanaka	tanaka	PROPN
ajlm-2565	209	3	k	k	PROPN
ajlm-2565	209	4	,	,	PUNCT
ajlm-2565	209	5	ogata	ogata	PROPN
ajlm-2565	209	6	s	s	PROPN
ajlm-2565	209	7	,	,	PUNCT
ajlm-2565	209	8	tanaka	tanaka	PROPN
ajlm-2565	209	9	h	h	PROPN
ajlm-2565	209	10	,	,	PUNCT
ajlm-2565	209	11	et	et	PROPN
ajlm-2565	209	12	al	al	PROPN
ajlm-2565	209	13	.	.	PUNCT
ajlm-2565	210	1	the	the	DET
ajlm-2565	210	2	relationship	relationship	NOUN
ajlm-2565	210	3	between	between	ADP
ajlm-2565	210	4	body	body	NOUN
ajlm-2565	210	5	mass	mass	NOUN
ajlm-2565	210	6	index	index	NOUN
ajlm-2565	210	7	and	and	CCONJ
ajlm-2565	210	8	uric	uric	ADJ
ajlm-2565	210	9	acid	acid	NOUN
ajlm-2565	210	10	:	:	PUNCT
ajlm-2565	210	11	a	a	DET
ajlm-2565	210	12	study	study	NOUN
ajlm-2565	210	13	on	on	ADP
ajlm-2565	210	14	japanese	japanese	ADJ
ajlm-2565	210	15	adult	adult	NOUN
ajlm-2565	210	16	twins	twin	NOUN
ajlm-2565	210	17	.	.	PUNCT
ajlm-2565	211	1	environ	environ	PROPN
ajlm-2565	211	2	health	health	PROPN
ajlm-2565	211	3	prev	prev	PROPN
ajlm-2565	211	4	med	med	PROPN
ajlm-2565	211	5	.	.	PUNCT
ajlm-2565	212	1	2015;20(5):347–353	2015;20(5):347–353	NUM
ajlm-2565	212	2	.	.	NOUN
ajlm-2565	212	3	https://doi.org/10.1007/s12199-015-0473-3	https://doi.org/10.1007/s12199-015-0473-3	PROPN
ajlm-2565	212	4	akther	akther	PROPN
ajlm-2565	212	5	mt	mt	PROPN
ajlm-2565	212	6	,	,	PUNCT
ajlm-2565	212	7	islam	islam	PROPN
ajlm-2565	212	8	mh	mh	PROPN
ajlm-2565	212	9	,	,	PUNCT
ajlm-2565	212	10	akter	akter	PROPN
ajlm-2565	212	11	s	s	PART
ajlm-2565	212	12	,	,	PUNCT
ajlm-2565	212	13	et	et	PROPN
ajlm-2565	212	14	al	al	PROPN
ajlm-2565	212	15	.	.	PUNCT
ajlm-2565	213	1	a	a	DET
ajlm-2565	213	2	study	study	NOUN
ajlm-2565	213	3	of	of	ADP
ajlm-2565	213	4	evaluation	evaluation	NOUN
ajlm-2565	213	5	of	of	ADP
ajlm-2565	213	6	serum	serum	NOUN
ajlm-2565	213	7	uric	uric	ADJ
ajlm-2565	213	8	acid	acid	NOUN
ajlm-2565	213	9	level	level	NOUN
ajlm-2565	213	10	in	in	ADP
ajlm-2565	213	11	obesity	obesity	NOUN
ajlm-2565	213	12	.	.	PUNCT
ajlm-2565	214	1	jcmcta	jcmcta	NOUN
ajlm-2565	214	2	.	.	PUNCT
ajlm-2565	215	1	2022;33(2):89–94	2022;33(2):89–94	X
ajlm-2565	215	2	.	.	PUNCT
ajlm-2565	215	3	namulindwa	namulindwa	PROPN
ajlm-2565	215	4	a	a	PRON
ajlm-2565	215	5	,	,	PUNCT
ajlm-2565	215	6	wasswa	wasswa	PROPN
ajlm-2565	215	7	jh	jh	PROPN
ajlm-2565	215	8	,	,	PUNCT
ajlm-2565	215	9	muyindike	muyindike	VERB
ajlm-2565	215	10	w	w	PROPN
ajlm-2565	215	11	,	,	PUNCT
ajlm-2565	215	12	tamukong	tamukong	ADJ
ajlm-2565	215	13	r	r	NOUN
ajlm-2565	215	14	,	,	PUNCT
ajlm-2565	215	15	oloro	oloro	PROPN
ajlm-2565	215	16	j.	j.	PROPN
ajlm-2565	215	17	prevalence	prevalence	NOUN
ajlm-2565	215	18	and	and	CCONJ
ajlm-2565	215	19	factors	factor	NOUN
ajlm-2565	215	20	associated	associate	VERB
ajlm-2565	215	21	with	with	ADP
ajlm-2565	215	22	adverse	adverse	ADJ
ajlm-2565	215	23	drug	drug	NOUN
ajlm-2565	215	24	events	event	NOUN
ajlm-2565	215	25	among	among	ADP
ajlm-2565	215	26	patients	patient	NOUN
ajlm-2565	215	27	on	on	ADP
ajlm-2565	215	28	dolutegravir	dolutegravir	NOUN
ajlm-2565	215	29	-	-	PUNCT
ajlm-2565	215	30	based	base	VERB
ajlm-2565	215	31	regimen	regiman	NOUN
ajlm-2565	215	32	at	at	ADP
ajlm-2565	215	33	the	the	DET
ajlm-2565	215	34	immune	immune	ADJ
ajlm-2565	215	35	suppression	suppression	NOUN
ajlm-2565	215	36	syndrome	syndrome	NOUN
ajlm-2565	215	37	clinic	clinic	NOUN
ajlm-2565	215	38	of	of	ADP
ajlm-2565	215	39	mbarara	mbarara	PROPN
ajlm-2565	215	40	regional	regional	ADJ
ajlm-2565	215	41	referral	referral	ADJ
ajlm-2565	215	42	hospital	hospital	NOUN
ajlm-2565	215	43	,	,	PUNCT
ajlm-2565	215	44	uganda	uganda	PROPN
ajlm-2565	215	45	:	:	PUNCT
ajlm-2565	215	46	a	a	DET
ajlm-2565	215	47	mixed	mixed	ADJ
ajlm-2565	215	48	design	design	NOUN
ajlm-2565	215	49	study	study	NOUN
ajlm-2565	215	50	.	.	PUNCT
ajlm-2565	216	1	aids	aids	PROPN
ajlm-2565	216	2	res	re	NOUN
ajlm-2565	216	3	ther	ther	ADV
ajlm-2565	216	4	.	.	PUNCT
ajlm-2565	217	1	2022;19(1):1–8	2022;19(1):1–8	NOUN
ajlm-2565	217	2	.	.	PUNCT
ajlm-2565	218	1	https://doi.org/10.1186/s12981-022-00442-7	https://doi.org/10.1186/s12981-022-00442-7	PROPN
ajlm-2565	218	2	bourgi	bourgi	PROPN
ajlm-2565	218	3	k	k	PROPN
ajlm-2565	218	4	,	,	PUNCT
ajlm-2565	218	5	rebeiro	rebeiro	ADJ
ajlm-2565	218	6	pf	pf	PROPN
ajlm-2565	218	7	,	,	PUNCT
ajlm-2565	218	8	turner	turner	PROPN
ajlm-2565	218	9	m	m	PROPN
ajlm-2565	218	10	,	,	PUNCT
ajlm-2565	218	11	et	et	PROPN
ajlm-2565	218	12	al	al	PROPN
ajlm-2565	218	13	.	.	PUNCT
ajlm-2565	219	1	greater	great	ADJ
ajlm-2565	219	2	weight	weight	NOUN
ajlm-2565	219	3	gain	gain	NOUN
ajlm-2565	219	4	in	in	ADP
ajlm-2565	219	5	treatment	treatment	NOUN
ajlm-2565	219	6	-	-	PUNCT
ajlm-2565	219	7	naive	naive	ADJ
ajlm-2565	219	8	persons	person	NOUN
ajlm-2565	219	9	starting	start	VERB
ajlm-2565	219	10	dolutegravir	dolutegravir	PROPN
ajlm-2565	219	11	-	-	PUNCT
ajlm-2565	219	12	based	base	VERB
ajlm-2565	219	13	antiretroviral	antiretroviral	ADJ
ajlm-2565	219	14	therapy	therapy	NOUN
ajlm-2565	219	15	.	.	PUNCT
ajlm-2565	220	1	clin	clin	PROPN
ajlm-2565	220	2	infect	infect	PROPN
ajlm-2565	220	3	dis	dis	PROPN
ajlm-2565	220	4	.	.	PUNCT
ajlm-2565	220	5	2020;70(7):1267–1274	2020;70(7):1267–1274	NOUN
ajlm-2565	220	6	.	.	PUNCT
ajlm-2565	221	1	https://doi.org/10.1093/cid/ciz407	https://doi.org/10.1093/cid/ciz407	PROPN
ajlm-2565	221	2	thivalapill	thivalapill	ADP
ajlm-2565	221	3	n	n	CCONJ
ajlm-2565	221	4	,	,	PUNCT
ajlm-2565	221	5	simelane	simelane	NOUN
ajlm-2565	221	6	t	t	PROPN
ajlm-2565	221	7	,	,	PUNCT
ajlm-2565	221	8	mthethwa	mthethwa	NOUN
ajlm-2565	221	9	n	n	CCONJ
ajlm-2565	221	10	,	,	PUNCT
ajlm-2565	221	11	et	et	PROPN
ajlm-2565	221	12	al	al	PROPN
ajlm-2565	221	13	.	.	PROPN
ajlm-2565	221	14	transition	transition	NOUN
ajlm-2565	221	15	to	to	ADP
ajlm-2565	221	16	dolutegravir	dolutegravir	PROPN
ajlm-2565	221	17	is	be	AUX
ajlm-2565	221	18	associated	associate	VERB
ajlm-2565	221	19	with	with	ADP
ajlm-2565	221	20	an	an	DET
ajlm-2565	221	21	increase	increase	NOUN
ajlm-2565	221	22	in	in	ADP
ajlm-2565	221	23	the	the	DET
ajlm-2565	221	24	rate	rate	NOUN
ajlm-2565	221	25	of	of	ADP
ajlm-2565	221	26	body	body	NOUN
ajlm-2565	221	27	mass	mass	NOUN
ajlm-2565	221	28	index	index	NOUN
ajlm-2565	221	29	change	change	NOUN
ajlm-2565	221	30	in	in	ADP
ajlm-2565	221	31	a	a	DET
ajlm-2565	221	32	cohort	cohort	NOUN
ajlm-2565	221	33	of	of	ADP
ajlm-2565	221	34	virally	virally	ADV
ajlm-2565	221	35	suppressed	suppress	VERB
ajlm-2565	221	36	adolescents	adolescent	NOUN
ajlm-2565	221	37	.	.	PUNCT
ajlm-2565	222	1	clin	clin	PROPN
ajlm-2565	222	2	infect	infect	PROPN
ajlm-2565	222	3	dis	dis	PROPN
ajlm-2565	222	4	.	.	PUNCT
ajlm-2565	223	1	2021;73(3):e580	2021;73(3):e580	PROPN
ajlm-2565	223	2	–	–	PUNCT
ajlm-2565	223	3	e586	e586	NUM
ajlm-2565	223	4	.	.	AUX
ajlm-2565	223	5	https://doi.org/10.1093/cid/ciaa1652	https://doi.org/10.1093/cid/ciaa1652	PROPN
ajlm-2565	223	6	kiconco	kiconco	PROPN
ajlm-2565	223	7	salr	salr	PROPN
ajlm-2565	223	8	,	,	PUNCT
ajlm-2565	223	9	udu	udu	NOUN
ajlm-2565	223	10	r	r	NOUN
ajlm-2565	223	11	,	,	PUNCT
ajlm-2565	223	12	tumusiime	tumusiime	NOUN
ajlm-2565	223	13	j	j	PROPN
ajlm-2565	223	14	,	,	PUNCT
ajlm-2565	223	15	bagenda	bagenda	PROPN
ajlm-2565	223	16	cn	cn	PROPN
ajlm-2565	223	17	,	,	PUNCT
ajlm-2565	223	18	rugera	rugera	NOUN
ajlm-2565	223	19	sp	sp	NOUN
ajlm-2565	223	20	.	.	PUNCT
ajlm-2565	224	1	(	(	PUNCT
ajlm-2565	224	2	2024	2024	NUM
ajlm-2565	224	3	)	)	PUNCT
ajlm-2565	224	4	prediction	prediction	NOUN
ajlm-2565	224	5	of	of	ADP
ajlm-2565	224	6	kidney	kidney	NOUN
ajlm-2565	224	7	dysfunction	dysfunction	NOUN
ajlm-2565	224	8	using	use	VERB
ajlm-2565	224	9	serum	serum	NOUN
ajlm-2565	224	10	uric	uric	ADJ
ajlm-2565	224	11	acid	acid	NOUN
ajlm-2565	224	12	/	/	SYM
ajlm-2565	224	13	serum	serum	NOUN
ajlm-2565	224	14	creatinine	creatinine	NOUN
ajlm-2565	224	15	ratio	ratio	NOUN
ajlm-2565	224	16	in	in	ADP
ajlm-2565	224	17	a	a	DET
ajlm-2565	224	18	population	population	NOUN
ajlm-2565	224	19	of	of	ADP
ajlm-2565	224	20	hiv	hiv	PROPN
ajlm-2565	224	21	patients	patient	NOUN
ajlm-2565	224	22	;	;	PUNCT
ajlm-2565	224	23	a	a	DET
ajlm-2565	224	24	cross	cross	ADJ
ajlm-2565	224	25	-	-	ADJ
ajlm-2565	224	26	sectional	sectional	ADJ
ajlm-2565	224	27	study	study	NOUN
ajlm-2565	224	28	in	in	ADP
ajlm-2565	224	29	south	south	ADJ
ajlm-2565	224	30	-	-	PUNCT
ajlm-2565	224	31	western	western	ADJ
ajlm-2565	224	32	uganda	uganda	PROPN
ajlm-2565	224	33	.	.	PUNCT
ajlm-2565	225	1	manuscript	manuscript	NOUN
ajlm-2565	225	2	submitted	submit	VERB
ajlm-2565	225	3	for	for	ADP
ajlm-2565	225	4	publication	publication	NOUN
ajlm-2565	225	5	.	.	PUNCT
ajlm-2565	226	1	uaratanawong	uaratanawong	PROPN
ajlm-2565	226	2	s	s	PROPN
ajlm-2565	226	3	,	,	PUNCT
ajlm-2565	226	4	suraamornkul	suraamornkul	PROPN
ajlm-2565	226	5	s	s	PROPN
ajlm-2565	226	6	,	,	PUNCT
ajlm-2565	226	7	angkeaw	angkeaw	PROPN
ajlm-2565	226	8	s	s	PROPN
ajlm-2565	226	9	,	,	PUNCT
ajlm-2565	226	10	uaratanawong	uaratanawong	PROPN
ajlm-2565	226	11	r.	r.	PROPN
ajlm-2565	226	12	prevalence	prevalence	NOUN
ajlm-2565	226	13	of	of	ADP
ajlm-2565	226	14	hyperuricemia	hyperuricemia	NOUN
ajlm-2565	226	15	in	in	ADP
ajlm-2565	226	16	bangkok	bangkok	PROPN
ajlm-2565	226	17	population	population	PROPN
ajlm-2565	226	18	.	.	PUNCT
ajlm-2565	227	1	clin	clin	PROPN
ajlm-2565	227	2	rheumatol	rheumatol	NOUN
ajlm-2565	227	3	.	.	PUNCT
ajlm-2565	228	1	2011;30(7):887–893	2011;30(7):887–893	X
ajlm-2565	228	2	.	.	X
ajlm-2565	228	3	https://doi.org/10.1007/s10067-011-1699-0	https://doi.org/10.1007/s10067-011-1699-0	PROPN
ajlm-2565	228	4	pirro	pirro	PROPN
ajlm-2565	228	5	m	m	PROPN
ajlm-2565	228	6	,	,	PUNCT
ajlm-2565	228	7	bianconi	bianconi	NOUN
ajlm-2565	228	8	v	v	NOUN
ajlm-2565	228	9	,	,	PUNCT
ajlm-2565	228	10	schiaroli	schiaroli	NOUN
ajlm-2565	228	11	e	e	NOUN
ajlm-2565	228	12	,	,	PUNCT
ajlm-2565	228	13	et	et	PROPN
ajlm-2565	228	14	al	al	PROPN
ajlm-2565	228	15	.	.	PROPN
ajlm-2565	229	1	elevated	elevated	PROPN
ajlm-2565	229	2	serum	serum	PROPN
ajlm-2565	229	3	uric	uric	ADJ
ajlm-2565	229	4	acid	acid	PROPN
ajlm-2565	229	5	levels	level	NOUN
ajlm-2565	229	6	are	be	AUX
ajlm-2565	229	7	associated	associate	VERB
ajlm-2565	229	8	with	with	ADP
ajlm-2565	229	9	endothelial	endothelial	ADJ
ajlm-2565	229	10	dysfunction	dysfunction	NOUN
ajlm-2565	229	11	in	in	ADP
ajlm-2565	229	12	hiv	hiv	PROPN
ajlm-2565	229	13	patients	patient	NOUN
ajlm-2565	229	14	receiving	receive	VERB
ajlm-2565	229	15	highly	highly	ADV
ajlm-2565	229	16	-	-	PUNCT
ajlm-2565	229	17	active	active	ADJ
ajlm-2565	229	18	antiretroviral	antiretroviral	ADJ
ajlm-2565	229	19	therapy	therapy	NOUN
ajlm-2565	229	20	.	.	PUNCT
ajlm-2565	230	1	atherosclerosis	atherosclerosis	NOUN
ajlm-2565	230	2	.	.	PUNCT
ajlm-2565	231	1	2018;272:101–107	2018;272:101–107	NUM
ajlm-2565	231	2	.	.	PUNCT
ajlm-2565	232	1	https://doi.org/10.1016/j.atherosclerosis.2018.03.031	https://doi.org/10.1016/j.atherosclerosis.2018.03.031	PROPN
ajlm-2565	232	2	molla	molla	PROPN
ajlm-2565	232	3	md	md	PROPN
ajlm-2565	232	4	,	,	PUNCT
ajlm-2565	232	5	bekele	bekele	PROPN
ajlm-2565	232	6	a	a	PROPN
ajlm-2565	232	7	,	,	PUNCT
ajlm-2565	232	8	melka	melka	ADJ
ajlm-2565	232	9	ds	ds	NOUN
ajlm-2565	232	10	,	,	PUNCT
ajlm-2565	232	11	et	et	PROPN
ajlm-2565	232	12	al	al	PROPN
ajlm-2565	232	13	.	.	PUNCT
ajlm-2565	233	1	hyperuricemia	hyperuricemia	PROPN
ajlm-2565	233	2	and	and	CCONJ
ajlm-2565	233	3	its	its	PRON
ajlm-2565	233	4	associated	associated	ADJ
ajlm-2565	233	5	factors	factor	NOUN
ajlm-2565	233	6	among	among	ADP
ajlm-2565	233	7	adult	adult	NOUN
ajlm-2565	233	8	staff	staff	NOUN
ajlm-2565	233	9	members	member	NOUN
ajlm-2565	233	10	of	of	ADP
ajlm-2565	233	11	the	the	DET
ajlm-2565	233	12	ethiopian	ethiopian	ADJ
ajlm-2565	233	13	public	public	PROPN
ajlm-2565	233	14	health	health	PROPN
ajlm-2565	233	15	institute	institute	PROPN
ajlm-2565	233	16	,	,	PUNCT
ajlm-2565	233	17	ethiopia	ethiopia	PROPN
ajlm-2565	233	18	.	.	PUNCT
ajlm-2565	234	1	int	int	PROPN
ajlm-2565	234	2	j	j	PROPN
ajlm-2565	234	3	gen	gen	PROPN
ajlm-2565	234	4	med	med	PROPN
ajlm-2565	234	5	.	.	PUNCT
ajlm-2565	235	1	2021;14:1437–1447	2021;14:1437–1447	NUM
ajlm-2565	235	2	.	.	PUNCT
ajlm-2565	236	1	https://doi.org/10.2147/ijgm.s308158	https://doi.org/10.2147/ijgm.s308158	PROPN
ajlm-2565	236	2	zinyando	zinyando	PROPN
ajlm-2565	236	3	e	e	PROPN
ajlm-2565	236	4	,	,	PUNCT
ajlm-2565	236	5	muswe	muswe	ADJ
ajlm-2565	236	6	r	r	NOUN
ajlm-2565	236	7	,	,	PUNCT
ajlm-2565	236	8	zhou	zhou	PROPN
ajlm-2565	237	1	dt	dt	PROPN
ajlm-2565	237	2	.	.	PUNCT
ajlm-2565	238	1	hyperuricemia	hyperuricemia	NOUN
ajlm-2565	238	2	and	and	CCONJ
ajlm-2565	238	3	the	the	DET
ajlm-2565	238	4	metabolic	metabolic	NOUN
ajlm-2565	238	5	syndrome	syndrome	NOUN
ajlm-2565	238	6	in	in	ADP
ajlm-2565	238	7	hiv+	hiv+	ADJ
ajlm-2565	238	8	adults	adult	NOUN
ajlm-2565	238	9	.	.	PUNCT
ajlm-2565	239	1	res	re	NOUN
ajlm-2565	239	2	j	j	PROPN
ajlm-2565	239	3	life	life	NOUN
ajlm-2565	239	4	sci	sci	PROPN
ajlm-2565	239	5	bioinform	bioinform	PROPN
ajlm-2565	239	6	pharm	pharm	PROPN
ajlm-2565	239	7	chem	chem	PROPN
ajlm-2565	239	8	sci	sci	PROPN
ajlm-2565	240	1	.	.	PROPN
ajlm-2565	241	1	2017;(3(3):55–63	2017;(3(3):55–63	NUM
ajlm-2565	241	2	https://doi.org/10.26479/2017.0303.03	https://doi.org/10.26479/2017.0303.03	NOUN
ajlm-2565	241	3	makusidi	makusidi	NOUN
ajlm-2565	241	4	m	m	NOUN
ajlm-2565	241	5	,	,	PUNCT
ajlm-2565	241	6	chijioke	chijioke	VERB
ajlm-2565	241	7	a	a	PRON
ajlm-2565	241	8	,	,	PUNCT
ajlm-2565	241	9	kolo	kolo	PROPN
ajlm-2565	241	10	p	p	PROPN
ajlm-2565	241	11	,	,	PUNCT
ajlm-2565	241	12	et	et	PROPN
ajlm-2565	241	13	al	al	PROPN
ajlm-2565	241	14	.	.	PUNCT
ajlm-2565	241	15	prevalence	prevalence	NOUN
ajlm-2565	241	16	and	and	CCONJ
ajlm-2565	241	17	pattern	pattern	NOUN
ajlm-2565	241	18	of	of	ADP
ajlm-2565	241	19	hyperuricemia	hyperuricemia	NOUN
ajlm-2565	241	20	in	in	ADP
ajlm-2565	241	21	a	a	DET
ajlm-2565	241	22	survey	survey	NOUN
ajlm-2565	241	23	among	among	ADP
ajlm-2565	241	24	inhabitants	inhabitant	NOUN
ajlm-2565	241	25	of	of	ADP
ajlm-2565	241	26	sokoto	sokoto	PROPN
ajlm-2565	241	27	metropolis	metropolis	PROPN
ajlm-2565	241	28	,	,	PUNCT
ajlm-2565	241	29	north	north	NOUN
ajlm-2565	241	30	western	western	PROPN
ajlm-2565	241	31	nigeria	nigeria	PROPN
ajlm-2565	241	32	.	.	PUNCT
ajlm-2565	242	1	res	re	NOUN
ajlm-2565	242	2	j	j	PROPN
ajlm-2565	242	3	health	health	PROPN
ajlm-2565	242	4	sci	sci	PROPN
ajlm-2565	242	5	.	.	PUNCT
ajlm-2565	242	6	2016;4(1):61–67	2016;4(1):61–67	NUM
ajlm-2565	242	7	.	.	PUNCT
ajlm-2565	243	1	tuono	tuono	PROPN
ajlm-2565	243	2	rdm	rdm	PROPN
ajlm-2565	243	3	,	,	PUNCT
ajlm-2565	243	4	samou	samou	PROPN
ajlm-2565	243	5	abf	abf	PROPN
ajlm-2565	243	6	,	,	PUNCT
ajlm-2565	243	7	mbiandjeu	mbiandjeu	PROPN
ajlm-2565	243	8	mt	mt	PROPN
ajlm-2565	243	9	,	,	PUNCT
ajlm-2565	243	10	well	well	ADV
ajlm-2565	243	11	pbakwa	pbakwa	NOUN
ajlm-2565	243	12	,	,	PUNCT
ajlm-2565	243	13	chuisseu	chuisseu	NOUN
ajlm-2565	243	14	pdd	pdd	NOUN
ajlm-2565	243	15	.	.	PUNCT
ajlm-2565	244	1	hyperuricemia	hyperuricemia	NOUN
ajlm-2565	244	2	and	and	CCONJ
ajlm-2565	244	3	associated	associated	ADJ
ajlm-2565	244	4	factors	factor	NOUN
ajlm-2565	244	5	:	:	PUNCT
ajlm-2565	244	6	the	the	DET
ajlm-2565	244	7	case	case	NOUN
ajlm-2565	244	8	of	of	ADP
ajlm-2565	244	9	outpatients	outpatient	NOUN
ajlm-2565	244	10	at	at	ADP
ajlm-2565	244	11	the	the	DET
ajlm-2565	244	12	bafoussam	bafoussam	NOUN
ajlm-2565	244	13	regional	regional	ADJ
ajlm-2565	244	14	hospital	hospital	NOUN
ajlm-2565	244	15	-	-	PUNCT
ajlm-2565	244	16	cameroon	cameroon	NOUN
ajlm-2565	244	17	,	,	PUNCT
ajlm-2565	244	18	an	an	DET
ajlm-2565	244	19	analytical	analytical	ADJ
ajlm-2565	244	20	cross	cross	ADJ
ajlm-2565	244	21	-	-	ADJ
ajlm-2565	244	22	sectional	sectional	ADJ
ajlm-2565	244	23	study	study	NOUN
ajlm-2565	244	24	.	.	PUNCT
ajlm-2565	245	1	health	health	PROPN
ajlm-2565	245	2	sci	sci	PROPN
ajlm-2565	245	3	rep	rep	PROPN
ajlm-2565	245	4	.	.	PROPN
ajlm-2565	245	5	2024;7(2):e1891	2024;7(2):e1891	NUM
ajlm-2565	245	6	.	.	PUNCT
ajlm-2565	246	1	https://doi.org/10.1002/hsr2.1891	https://doi.org/10.1002/hsr2.1891	PROPN
ajlm-2565	246	2	bindler	bindler	PROPN
ajlm-2565	246	3	rc	rc	PROPN
ajlm-2565	246	4	,	,	PUNCT
ajlm-2565	246	5	daratha	daratha	PROPN
ajlm-2565	246	6	kb	kb	PROPN
ajlm-2565	246	7	,	,	PUNCT
ajlm-2565	246	8	bindler	bindler	PROPN
ajlm-2565	246	9	rj	rj	PROPN
ajlm-2565	246	10	,	,	PUNCT
ajlm-2565	246	11	short	short	PROPN
ajlm-2565	246	12	r.	r.	PROPN
ajlm-2565	246	13	serum	serum	PROPN
ajlm-2565	246	14	uric	uric	ADJ
ajlm-2565	246	15	acid	acid	NOUN
ajlm-2565	246	16	:	:	PUNCT
ajlm-2565	246	17	relationships	relationship	NOUN
ajlm-2565	246	18	with	with	ADP
ajlm-2565	246	19	biomarkers	biomarker	NOUN
ajlm-2565	246	20	in	in	ADP
ajlm-2565	246	21	adolescents	adolescent	NOUN
ajlm-2565	246	22	and	and	CCONJ
ajlm-2565	246	23	changes	change	NOUN
ajlm-2565	246	24	over	over	ADP
ajlm-2565	246	25	1	1	NUM
ajlm-2565	246	26	year	year	NOUN
ajlm-2565	246	27	.	.	PUNCT
ajlm-2565	247	1	j	j	PROPN
ajlm-2565	247	2	pediatr	pediatr	PROPN
ajlm-2565	247	3	endocrinol	endocrinol	VERB
ajlm-2565	247	4	metab	metab	NOUN
ajlm-2565	247	5	.	.	PUNCT
ajlm-2565	248	1	2014;27(5–6):467–473	2014;27(5–6):467–473	X
ajlm-2565	248	2	.	.	PUNCT
ajlm-2565	249	1	https://doi.org/10.1515/jpem-2013-0255	https://doi.org/10.1515/jpem-2013-0255	PROPN
ajlm-2565	249	2	cheserek	cheserek	PROPN
ajlm-2565	249	3	mj	mj	PROPN
ajlm-2565	249	4	,	,	PUNCT
ajlm-2565	249	5	shi	shi	PROPN
ajlm-2565	249	6	y	y	PROPN
ajlm-2565	249	7	,	,	PUNCT
ajlm-2565	249	8	le	le	PROPN
ajlm-2565	249	9	g.	g.	PROPN
ajlm-2565	249	10	association	association	PROPN
ajlm-2565	249	11	of	of	ADP
ajlm-2565	249	12	hyperuricemia	hyperuricemia	NOUN
ajlm-2565	249	13	with	with	ADP
ajlm-2565	249	14	metabolic	metabolic	NOUN
ajlm-2565	249	15	syndrome	syndrome	NOUN
ajlm-2565	249	16	among	among	ADP
ajlm-2565	249	17	university	university	NOUN
ajlm-2565	249	18	workers	worker	NOUN
ajlm-2565	249	19	:	:	PUNCT
ajlm-2565	249	20	sex	sex	NOUN
ajlm-2565	249	21	and	and	CCONJ
ajlm-2565	249	22	occupational	occupational	ADJ
ajlm-2565	249	23	differences	difference	NOUN
ajlm-2565	249	24	.	.	PUNCT
ajlm-2565	250	1	afr	afr	PROPN
ajlm-2565	250	2	health	health	PROPN
ajlm-2565	250	3	sci	sci	PROPN
ajlm-2565	250	4	.	.	PUNCT
ajlm-2565	251	1	2018;18(4):842–851	2018;18(4):842–851	X
ajlm-2565	251	2	.	.	PUNCT
ajlm-2565	252	1	https://doi.org/10.4314/ahs.v18i4.2	https://doi.org/10.4314/ahs.v18i4.2	PROPN
ajlm-2565	252	2	duan	duan	PROPN
ajlm-2565	252	3	y	y	PROPN
ajlm-2565	252	4	,	,	PUNCT
ajlm-2565	252	5	liang	liang	PROPN
ajlm-2565	252	6	w	w	PROPN
ajlm-2565	252	7	,	,	PUNCT
ajlm-2565	252	8	zhu	zhu	PROPN
ajlm-2565	252	9	l	l	NOUN
ajlm-2565	252	10	,	,	PUNCT
ajlm-2565	252	11	et	et	PROPN
ajlm-2565	252	12	al	al	PROPN
ajlm-2565	252	13	.	.	PROPN
ajlm-2565	252	14	asociación	asociación	PROPN
ajlm-2565	252	15	entre	entre	PROPN
ajlm-2565	252	16	la	la	PROPN
ajlm-2565	252	17	concentración	concentración	PROPN
ajlm-2565	252	18	de	de	X
ajlm-2565	252	19	ácido	ácido	VERB
ajlm-2565	252	20	úrico	úrico	NOUN
ajlm-2565	252	21	en	en	ADP
ajlm-2565	252	22	suero	suero	PROPN
ajlm-2565	252	23	y	y	PROPN
ajlm-2565	252	24	la	la	PROPN
ajlm-2565	252	25	obesidad	obesidad	PROPN
ajlm-2565	252	26	entre	entre	PROPN
ajlm-2565	252	27	los	los	PROPN
ajlm-2565	252	28	estudiantes	estudiantes	PROPN
ajlm-2565	252	29	universitarios	universitarios	PROPN
ajlm-2565	252	30	(	(	PUNCT
ajlm-2565	252	31	china	china	PROPN
ajlm-2565	252	32	)	)	PUNCT
ajlm-2565	252	33	.	.	PUNCT
ajlm-2565	253	1	nutr	nutr	PROPN
ajlm-2565	253	2	hosp	hosp	PROPN
ajlm-2565	253	3	.	.	PUNCT
ajlm-2565	254	1	2015;31(6):2407–2411	2015;31(6):2407–2411	PROPN
ajlm-2565	254	2	.	.	PUNCT
ajlm-2565	255	1	ewenighi	ewenighi	PROPN
ajlm-2565	255	2	chinwe	chinwe	PROPN
ajlm-2565	256	1	o	o	PROPN
ajlm-2565	256	2	,	,	PUNCT
ajlm-2565	256	3	uchechukwu	uchechukwu	PROPN
ajlm-2565	256	4	d	d	PROPN
ajlm-2565	256	5	,	,	PUNCT
ajlm-2565	256	6	uchechukwu	uchechukwu	PROPN
ajlm-2565	256	7	e	e	PROPN
ajlm-2565	256	8	,	,	PUNCT
ajlm-2565	256	9	et	et	PROPN
ajlm-2565	256	10	al	al	PROPN
ajlm-2565	256	11	.	.	PUNCT
ajlm-2565	257	1	prevalence	prevalence	NOUN
ajlm-2565	257	2	of	of	ADP
ajlm-2565	257	3	hyperuricemia	hyperuricemia	NOUN
ajlm-2565	257	4	and	and	CCONJ
ajlm-2565	257	5	its	its	PRON
ajlm-2565	257	6	risk	risk	NOUN
ajlm-2565	257	7	factors	factor	NOUN
ajlm-2565	257	8	in	in	ADP
ajlm-2565	257	9	healthy	healthy	ADJ
ajlm-2565	257	10	male	male	ADJ
ajlm-2565	257	11	adults	adult	NOUN
ajlm-2565	257	12	from	from	ADP
ajlm-2565	257	13	abakaliki	abakaliki	ADJ
ajlm-2565	257	14	metropolis	metropolis	PROPN
ajlm-2565	257	15	,	,	PUNCT
ajlm-2565	257	16	nigeria	nigeria	PROPN
ajlm-2565	257	17	.	.	PUNCT
ajlm-2565	258	1	j	j	PROPN
ajlm-2565	258	2	mol	mol	ADP
ajlm-2565	258	3	pathophysiol	pathophysiol	PROPN
ajlm-2565	258	4	.	.	PUNCT
ajlm-2565	259	1	2015;4(3):95	2015;4(3):95	X
ajlm-2565	259	2	.	.	PUNCT
ajlm-2565	260	1	https://doi.org/10.5455/jmp.20150915011842	https://doi.org/10.5455/jmp.20150915011842	PROPN
ajlm-2565	260	2	chen	chen	PROPN
ajlm-2565	261	1	d	d	PROPN
ajlm-2565	261	2	,	,	PUNCT
ajlm-2565	261	3	lu	lu	PROPN
ajlm-2565	261	4	c	c	NOUN
ajlm-2565	261	5	,	,	PUNCT
ajlm-2565	261	6	chen	chen	PROPN
ajlm-2565	261	7	k	k	PROPN
ajlm-2565	261	8	,	,	PUNCT
ajlm-2565	261	9	et	et	PROPN
ajlm-2565	261	10	al	al	PROPN
ajlm-2565	261	11	.	.	PROPN
ajlm-2565	261	12	association	association	PROPN
ajlm-2565	261	13	between	between	ADP
ajlm-2565	261	14	anthropometric	anthropometric	ADJ
ajlm-2565	261	15	indices	index	NOUN
ajlm-2565	261	16	and	and	CCONJ
ajlm-2565	261	17	hyperuricemia	hyperuricemia	NOUN
ajlm-2565	261	18	:	:	PUNCT
ajlm-2565	261	19	a	a	DET
ajlm-2565	261	20	nationwide	nationwide	ADJ
ajlm-2565	261	21	study	study	NOUN
ajlm-2565	261	22	in	in	ADP
ajlm-2565	261	23	china	china	PROPN
ajlm-2565	261	24	.	.	PUNCT
ajlm-2565	262	1	clin	clin	PROPN
ajlm-2565	262	2	rheumatol	rheumatol	PROPN
ajlm-2565	262	3	.	.	PUNCT
ajlm-2565	263	1	2024;43(3):907–920	2024;43(3):907–920	X
ajlm-2565	263	2	.	.	PUNCT
ajlm-2565	264	1	https://doi.org/10.1007/s10067-024-06884-w	https://doi.org/10.1007/s10067-024-06884-w	PROPN
ajlm-2565	264	2	rathmann	rathmann	VERB
ajlm-2565	264	3	w	w	PROPN
ajlm-2565	264	4	,	,	PUNCT
ajlm-2565	264	5	haastert	haastert	NOUN
ajlm-2565	264	6	b	b	NOUN
ajlm-2565	264	7	,	,	PUNCT
ajlm-2565	264	8	icks	ick	VERB
ajlm-2565	264	9	a	a	PRON
ajlm-2565	264	10	,	,	PUNCT
ajlm-2565	264	11	giani	giani	PROPN
ajlm-2565	264	12	g	g	PROPN
ajlm-2565	264	13	,	,	PUNCT
ajlm-2565	264	14	roseman	roseman	PROPN
ajlm-2565	264	15	jm	jm	PROPN
ajlm-2565	264	16	.	.	PROPN
ajlm-2565	264	17	ten	ten	NUM
ajlm-2565	264	18	-	-	PUNCT
ajlm-2565	264	19	year	year	NOUN
ajlm-2565	264	20	change	change	NOUN
ajlm-2565	264	21	in	in	ADP
ajlm-2565	264	22	serum	serum	NOUN
ajlm-2565	264	23	uric	uric	ADJ
ajlm-2565	264	24	acid	acid	NOUN
ajlm-2565	264	25	and	and	CCONJ
ajlm-2565	264	26	its	its	PRON
ajlm-2565	264	27	relation	relation	NOUN
ajlm-2565	264	28	to	to	ADP
ajlm-2565	264	29	changes	change	NOUN
ajlm-2565	264	30	in	in	ADP
ajlm-2565	264	31	other	other	ADJ
ajlm-2565	264	32	metabolic	metabolic	NOUN
ajlm-2565	264	33	risk	risk	NOUN
ajlm-2565	264	34	factors	factor	NOUN
ajlm-2565	264	35	in	in	ADP
ajlm-2565	264	36	young	young	ADJ
ajlm-2565	264	37	black	black	ADJ
ajlm-2565	264	38	and	and	CCONJ
ajlm-2565	264	39	white	white	ADJ
ajlm-2565	264	40	adults	adult	NOUN
ajlm-2565	264	41	:	:	PUNCT
ajlm-2565	264	42	the	the	DET
ajlm-2565	264	43	cardia	cardia	NOUN
ajlm-2565	264	44	study	study	NOUN
ajlm-2565	264	45	.	.	PUNCT
ajlm-2565	265	1	eur	eur	PROPN
ajlm-2565	265	2	j	j	PROPN
ajlm-2565	265	3	epidemiol	epidemiol	PROPN
ajlm-2565	265	4	.	.	PUNCT
ajlm-2565	266	1	2007;22(7):439–445	2007;22(7):439–445	PROPN
ajlm-2565	266	2	.	.	PUNCT
ajlm-2565	267	1	https://doi.org/10.1007/s10654-007-9132-3	https://doi.org/10.1007/s10654-007-9132-3	NUM
ajlm-2565	268	1	chen	chen	PROPN
ajlm-2565	268	2	m	m	PROPN
ajlm-2565	268	3	-	-	PROPN
ajlm-2565	268	4	y	y	PROPN
ajlm-2565	268	5	,	,	PUNCT
ajlm-2565	268	6	zhao	zhao	PROPN
ajlm-2565	268	7	c	c	X
ajlm-2565	268	8	-	-	PUNCT
ajlm-2565	268	9	c	c	PROPN
ajlm-2565	268	10	,	,	PUNCT
ajlm-2565	268	11	li	li	PROPN
ajlm-2565	268	12	t	t	PROPN
ajlm-2565	268	13	-	-	PUNCT
ajlm-2565	268	14	t	t	PROPN
ajlm-2565	268	15	,	,	PUNCT
ajlm-2565	268	16	et	et	PROPN
ajlm-2565	268	17	al	al	PROPN
ajlm-2565	268	18	.	.	PROPN
ajlm-2565	268	19	serum	serum	PROPN
ajlm-2565	268	20	uric	uric	ADJ
ajlm-2565	268	21	acid	acid	PROPN
ajlm-2565	268	22	levels	level	NOUN
ajlm-2565	268	23	are	be	AUX
ajlm-2565	268	24	associated	associate	VERB
ajlm-2565	268	25	with	with	ADP
ajlm-2565	268	26	obesity	obesity	NOUN
ajlm-2565	268	27	but	but	CCONJ
ajlm-2565	268	28	not	not	PART
ajlm-2565	268	29	cardio	cardio	NOUN
ajlm-2565	268	30	-	-	PUNCT
ajlm-2565	268	31	cerebrovascular	cerebrovascular	ADJ
ajlm-2565	268	32	events	event	NOUN
ajlm-2565	268	33	in	in	ADP
ajlm-2565	268	34	chinese	chinese	ADJ
ajlm-2565	268	35	inpatients	inpatient	NOUN
ajlm-2565	268	36	with	with	ADP
ajlm-2565	268	37	type	type	NOUN
ajlm-2565	268	38	2	2	NUM
ajlm-2565	268	39	diabetes	diabetes	NOUN
ajlm-2565	268	40	.	.	PUNCT
ajlm-2565	269	1	sci	sci	PROPN
ajlm-2565	269	2	rep	rep	PROPN
ajlm-2565	269	3	.	.	PROPN
ajlm-2565	269	4	2017;7(1):40009	2017;7(1):40009	NUM
ajlm-2565	269	5	.	.	PUNCT
ajlm-2565	270	1	https://doi.org/10.1038/srep40009	https://doi.org/10.1038/srep40009	PROPN
ajlm-2565	270	2	yang	yang	PROPN
ajlm-2565	270	3	c	c	PROPN
ajlm-2565	270	4	,	,	PUNCT
ajlm-2565	270	5	yang	yang	PROPN
ajlm-2565	270	6	s	s	PROPN
ajlm-2565	270	7	,	,	PUNCT
ajlm-2565	270	8	feng	feng	PROPN
ajlm-2565	270	9	c	c	AUX
ajlm-2565	270	10	,	,	PUNCT
ajlm-2565	270	11	et	et	PROPN
ajlm-2565	270	12	al	al	PROPN
ajlm-2565	270	13	.	.	PROPN
ajlm-2565	270	14	associations	association	NOUN
ajlm-2565	270	15	of	of	ADP
ajlm-2565	270	16	hyperuricemia	hyperuricemia	NOUN
ajlm-2565	270	17	and	and	CCONJ
ajlm-2565	270	18	obesity	obesity	NOUN
ajlm-2565	270	19	with	with	ADP
ajlm-2565	270	20	remission	remission	NOUN
ajlm-2565	270	21	of	of	ADP
ajlm-2565	270	22	nonalcoholic	nonalcoholic	ADJ
ajlm-2565	270	23	fatty	fatty	NOUN
ajlm-2565	270	24	liver	liver	NOUN
ajlm-2565	270	25	disease	disease	NOUN
ajlm-2565	270	26	among	among	ADP
ajlm-2565	270	27	chinese	chinese	ADJ
ajlm-2565	270	28	men	man	NOUN
ajlm-2565	270	29	:	:	PUNCT
ajlm-2565	270	30	a	a	DET
ajlm-2565	270	31	retrospective	retrospective	ADJ
ajlm-2565	270	32	cohort	cohort	NOUN
ajlm-2565	270	33	study	study	NOUN
ajlm-2565	270	34	.	.	PUNCT
ajlm-2565	271	1	plos	plos	PROPN
ajlm-2565	271	2	one	one	NUM
ajlm-2565	271	3	.	.	PUNCT
ajlm-2565	272	1	2018;13(2):e0192396	2018;13(2):e0192396	NUM
ajlm-2565	272	2	.	.	PUNCT
ajlm-2565	273	1	https://doi.org/10.1371/journal.pone.0192396	https://doi.org/10.1371/journal.pone.0192396	NOUN
ajlm-2565	273	2	zhu	zhu	NOUN
ajlm-2565	273	3	c	c	X
ajlm-2565	273	4	,	,	PUNCT
ajlm-2565	273	5	cui	cui	NOUN
ajlm-2565	273	6	r	r	NOUN
ajlm-2565	273	7	,	,	PUNCT
ajlm-2565	273	8	gao	gao	PROPN
ajlm-2565	273	9	m	m	PROPN
ajlm-2565	273	10	,	,	PUNCT
ajlm-2565	273	11	et	et	PROPN
ajlm-2565	273	12	al	al	PROPN
ajlm-2565	273	13	.	.	PUNCT
ajlm-2565	274	1	the	the	DET
ajlm-2565	274	2	associations	association	NOUN
ajlm-2565	274	3	of	of	ADP
ajlm-2565	274	4	serum	serum	PROPN
ajlm-2565	274	5	uric	uric	ADJ
ajlm-2565	274	6	acid	acid	NOUN
ajlm-2565	274	7	with	with	ADP
ajlm-2565	274	8	obesity	obesity	NOUN
ajlm-2565	274	9	-	-	PUNCT
ajlm-2565	274	10	related	relate	VERB
ajlm-2565	274	11	acanthosis	acanthosis	NOUN
ajlm-2565	274	12	nigricans	nigrican	NOUN
ajlm-2565	274	13	and	and	CCONJ
ajlm-2565	274	14	related	relate	VERB
ajlm-2565	274	15	metabolic	metabolic	NOUN
ajlm-2565	274	16	indices	index	NOUN
ajlm-2565	274	17	.	.	PUNCT
ajlm-2565	275	1	int	int	NOUN
ajlm-2565	275	2	j	j	PROPN
ajlm-2565	275	3	endocrinol	endocrinol	NOUN
ajlm-2565	275	4	.	.	PUNCT
ajlm-2565	276	1	2017;2017:5438157	2017;2017:5438157	NUM
ajlm-2565	276	2	.	.	PUNCT
ajlm-2565	277	1	https://doi.org/10.1155/2017/5438157	https://doi.org/10.1155/2017/5438157	PROPN
ajlm-2565	277	2	oyama	oyama	PROPN
ajlm-2565	277	3	c	c	PROPN
ajlm-2565	277	4	,	,	PUNCT
ajlm-2565	277	5	takahashi	takahashi	PROPN
ajlm-2565	277	6	t	t	PROPN
ajlm-2565	277	7	,	,	PUNCT
ajlm-2565	277	8	oyamada	oyamada	PROPN
ajlm-2565	277	9	m	m	PROPN
ajlm-2565	277	10	,	,	PUNCT
ajlm-2565	277	11	et	et	PROPN
ajlm-2565	277	12	al	al	PROPN
ajlm-2565	277	13	.	.	PROPN
ajlm-2565	277	14	serum	serum	PROPN
ajlm-2565	277	15	uric	uric	PROPN
ajlm-2565	277	16	acid	acid	NOUN
ajlm-2565	277	17	as	as	ADP
ajlm-2565	277	18	an	an	DET
ajlm-2565	277	19	obesity	obesity	NOUN
ajlm-2565	277	20	-	-	PUNCT
ajlm-2565	277	21	related	relate	VERB
ajlm-2565	277	22	indicator	indicator	NOUN
ajlm-2565	277	23	in	in	ADP
ajlm-2565	277	24	early	early	ADJ
ajlm-2565	277	25	adolescence	adolescence	NOUN
ajlm-2565	277	26	.	.	PUNCT
ajlm-2565	278	1	tohoku	tohoku	PROPN
ajlm-2565	278	2	j	j	PROPN
ajlm-2565	278	3	exp	exp	NOUN
ajlm-2565	278	4	med	med	PROPN
ajlm-2565	278	5	.	.	PUNCT
ajlm-2565	279	1	2006;209(3):257–262	2006;209(3):257–262	NUM
ajlm-2565	279	2	.	.	PUNCT
ajlm-2565	279	3	https://doi.org/10.1620/tjem.209.257	https://doi.org/10.1620/tjem.209.257	PROPN
ajlm-2565	279	4	sivakumar	sivakumar	PROPN
ajlm-2565	279	5	k	k	PROPN
ajlm-2565	279	6	,	,	PUNCT
ajlm-2565	279	7	thamarai	thamarai	NOUN
ajlm-2565	279	8	r	r	NOUN
ajlm-2565	279	9	,	,	PUNCT
ajlm-2565	279	10	pragatha	pragatha	PROPN
ajlm-2565	279	11	rj	rj	PROPN
ajlm-2565	279	12	.	.	PUNCT
ajlm-2565	280	1	screening	screen	VERB
ajlm-2565	280	2	of	of	ADP
ajlm-2565	280	3	serum	serum	PROPN
ajlm-2565	280	4	uric	uric	ADJ
ajlm-2565	280	5	acid	acid	NOUN
ajlm-2565	280	6	in	in	ADP
ajlm-2565	280	7	obese	obese	ADJ
ajlm-2565	280	8	individuals	individual	NOUN
ajlm-2565	280	9	in	in	ADP
ajlm-2565	280	10	rural	rural	ADJ
ajlm-2565	280	11	population	population	NOUN
ajlm-2565	280	12	.	.	PUNCT
ajlm-2565	281	1	int	int	PROPN
ajlm-2565	282	1	j	j	PROPN
ajlm-2565	282	2	sci	sci	PROPN
ajlm-2565	282	3	study	study	NOUN
ajlm-2565	282	4	.	.	PUNCT
ajlm-2565	283	1	2014;2(2):1–4	2014;2(2):1–4	X
ajlm-2565	283	2	.	.	PUNCT
ajlm-2565	283	3	haq	haq	PROPN
ajlm-2565	283	4	au	au	PROPN
ajlm-2565	283	5	,	,	PUNCT
ajlm-2565	283	6	mahmood	mahmood	PROPN
ajlm-2565	283	7	r	r	PROPN
ajlm-2565	283	8	,	,	PUNCT
ajlm-2565	283	9	safi	safi	PROPN
ajlm-2565	283	10	aj	aj	PROPN
ajlm-2565	283	11	,	,	PUNCT
ajlm-2565	283	12	rehman	rehman	PROPN
ajlm-2565	283	13	ju	ju	PROPN
ajlm-2565	283	14	,	,	PUNCT
ajlm-2565	283	15	jillani	jillani	NOUN
ajlm-2565	283	16	g	g	PROPN
ajlm-2565	283	17	,	,	PUNCT
ajlm-2565	283	18	haq	haq	PROPN
ajlm-2565	283	19	iu	iu	PROPN
ajlm-2565	283	20	.	.	PROPN
ajlm-2565	283	21	association	association	PROPN
ajlm-2565	283	22	of	of	ADP
ajlm-2565	283	23	serum	serum	PROPN
ajlm-2565	283	24	uric	uric	ADJ
ajlm-2565	283	25	acid	acid	NOUN
ajlm-2565	283	26	with	with	ADP
ajlm-2565	283	27	obesity	obesity	NOUN
ajlm-2565	283	28	.	.	PUNCT
ajlm-2565	284	1	j	j	PROPN
ajlm-2565	284	2	postgrad	postgrad	PROPN
ajlm-2565	284	3	med	med	PROPN
ajlm-2565	284	4	instit	instit	PROPN
ajlm-2565	284	5	.	.	PUNCT
ajlm-2565	285	1	2009;23(3):227–230	2009;23(3):227–230	X
ajlm-2565	285	2	.	.	PUNCT
ajlm-2565	285	3	essa	essa	PROPN
ajlm-2565	285	4	sa	sa	PROPN
ajlm-2565	285	5	,	,	PUNCT
ajlm-2565	285	6	mishari	mishari	PROPN
ajlm-2565	285	7	ak	ak	PROPN
ajlm-2565	285	8	,	,	PUNCT
ajlm-2565	285	9	kadhom	kadhom	PROPN
ajlm-2565	285	10	qi	qi	PROPN
ajlm-2565	285	11	.	.	PROPN
ajlm-2565	285	12	association	association	PROPN
ajlm-2565	285	13	between	between	ADP
ajlm-2565	285	14	serum	serum	PROPN
ajlm-2565	285	15	uric	uric	ADJ
ajlm-2565	285	16	acid	acid	NOUN
ajlm-2565	285	17	and	and	CCONJ
ajlm-2565	285	18	obesity	obesity	NOUN
ajlm-2565	285	19	.	.	PUNCT
ajlm-2565	286	1	j	j	PROPN
ajlm-2565	286	2	babylon	babylon	PROPN
ajlm-2565	286	3	univ	univ	PROPN
ajlm-2565	286	4	.	.	PUNCT
ajlm-2565	287	1	2015;2(23):899–903	2015;2(23):899–903	NOUN
ajlm-2565	287	2	.	.	PUNCT
ajlm-2565	288	1	choi	choi	PROPN
ajlm-2565	288	2	hk	hk	PROPN
ajlm-2565	288	3	,	,	PUNCT
ajlm-2565	288	4	atkinson	atkinson	PROPN
ajlm-2565	288	5	k	k	PROPN
ajlm-2565	288	6	,	,	PUNCT
ajlm-2565	288	7	karlson	karlson	PROPN
ajlm-2565	288	8	ew	ew	PROPN
ajlm-2565	288	9	,	,	PUNCT
ajlm-2565	288	10	willett	willett	PROPN
ajlm-2565	288	11	w	w	PROPN
ajlm-2565	288	12	,	,	PUNCT
ajlm-2565	288	13	curhan	curhan	PROPN
ajlm-2565	288	14	g.	g.	PROPN
ajlm-2565	288	15	purine	purine	NOUN
ajlm-2565	288	16	-	-	PUNCT
ajlm-2565	288	17	rich	rich	ADJ
ajlm-2565	288	18	foods	food	NOUN
ajlm-2565	288	19	,	,	PUNCT
ajlm-2565	288	20	dairy	dairy	NOUN
ajlm-2565	288	21	and	and	CCONJ
ajlm-2565	288	22	protein	protein	NOUN
ajlm-2565	288	23	intake	intake	NOUN
ajlm-2565	288	24	,	,	PUNCT
ajlm-2565	288	25	and	and	CCONJ
ajlm-2565	288	26	the	the	DET
ajlm-2565	288	27	risk	risk	NOUN
ajlm-2565	288	28	of	of	ADP
ajlm-2565	288	29	gout	gout	NOUN
ajlm-2565	288	30	in	in	ADP
ajlm-2565	288	31	men	man	NOUN
ajlm-2565	288	32	.	.	PUNCT
ajlm-2565	289	1	n	n	PROPN
ajlm-2565	289	2	engl	engl	PROPN
ajlm-2565	289	3	j	j	PROPN
ajlm-2565	289	4	med	med	PROPN
ajlm-2565	289	5	.	.	PUNCT
ajlm-2565	290	1	2004;350(11):1093–1103	2004;350(11):1093–1103	NUM
ajlm-2565	290	2	.	.	PUNCT
ajlm-2565	291	1	https://doi.org/10.1056/nejmoa035700	https://doi.org/10.1056/nejmoa035700	PROPN
ajlm-2565	291	2	matsuura	matsuura	PROPN
ajlm-2565	291	3	f	f	PROPN
ajlm-2565	291	4	,	,	PUNCT
ajlm-2565	291	5	yamashita	yamashita	PROPN
ajlm-2565	291	6	s	s	PROPN
ajlm-2565	291	7	,	,	PUNCT
ajlm-2565	291	8	nakamura	nakamura	PROPN
ajlm-2565	291	9	t	t	PROPN
ajlm-2565	291	10	,	,	PUNCT
ajlm-2565	291	11	et	et	PROPN
ajlm-2565	291	12	al	al	PROPN
ajlm-2565	291	13	.	.	PROPN
ajlm-2565	291	14	effect	effect	NOUN
ajlm-2565	291	15	of	of	ADP
ajlm-2565	291	16	visceral	visceral	ADJ
ajlm-2565	291	17	fat	fat	ADJ
ajlm-2565	291	18	accumulation	accumulation	NOUN
ajlm-2565	291	19	on	on	ADP
ajlm-2565	291	20	uric	uric	ADJ
ajlm-2565	291	21	acid	acid	NOUN
ajlm-2565	291	22	metabolism	metabolism	NOUN
ajlm-2565	291	23	in	in	ADP
ajlm-2565	291	24	male	male	ADJ
ajlm-2565	291	25	obese	obese	ADJ
ajlm-2565	291	26	subjects	subject	NOUN
ajlm-2565	291	27	:	:	PUNCT
ajlm-2565	291	28	visceral	visceral	ADJ
ajlm-2565	291	29	fat	fat	ADJ
ajlm-2565	291	30	obesity	obesity	NOUN
ajlm-2565	291	31	is	be	AUX
ajlm-2565	291	32	linked	link	VERB
ajlm-2565	291	33	more	more	ADV
ajlm-2565	291	34	closely	closely	ADV
ajlm-2565	291	35	to	to	ADP
ajlm-2565	291	36	overproduction	overproduction	NOUN
ajlm-2565	291	37	of	of	ADP
ajlm-2565	291	38	uric	uric	ADJ
ajlm-2565	291	39	acid	acid	NOUN
ajlm-2565	291	40	than	than	ADP
ajlm-2565	291	41	subcutaneous	subcutaneous	ADJ
ajlm-2565	291	42	fat	fat	ADJ
ajlm-2565	291	43	obesity	obesity	NOUN
ajlm-2565	291	44	.	.	PUNCT
ajlm-2565	292	1	metabolism	metabolism	NOUN
ajlm-2565	292	2	.	.	PUNCT
ajlm-2565	293	1	1998;47(8):929–933	1998;47(8):929–933	NUM
ajlm-2565	293	2	.	.	PUNCT
ajlm-2565	294	1	https://doi.org/10.1016/s0026-0495(98)90346-8	https://doi.org/10.1016/s0026-0495(98)90346-8	PROPN
ajlm-2565	294	2	fabregat	fabregat	PROPN
ajlm-2565	294	3	i	i	PROPN
ajlm-2565	294	4	,	,	PUNCT
ajlm-2565	294	5	revilla	revilla	PROPN
ajlm-2565	294	6	e	e	PROPN
ajlm-2565	294	7	,	,	PUNCT
ajlm-2565	294	8	machado	machado	PROPN
ajlm-2565	294	9	a.	a.	PROPN
ajlm-2565	294	10	short	short	ADJ
ajlm-2565	294	11	-	-	PUNCT
ajlm-2565	294	12	term	term	NOUN
ajlm-2565	294	13	control	control	NOUN
ajlm-2565	294	14	of	of	ADP
ajlm-2565	294	15	the	the	DET
ajlm-2565	294	16	pentose	pentose	NOUN
ajlm-2565	294	17	phosphate	phosphate	NOUN
ajlm-2565	294	18	cycle	cycle	NOUN
ajlm-2565	294	19	by	by	ADP
ajlm-2565	294	20	insulin	insulin	NOUN
ajlm-2565	294	21	could	could	AUX
ajlm-2565	294	22	be	be	AUX
ajlm-2565	294	23	modulated	modulate	VERB
ajlm-2565	294	24	by	by	ADP
ajlm-2565	294	25	the	the	DET
ajlm-2565	294	26	nadphnadp	nadphnadp	PROPN
ajlm-2565	294	27	ratio	ratio	NOUN
ajlm-2565	294	28	in	in	ADP
ajlm-2565	294	29	rat	rat	NOUN
ajlm-2565	294	30	adipocytes	adipocyte	NOUN
ajlm-2565	294	31	and	and	CCONJ
ajlm-2565	294	32	hepatocytes	hepatocyte	NOUN
ajlm-2565	294	33	.	.	PUNCT
ajlm-2565	295	1	biochem	biochem	PROPN
ajlm-2565	295	2	biophys	biophy	VERB
ajlm-2565	295	3	res	re	NOUN
ajlm-2565	295	4	comm	comm	NOUN
ajlm-2565	295	5	.	.	PUNCT
ajlm-2565	296	1	1987;146(2):920–925	1987;146(2):920–925	X
ajlm-2565	296	2	.	.	PUNCT
ajlm-2565	297	1	https://doi.org/10.1016/0006-291x(87)90618-8	https://doi.org/10.1016/0006-291x(87)90618-8	PROPN
ajlm-2565	297	2	fox	fox	VERB
ajlm-2565	297	3	ih	ih	PROPN
ajlm-2565	297	4	.	.	PUNCT
ajlm-2565	298	1	metabolic	metabolic	ADJ
ajlm-2565	298	2	basis	basis	NOUN
ajlm-2565	298	3	for	for	ADP
ajlm-2565	298	4	disorders	disorder	NOUN
ajlm-2565	298	5	of	of	ADP
ajlm-2565	298	6	purine	purine	NOUN
ajlm-2565	298	7	nucleotide	nucleotide	NOUN
ajlm-2565	298	8	degradation	degradation	NOUN
ajlm-2565	298	9	.	.	PUNCT
ajlm-2565	299	1	metabolism	metabolism	NOUN
ajlm-2565	299	2	.	.	PUNCT
ajlm-2565	300	1	1981;30(6):616–634	1981;30(6):616–634	X
ajlm-2565	300	2	.	.	PUNCT
ajlm-2565	301	1	https://doi.org/10.1016/0026-0495(81)90142-6	https://doi.org/10.1016/0026-0495(81)90142-6	PROPN
ajlm-2565	301	2	su	su	PROPN
ajlm-2565	302	1	s	s	PROPN
ajlm-2565	302	2	-	-	PROPN
ajlm-2565	302	3	y	y	PROPN
ajlm-2565	302	4	,	,	PUNCT
ajlm-2565	302	5	lin	lin	PROPN
ajlm-2565	302	6	t	t	PROPN
ajlm-2565	302	7	-	-	PUNCT
ajlm-2565	302	8	h	h	PROPN
ajlm-2565	302	9	,	,	PUNCT
ajlm-2565	302	10	liu	liu	PROPN
ajlm-2565	302	11	y	y	PROPN
ajlm-2565	302	12	-	-	PUNCT
ajlm-2565	302	13	h	h	PROPN
ajlm-2565	302	14	,	,	PUNCT
ajlm-2565	302	15	et	et	PROPN
ajlm-2565	302	16	al	al	PROPN
ajlm-2565	302	17	.	.	PUNCT
ajlm-2565	302	18	sex	sex	NOUN
ajlm-2565	302	19	difference	difference	NOUN
ajlm-2565	302	20	in	in	ADP
ajlm-2565	302	21	the	the	DET
ajlm-2565	302	22	associations	association	NOUN
ajlm-2565	302	23	among	among	ADP
ajlm-2565	302	24	obesity	obesity	NOUN
ajlm-2565	302	25	-	-	PUNCT
ajlm-2565	302	26	related	relate	VERB
ajlm-2565	302	27	indices	index	NOUN
ajlm-2565	302	28	with	with	ADP
ajlm-2565	302	29	hyperuricemia	hyperuricemia	NOUN
ajlm-2565	302	30	in	in	ADP
ajlm-2565	302	31	a	a	DET
ajlm-2565	302	32	large	large	ADJ
ajlm-2565	302	33	taiwanese	taiwanese	ADJ
ajlm-2565	302	34	population	population	NOUN
ajlm-2565	302	35	study	study	NOUN
ajlm-2565	302	36	.	.	PUNCT
ajlm-2565	303	1	nutrients	nutrient	NOUN
ajlm-2565	303	2	.	.	PUNCT
ajlm-2565	304	1	2023;15(15):3419	2023;15(15):3419	X
ajlm-2565	304	2	.	.	PUNCT
ajlm-2565	305	1	https://doi.org/10.3390/nu15153419	https://doi.org/10.3390/nu15153419	X